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1 SUMMARY 
 
Cancer is one of the major causes of mortality and challenges the human race in the 
last few decades. Cancer is a disease involving dynamic changes in the genome. The 
genomes of the cells are constantly altered at multiple sites. Two types of genes are 
invariably targeted during the tumor development, which are oncogenes and tumor 
suppressor genes. 
 
The Programmed Cell Death 4 gene (Pdcd4) is a novel tumor suppressor gene originally 
identified as a gene upregulated during apoptosis. It has been shown that Pdcd4 
suppresses the tumor promoter TPA induced transformation of keratinocytes. Because 
Pdcd4 interacts with eucaryotic translation initiation factor eIF4A, it was suggested that 
Pdcd4 might be involved in controlling the translation of certain, as yet unknown 
proteins. However, lack of a well-characterized cell system hampers the analysis of 
molecular functions of Pdcd4.  
 
To study the molecular functions of the Pdcd4 tumor suppressor gene by a reverse 
genetic approach, a knock-down system was developed. The system was generated by 
employing the RNAi technology mediated via siRNA directed against the human Pdcd4 
gene (Hpdcd4) in HeLa cells. Dual luciferase constructs containing different Internal 
Ribosome Entry Site Elements (IRES) of genes involved in cell growth, cell cycle control 
and apoptosis were used to study the effect of Hpdcd4 on cap-independent translation 
and thereby to function as a cell-growth/death regulator. The results obtained show 
that Pdcd4 acts in an inhibitory manner on several IRES elements under normal 
physiological conditions.  
 
The 1D-SDS-PAGE analysis showed that the expression of several transcription factors 
was affected by Hpdcd4. While c-Myc expression was lower, c-Jun and C/EBPβ 
expression was higher in the absence than in the presence of Hpdcd4. Additionally, in 
the Hpdcd4 knock-down cells phosphorylation of ATF-2 and c-Jun were less efficient 
compared to the HeLa wild-type (WT) cells. To identify novel molecular targets of 
Hpdcd4 in a holistic way, a proteomic approach was performed using 2D-SDS-PAGE 
followed by mass spectrometry of HeLa WT and Hpdcd4 knock-down cells. Thereby, 
several novel targets of Hpdcd4 were identified. In the absence of Hpdcd4, 
cytokeratin-17 (CK-17) as well as Aldo Keto Reductase 1 (AKR1) family members C2 
and C3 were overexpressed. In addition, cytokeratin-8 (CK-8) and Glutamyl Prolyl 
Bifunctional tRNA synthetase (GluProRS) appeared to be biochemically modified in the 
Pdcd4 knock-down cells compared to the HeLa WT cells. The differential expression of 
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these target proteins was confirmed by 1D/2D-SDS-PAGE followed by immunoblotting 
with specific antibodies. The overexpression of CK-17 and the biochemical modification 
of CK-8 in the absence of Hpdcd4 were reproducible. The identity of AKR1C2 and C3 as 
well as GluProRS is yet to be assessed and proved as potential targets of HPdcd4. 
 
It was also investigated whether Hpdcd4 has an effect on the mRNA level of CK-17, 
c-Myc and c-Jun. The mRNA expression level of these genes was consistent with the 
respective protein expression except for c-Jun. It was further analyzed whether Hpdcd4 
is influencing the transcription or the stability of the mRNA transcripts. To analyze the 
effect of Hpdcd4 on the turn-over of the CK-17 and the c-Myc mRNAs, cells were 
treated with a transcription-inhibitor actinomycin-D and mRNA levels were analyzed by 
northern blotting in a time-dependent manner. It appeared that Hpdcd4 is enhancing 
the degradation of CK-17 and c-Myc mRNA transcripts. In addition to that Hpdcd4 
seems to be involved in nonsense-mediated mRNA decay.  
 
In addition to the HeLa knock-down system, in the chicken B-cell line DT40, a Pdcd4 
knock-out model has been developed wherein both functional copies of the gene were 
eliminated by homologous recombination. It was shown that chicken Pdcd4 knock-out 
cells are viable and grow with the same doubling time as DT40 WT cells. However, 
there was no difference in the overall rate of protein synthesis between knock-out and 
WT cells. The two systems developed in the present work will be useful in further 
elucidating the molecular functions of tumor suppressor Pdcd4 by utilizing the 
molecular targets identified here. 
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2 INTRODUCTION 
2.1 Cancer 
2.1.1 Cancer Statistics 
 
Cancer is the uncontrolled growth and spread of cells that may affect almost any tissue 
of the body. People are affected by lung, colorectal and stomach cancers which are 
among the five most common cancers in the world. While men are mostly affected by 
lung and stomach cancer, breast and cervical cancers are most common among women 
worldwide (WHO, 2006).  
 
More than 11 million people are diagnosed with cancer every year. It is estimated that 
there will be 16 million new cases every year by 2020. Cancer causes 7 million deaths 
every year (12.5%) worldwide (WHO, 2006). The cancer statistics necessitates the 
inevitability of the focus of scientific research towards cancer aimed at reducing causes 
and consequences of cancer. Although the causes of cancer are at the genetic level, 
understanding the cancer cell physiology is also essential to unknot the complexity of 
cancer. Over the past 25 years cancer research has developed a rich body of 
information about cancer cell physiology and eventually it has been transferred into 
knowledge and several rules are made to codify it. The rules are explained in the 
following section. 
2.1.2 Cancer Cell Physiology 
 
A quarter century of rapid advances in cancer research characterized a vast catalog of 
cancer cell genotypes. However, there are six essential alterations in cell physiology 
that collectively dictate malignant growth which are: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell 
death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Fig.1) (Hanahan and Weinberg, 2000). Almost all types of 
human tumors share these six capabilities. During tumor development, each of these 
physiological changes is acquired. The six acquired capabilities of cancer cells are 
discussed in detail. 
 
Self-Sufficiency in Growth Signals 
Normal cells require mitogenic growth signals before they can move from a quiescent 
state into an active proliferative state. These signals are transmitted into the cell by 
transmembrane receptors that bind distinctive classes of signaling molecules: diffusible 
growth factors, extracellular matrix components, and cell-to-cell adhesion/interaction 
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molecules. Tumor cells generate their own growth signals, thereby largely reducing 
their dependence for such exogenous growth stimulation. This disrupts the homeostatic 
mechanisms within the cells and the tissue environment. Although many oncogenes 
modulate this acquired growth signal autonomy, the SOS-Ras-Raf-MAPK cascade is 
proved to play a central role.   
 
 
 
 
 
Figure 1: Acquired capabilities of the tumor cells (Hanahan and Weinberg, 2000) 
 
Most of the cancer cells acquire these six functional capabilities through various mechanistic strategies and 
during various time periods of the tumor development. 
 
Insensitivity to Antigrowth signals 
Multiple anti-proliferative signals operate within a tissue to maintain cellular quiescence 
and tissue homeostasis. These signals include both soluble growth inhibitors and 
immobilized inhibitors embedded in the extracellular matrix and on the surfaces of 
nearby cells. These growth-inhibitory signals are received by transmembrane cell 
surface receptors coupled to intracellular signaling circuits. Antigrowth signals can block 
proliferation by two distinct mechanisms. They force the cells from the active 
proliferative cycle into the quiescent (G0) state. Alternatively, they induce cells to enter 
into post-mitotic states, usually differentiation. Much of the circuitry that enables 
normal cells to respond to antigrowth signals is associated with the cell cycle clock. The 
cancer cells evade these anti-proliferative signals to prosper uncontrollably. Several 
tumor suppressor genes function at this level. Moreover, all anti-proliferative signals 
are funneled through the retinoblastoma protein and the related proteins p107 and 
p130.  
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Evading Apoptosis 
The expansion of tumor cell population is determined not only by the rate of cell 
proliferation but also by the rate of cell death. Programmed cell death, apoptosis 
represents a major source for limiting the cell number. Once triggered by a variety of 
physiologic signals, apoptosis unfolds in a precisely choreographed series of steps. In a 
span of 30-120 min, cellular membranes are disrupted, the cytoplasmic and nuclear 
skeletons are broken down, the cytosol is extruded, the chromosomes are degraded, 
and the nucleus is fragmented. Eventually, the shriveled cell corpse is engulfed by 
nearby cells in a tissue and disappears, typically within 24 hr (Wyllie et al., 1980). 
 
The apoptotic program can be broadly divided into three classes of components, the 
signals, sensors and effectors. Apoptotic signals include the survival and death factors 
influencing the cell from the extra- and intracellular environment. The survival signals 
are conveyed by the insulin-like growth factor-1 (IGF-1) or IGF-2 and interleukin-3 
(IL-3) receptor-ligand pairs, whereas Fas and tumor necrosis factor-α (TNF-α) 
receptor-ligand pairs mediate the death signals. Most of the signals that elicit apoptosis 
converge on the mitochondria, which respond to proapoptotic signals by releasing 
cytochrome c, a potent catalyst of apoptosis (Green and Reed, 1998). The ultimate 
effectors of apoptosis include an array of intracellular proteases termed caspases 
(Thornberry and Lazebnik, 1998). Two “gatekeeper” caspases-8 and -9 are activated 
by death receptors such as Fas or by the cytochrome c released from mitochondria, 
respectively. These proximal caspases trigger the activation of more than 10 effector 
caspases that execute the death program, through selective destruction of subcellular 
structures, organelles, and of the genome. 
 
Resistance to apoptosis can be acquired by cancer cells through a variety of strategies. 
Firstly, loss of a proapoptotic regulator through mutation involves the p53 tumor 
suppressor gene which results in the removal of a key component of the DNA damage 
sensor that can induce the apoptotic effector cascade (Harris, 1996). Secondly, the 
signals evoked by other abnormalities, including hypoxia and oncogene 
hyperexpression/activity, are also funneled in part via p53 to the apoptotic machinery; 
these two are impaired at eliciting apoptosis when p53 function is lost (Levine, 1997). 
 
Limitless Replicative Potential 
It was demonstrated that cells in culture have a finite replicative potential (Hayflick, 
1997). Once cell populations have progressed through a certain number of doublings, 
they stop growing, a process termed senescence. Most types of tumor cells that are 
propagated in culture appear to be immortalized, suggesting that limitless replicative 
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potential is a phenotype that was acquired in vivo during tumor progression and was 
essential for the development of their malignant growth state (Hayflick, 1997).  
 
From several studies it was evident that telomere maintenance is a major strategy 
acquired by all the malignant cells to gain limitless replicative potential (Shay, 1997). 
Telomeres, the ends of chromosomes, are composed of several thousand repeats of a 
short 6 bp sequence element. DNA polymerases are unable to completely replicate the 
3′ ends of chromosomal DNA. Thus every chromosome loses 50-100 bp of telomeric 
DNA from the ends during each S phase. The progressive erosion of telomeres through 
successive cycles of replication eventually causes them to lose their ability to protect 
the ends of chromosomal DNA. The unprotected chromosomal ends participate in 
end-to-end chromosomal fusions; resulting in the death of the affected cell (Counter et 
al., 1992). 
 
For the maintenance of telomere, almost 85%-90% of the cancer cells upregulate the 
expression of the telomerase enzyme. This enzyme adds hexanucleotide repeats onto 
the ends of telomeric DNA (Bryan and Cech, 1999), or activates another mechanism, 
which appears to maintain telomeres through recombination-based interchromosomal 
exchanges of sequence information (Bryan et al., 1995). By any one mechanism, 
telomeres are maintained at a length above a critical threshold, and this in turn permits 
unlimited multiplication of descendant cells. Both mechanisms seem to be strongly 
suppressed in most normal human cells in order to deny them unlimited replicative 
potential. 
 
Sustained Angiogenesis 
The supply of oxygen and nutrients by the vasculature to the tissue is crucial for cell 
function and survival. Angiogenesis, the growth of new blood vessels is carefully 
regulated. In order to progress to a larger size, incipient neoplasias must develop 
angiogenic ability (Bouck et al., 1996 and Folkman, 1997). During tumor development, 
the ability to induce and sustain angiogenesis is acquired in a discrete step, an 
“angiogenic switch”. It is proved to be an early to midstage event in many human 
cancers. Tumors appear to activate the angiogenic switch by changing the balance of 
angiogenesis inducers and countervailing inhibitors (Hanahan and Folkman, 1996). 
  
Tissue Invasion and Metastasis 
During the development of most types of human cancers, primary tumor masses move 
out, invade adjacent tissues, and thence travel to distant sites where they may succeed 
in forming new colonies. These distant settlements of tumor cells, metastases, are the 
cause of 90% of human cancer deaths (Sporn, 1996). The capability for invasion and 
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metastasis enables cancer cells to escape the primary tumor mass and colonize new 
terrain in the body where, at least initially, nutrients and space are not limiting. Like 
the formation of the primary tumor mass, successful invasion and metastasis depend 
upon all of the other five acquired hallmark capabilities.  
2.1.3 Cancer Cell Genetics  
 
Cancer is a disease involving dynamic changes in the genome. The genomes of the 
cells are constantly altered at multiple sites; disruptions range from subtle mutations to 
obvious chromosomal lesions (Kinzler and Vogelstein, 1996). The tumor development 
proceeds via a process analogous to Darwinian evolution, in which a succession of 
genetic changes, each conferring a growth advantage, leads to the progressive 
conversion of normal cells into cancer cells (Foulds, 1974; Nowell, 1976). All cancers 
must acquire the six capabilities, though the order and means of acquiring them vary 
significantly. Induction of genetic lesions on several critical genes confers several 
capabilities. Trillions of potential target cells, each harboring hundreds of susceptible 
cancer critical genes, are constantly subject to a significant mutation rate in a human 
life time. These cancer critical genes are divided into two types, which are oncogenes 
and tumor suppressor genes. These genes and the various types of mutations that 
affect them are discussed in detail.  
 
Mutations 
Mutations are changes in the bases or in the arrangement of the bases that make up a 
gene. These chromosomal aberrations occasionally produce cells that can escape the 
normal constraints and flourish as pathological tumors. Hereditary mutations are gene 
changes that come from a parent, therefore exist in all cells of the body, including 
reproductive cells and therefore can be passed to every next generation. These are also 
called germline mutations. This type of mutation is a major cause for 5-10% of 
cancers. Most cancers are caused by acquired mutations. An acquired mutation occurs 
when DNA in a cell changes during the person’s life. This can be caused by 
environmental influences such as exposure to radiation or toxins. Unlike the inherited 
genes, an acquired mutation starts in one cell of the body and is found only in the 
offspring of that cell. These are also called sporadic or somatic mutations.  
 
Oncogenes 
Oncogenes are genes whose protein products stimulate or enhance the division and 
viability of cells. This first category also includes genes that contribute to tumor growth 
by inhibiting cell death. The normal versions of genes in the first group are called 
proto-oncogenes. Proto-oncogenes are dominant and the mutated versions of these 
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genes, which are called oncogenes, gain new functions in the cells. The cell growth 
pathway starts with a growth factor, which binds to a growth factor receptor and the 
signal from the receptor is sent through a signal transducer. A transcription factor is 
produced and drives the cell for cell division. If any abnormality is detected, the cell is 
made to commit suicide by a programmed cell death regulator. More than 100 
oncogenes have been identified at all the levels of this cell growth and death pathway 
and are involved in the multistep process of tumorigenesis (Gronbaek and Guldberg, 
2006).  
2.1.4 Tumor Suppressor Genes 
 
Tumor suppressor genes either have a dampening or repressive effect on the regulation 
of the cell cycle or promote apoptosis, and sometimes do both. Mutations in tumor 
suppressor genes are recessive and these genes undergo bi-allelic inactivation in 
tumors and thereby loose their function. Tumor suppressor genes regulate diverse 
cellular activities, including cell cycle checkpoint responses, detection and repair of DNA 
damage, protein ubiquitination and degradation, mitogenic signaling, cell specification, 
differentiation and migration, and tumor angiogenesis. Analysis of the tumor 
suppressor genes is a central part of present cancer research. The functions of tumor 
suppressor genes can be divided into four major categories (Sherr, 2004) such as 1) 
Repression of genes that is essential for continuing the cell cycle thereby effectively 
inhibiting the cell division. 2) Coupling the cell cycle to DNA damage. If the damage can 
be repaired, the cell cycle can continue. 3) Inducing the programmed cell death. For 
example, if the DNA damage can not be repaired, the cell usually initiates apoptosis, to 
remove the threat that it poses for the entire organism. 4) Some proteins involved in 
cell adhesion prevent tumor cells from dispersing and thereby inhibit metastasis 
(Hirohashi and Kanai, 2003). About 30 tumor suppressor genes have been well studied, 
including p53, BRCA1, BRCA2, APC, and RB1. The tumor suppressor gene database 
contains updated information on 174 identified and putative tumor suppressor genes 
from human beings and other organisms (Yang, 2003).  
2.1.5 Mechanisms of Inactivation of the Tumor Suppressor Genes 
 
Mutations of tumor suppressor genes have been widely found in many cancers. 
Abnormalities of the p53 gene, in particular acquired mutations have been found in 
more than 50% of the human cancers, including lung, colorectal and breast cancer as 
well as many other cancers. Acquired changes in many other tumor suppressor genes 
also contribute to the development of non-inherited cancers. Although there are many 
mechanisms operating in the cancer-prone cells to eliminate the tumor suppressor 
genes, the cells with inherited defect in one copy of a tumor suppressor gene loose 
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their remaining good copy by six possible ways (Alberts et al., 2002). The normal copy 
of the gene can be eliminated by point mutation, deletion, gene conversion, mitotic 
recombination, non dysjunction and duplication, and chromosome loss. The table 1 lists 
some of the most commonly mutated tumor suppressor genes and the inherited and 
non-inherited cancers caused by them (ACS, 2005).  
 
Table 1: The Tumor suppressor genes and human cancers 
 
Gene  Inherited cancer  Non-inherited cancers 
RBI Retinoblastoma Many different cancers  
P53s Li-Fraumeni syndrome 
(leukemia & brain tumors) 
Many different cancers 
INK4a Melanoma Many different cancers 
APC Colorectal cancer  
(with familial polyposis) 
Most colorectal cancers 
MLH1, MSH2, 
or MSH6 
Colorectal cancer  
(without polyposis) 
Colorectal, gastric, endometrial 
cancers  
BRCA1, BRCA2 Breast & ovarian cancers Only rare ovarian cancers 
WTI Wilms tumor Wilms tumors 
NF1, NF2 Nerve & brain tumors Colon cancers and melanomas 
 
In addition to the above mentioned mechanisms a new concept about the mechanism 
of inactivation of tumor suppressor genes was proposed. Loss of tumor suppressor 
activity occurs not only through the gene mutation or deletion but also alternatively as 
a result of altered gene expression (Macleod, 2004; Quon et al., 2001). An example for 
such a gene is the programmed cell death 4 gene (Pdcd4), a novel cancer-associated 
gene, with putative tumor suppressor activity which was identified to be up or 
downregulated in many cancers (Jansen 2004). A detailed introduction about Pdcd4 is 
given in the section 2.2.  
2.1.6 Cancer Therapeutics 
 
Treating abnormalities of tumor suppressor genes is even more difficult, since the 
normal tumor suppressor gene has to be restored (Ames, 1995). Cancer gene therapy 
is one of the most promising areas of cancer therapeutics. Unlike the radiation and 
chemotherapy, the toxicity is only restricted to the tumor cells. As gene expression is 
cell-type specific, the transcription is targeted using a range of promoters which are 
tissue-specific, tumor-specific and inducible by exogenous agents. The major stumbling 
block lies in the mode of transfer of new DNA into the cancer cells (Hirst, 2002). In 
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addition to that problem, most cancers have several accumulated oncogene and tumor 
suppressor gene mutations, so replacing one gene may not curb the cancer cell growth 
or invasion. Though the cancer prevention and therapy is a daunting task, increasingly 
novel cancer-critical genes are identified and targets are explored for the treatment.  
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2.2 Pdcd4 – A Novel Putative Tumor Suppressor  
2.2.1 The Cloning of Pdcd4 
 
In 1995 Shibahara et al. cloned a mouse cDNA termed MA-3 that was upregulated 
during apoptosis in all cell lines tested and termed it as Programmed Cell Death 4 
(Pdcd4). This study was followed by the identification of a homologous coding sequence 
called TIS for topoisomerase inhibitor suppressed gene by Onishi and Kizaki (1996). In 
the following years the cDNAs of the human (H731 and 197/15a), chicken (Pdcd4) and 
rat homologues (DUG) of Pdcd4 were identified (Matshuhasi et al., 1997; Azzoni et al., 
1998; Schlichter, 2001a; Goke et al., 2002). In addition to the vertebrates, distantly 
related organisms such as the fruit fly Drosophila melanogaster (referred to the map 
element CG10990) or the marine sponge Suberites domunculata (Wagner et al., 1998) 
also possess the homologous counterparts of Pdcd4.  
2.2.2 The Sequence Motifs of Pdcd4  
 
The mouse gene spans about 21 Kb including 11 exons. The intron-exon junctions 
followed the GT-AG rule of eucaryotic genes. By primer extension experiments the 
transcription start site was located 192 bp upstream of the start codon. Analysis of the 
5´-flanking region of the gene revealed two functionally active TATA sequences at 
position -21 and a CAAT-box at -81 (Onishi et al., 1998). Furthermore, putative binding 
sites for NFκB (from positions -488 to -470), NF1 (-326 to -314) and two C/EBPβ 
binding sites (-424 to -416 and -254 to -246) were found. However, the functionality of 
these sequences in transcription has yet to be tested. Concomitantly, the human Pdcd4 
(Hpdcd4) gene was mapped to chromosome band 10q24 by in situ hybridization 
(Soejima et al., 1999) 
2.2.3 The Structure of Pdcd4 
 
Pdcd4 is a 55 KDa nuclear protein contains two conserved MA-3 domains, believed to 
be largely alpha-helical in the region of aa 164-275 and 329-440, respectively. 
Secondary structure of the C-terminal MA-3 domain was determined by NMR 
experiments (Waters et al., 2006). Two nuclear export signals (NES) at 182-192 and 
241-251 were identified, one of which was shown to be very potent, 182-192 (Boehm 
et al., 2003). In addition, it was also found by the same investigators that the Pdcd4 
protein has intrinsic RNA-binding activity and that the amino-terminal part of the 
protein is responsible for this activity. The domain organization of Pdcd4 is shown in 
figure 2. Two potential nuclear localization signals (NLS) have been predicted at the N- 
and C-terminus of the protein, but have not been proved experimentally. Furthermore, 
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the protein contains multiple phoshoprylation sites for protein kinases such as protein 
kinase C, proline-directed protein kinase and casein kinase II. It has been shown that 
Pdcd4 is phosphorylated by Akt kinase at the sites of Ser-67 and Ser-457, both in vitro 
and in vivo (Palamarchuk et al., 2005).  
 
RNA 
Binding 
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N-terminus terminusC-
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E
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Figure 2: The domain organization of Pdcd4 
 
Pdcd4 contains two MA-3 domains. There are two nuclear exporting signals present within the N-terminal 
MA-3 domain. A RNA binding domain is present in the N-terminal part of the protein.  
 
2.2.4 The Subcellular Localization of Pdcd4 
 
Immunofluorescence studies in human and quail fibroblast cell line using Pdcd4 and 
hemagglutinin (HA) antibodies against recombinant Pdcd4 and HA-tagged Pdcd4 fusion 
proteins, respectively, revealed a nuclear localization of Pdcd4 (Yoshinaga et al., 1999; 
Schlichter et al., 2001b). Further, it has been shown that although Pdcd4 protein is 
predominantly a nuclear protein under normal growth conditions, it is exported from 
nucleus by a leptomycin B-sensitive mechanism upon serum withdrawal (Bohm et al., 
2003). Moreover, preliminary experiments using yeast two-hybrid system and 
separation of polysomes from cytosol in HeLa cells by sucrose density gradient 
centrifugation showed the localization of Pdcd4 to the ribosome complex (Kang 2002). 
2.2.5 The Regulation and Expression of Pdcd4 
 
Northern blot analysis of normal mouse tissues revealed higher Pdcd4 expression levels 
in the liver followed by testis, lung, brain, kidney and spleen (Onishi et al., 1998). 
Lower levels were found in skeletal muscle and heart. In most tissues the major 
transcript identified was about 2.3 kb. A similar expression pattern of Pdcd4 in mouse 
adult tissues was also found by Shibahara et al (1995) with strongest hybridization 
signals in thymus, followed by liver, intermediate signals in brain, kidney and spleen 
and least signals in lung and heart.   
 
The expression of Pdcd4 is modulated by different cytokines. Downregulation was found 
in both human natural killer and T cells by IL-2 and IL-15, but upregulation by 
treatment with IL-12, whereas IL-4 and IL-7 had no effect (Azzoni et al., 1998). 
Programmed cell death plays an important role during embryogenesis. The ovulated 
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egg is destined to undergo cell death if not fertilized. Pdcd4 levels are abundant in 
oocytes and embryonic Pdcd4 expression seems to be induced at the 8-cell stage in 
mouse embryos (Jurisicova et al., 1998). V-myb was identified as an inducer of chicken 
Pdcd4 expression (Schlichter et al., 2001b). Moreover, cloning of the promoter region 
of the Pdcd4 gene revealed the existence of myb binding sites and Pdcd4 
promoter/reporter gene constructs demonstrated the functional activity of these sites 
(Schlichter et al., 2001b). Additionally, targeted disruption of c-myb in the chicken 
DT40 B-cell line lowered the expression of the Pdcd4 gene (Appl and Klempnauer, 
2002).  
 
Pdcd4 was first identified as a gene upregulated during apoptosis (Shibahara et al., 
1995). In this study, T-cell lines, a hematopoietic progenitor cell line or a B-cell line 
were stimulated with ionomycin, dexamethasone, deprived of IL-3 or IL-2 or stimulated 
by cross-linking of surface IgM, respectively. Recently, it has been shown that 
adenoviral transfer of the Fas ligand gene elevates expression of Pdcd4 and induces 
apoptosis in HEK 293 cells (Goke et al., 2002). However, other apoptotic stimuli like 
UV-irradiation, treatment with Ara-C or topoisomerase inhibitors failed to enhance or 
even suppressed Pdcd4 expression in other cell lines (Onishi et al., 1998; Onishi and 
Kizaki, 1996). This suggests that Pdcd4 expression might be different depending on the 
apoptotic stimulus used. 
 
Phospholipase Cb3 (PLCB3) expression is frequently lost in sporadic tumors. 
Restoration of the PLCB3 levels in neuroendocrine cell lines suppresses cell growth and 
alters the phenotype indicating that PLCB3 might be relevant in tumorigenesis 
(Stalberg et al., 1999). By reverse transcription (RT) differential display it was shown 
that Pdcd4 is upregulated in PLCB3 transfected cells (Stalberg et al., 2001) stressing 
the impact of Pdcd4 as a tumor suppressor. The role of Pdcd4 in cell growth regulation 
is further emphasized by the fact that it is elevated at the mRNA and protein levels in 
cellular senescence (Kang et al., 2002). Additionally, for a human colon carcinoma cell 
line, it has been shown that after treatment with NS-398, a selective 
cyclo-oxygenase-2 (COX-2) inhibitor, mRNA levels of Pdcd4 were upregulated (Zhang 
and DuBois, 2001). COX-2 is a target of nonsteroidal anti-inflammatory drugs and 
inhibition of COX-2 may contribute to the anticancer effect of these drugs. 
 
It has been shown that expression of Pdcd4 is low in human pancreatic cancer and is 
correlated with the differentiation levels of cancer (Ma et al., 2005). Pdcd4 is 
suppressed in squamous cell carcinoma, the most frequent malignant tumor of the oral 
cavity (Carinci et al., 2005). Moreover, nasal natural killer/T-cell lymphoma is an 
aggressive subtype of non-Hodgkin lymphoma that is closely associated with 
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Epstein-Barr virus and Pdcd4 was identified as a putative contributor of the disease 
progression (Zhang et al., 2006).  
2.2.6 The Cellular Functions of Pdcd4 
 
A system that was developed for the identification of proteins that drive tumor 
promotion is the mouse epidermal JB6 model of transformation response. The 
experiments using this model suggested a tumor suppressor function for Pdcd4 (Cmarik 
et al., 1999). It has been shown that the transactivation of transcription factors 
activator protein1 (AP-1) and NF-κB is essential for tetradecanoylphorbol acetate 
(TPA)- or TNFα-induced neoplastic transformation (Hsu and Twu, 2000). TPA-induced 
AP-1 dependent transactivation and basal AP-1 activity was inhibited in a 
concentration-dependent manner and similar results from another cell line confirmed 
this observation (Yang et al., 2003b). The inhibition involves phosphorylation of Pdcd4 
at Ser-67 and Ser-457 by Akt kinase (Palamarchuk et al., 2005). Besides its effect on 
AP-1 there is evidence that Pdcd4 also acts via other signaling pathways, including 
TGFβ (zhang, 2006).  
 
Sequence alignments revealed a significant amino acid homology of Pdcd4 with the 
proteins of eIF4G family (Goke et al., 2002). Additionally, Pdcd4 contains two 
conserved MA-3 domains which is also present in the eucaryotic translation initiation 
factors eIF4G I and eIF4G II. The MA-3 domain is thought to be involved in 
protein-protein interactions and enables eIF4G to interact with eIF4A (Ponting, 2000). 
The eIF4A is an ATP-dependent RNA helicase that unwinds the mRNA to allow the 
ribosome to migrate in the 3′direction to locate the initiation codon AUG. Moreover, it 
has been shown by coimmunoprecipitation experiments that Pdcd4 directly interacts 
with eIF4A suggesting that Pdcd4 has an impact on protein translation (Goke et al., 
2002) which was confirmed by Yang et al. who identified eIF4A as a Pdcd4-interacting 
protein using a yeast two-hybrid system (2003a). Multicolor confocal 
immunofluorescence microscopy revealed a colocalization of eIF4A with Pdcd4 in the 
cytoplasm with a concentrated perinuclear distribution. Furthermore, Pdcd4 inhibited 
helicase activity in a concentration-dependent manner and acts as a specific dominant 
inhibitor of eIF4A (Yang et al., 2003a). This data were confirmed by in vitro and in vivo 
translation assays showing that Pdcd4 preferentially inhibits cap-dependent translation. 
Moreover, in in vitro binding assays Pdcd4 prevented binding of eIF4A to the C-terminal 
part of eIF4G. Interestingly, the mechanisms of action of Pdcd4 and the impact on 
protein translation seem to be even more complex since Kang et al. recently reported a 
direct interaction of Pdcd4 with eIF4G (2002). The inhibitory effect of Pdcd4 on 
translation initiation factors might explain its function as transformation inhibitor. 
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2.2.7 The Molecular Mechanisms of the Functions of Pdcd4 
 
It has been shown that Pdcd4 suppresses the transactivation of AP-1 responsive 
promoters by c-Jun, suggesting that the transformation-suppressor activity of Pdcd4 
might be partly due to the inhibition of c-Jun activity. Bitomsky et al. (2004) addressed 
the mechanisms of inhibition of c-Jun by Pdcd4. It was shown that Pdcd4 interferes 
with the phosphorylation of c-Jun by Jun N-terminal kinase (JNK). Moreover, it was 
suggested that Pdcd4 interacts with c-Jun and thereby blocks the phosphorylation of 
c-Jun. In addition to affecting c-Jun phosphorylation, Pdcd4 blocks the recruitment of 
the coactivator p300 by c-Jun. 
 
Lankat-Buttgereit et al. (2004) showed that Pdcd4 suppresses carbonic anhydrase type 
II protein expression in HEK293 and Bon-1 carcinoid cells. As the tumor cells require a 
high bicarbonate flux for their growth, carbonic anhydrase suppression results in 
growth inhibition. Similar to Pdcd4, carbonic anhydrase inhibitor ethoxyzolamide 
reduces growth of several endocrine tumor cell lines. Thus, it was suggested that the 
translation inhibitor Pdcd4 represses endocrine tumor cell growth by suppression of 
carbonic anhydrase II. 
 
Jansen et al. (2004) studied the relevance of Pdcd4 in a range of human cancers 
derived from multiple tissue sites. The hypothesis tested was that Pdcd4 levels would 
be prognostic or fundamental for antitumor activity of current or exploratory 
chemotherapeutic compounds. Pdcd4 expression patterns from the national cancer 
institute drug-screening panel of 60 human cancer cells (NCI60) were analyzed by 
western blotting. It revealed a frequent reduction of Pdcd4 protein levels in renal-, 
lung-, and glia-derived tumors. Pdcd4 was found to correlate with the antitumor 
activity of geldanamycin and tamoxifen. It was observed that the increased sensitivity 
of UO-31 cells to geldanamycin was accompanied by enhanced cell cycle arrest and 
apoptosis.  
 
Eucaryotic cells regulate gene expression at multiple levels, such as transcription, 
splicing, stability and translation of mRNA. Transcriptional dysregulation is a 
well-studied contributor to cancer pathogenesis; increasing evidence implicates altered 
translational regulation as well (Jansen et al., 2005). Translation initiation is the 
predominant rate-limiting step of protein synthesis for most mRNAs. Exposure to skin 
tumor promoters, such as TPA enhances the formation of the translation initiation 
complex. Several tumors and tumor cell lines show elevated levels of components of 
the translation initiation complex, including eIF4A (Eberle et al., 1997), eIF4E (De 
Benedetti and Harris, 1999), and eIF4G (Bauer et al., 2001). Pdcd4 seems to be the 
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first example of a protein in mammalian cells that inhibits directly the helicase activity 
of eIF4A, a component of the translation initiation complex.  Jansen et al. (2005) 
generated a transgenic mouse that overexpresses Pdcd4 in the epidermis to ascertain 
whether Pdcd4 suppresses tumor development in vivo. In response to the 7, 
12-dimethylbenz(a) anthracene/TPA mouse skin carcinogenesis protocol, Pdcd4 
overexpressing mice showed significant reductions in the papilloma formation, 
carcinoma incidence, and papilloma-to-carcinoma conversion frequency compared to 
wild-type (WT) mice.  
 
The translational efficiency of an mRNA engineered to form a structured 5´untranslated 
region (UTR) was attenuated in primary keratinocytes when Pdcd4 was overexpressed. 
Pdcd4 inhibited by 46%, the TPA-induced AP-1-dependent transcription, an event 
involved in tumorigenesis. Cyclin dependent kinase and ornithine decarboxylase are 
candidates for Pdcd4-regulated translation as their mRNAs contain 5´structured UTRs. 
These results extend to an in vivo model to confirm the observations that Pdcd4 inhibits 
both translation initiation and AP-1 activation while decreasing benign tumor 
development and malignant progression.  
 
Zhang et al. (2006) elucidated the function and regulatory mechanisms of expression 
of Pdcd4 in human hepatocellular carcinoma. It was reported that Pdcd4 protein is 
downregulated and it is a proapoptotic molecule which is involved in transforming 
growth factor-β1 (TGF-β1)-induced apoptosis in human hepatocarcinoma cells. 
 
Furthermore, it was reported recently that Pdcd4 suppresses tumor progression in 
human colon carcinoma cells by downregulating MAP4K1 transcription, with consequent 
inhibition of c-Jun activation and AP-1 transcription (Yang et al., 2006). Pdcd4 blocks 
c-Jun activation by inhibiting the expression of mitogen-activated protein kinase kinase 
kinase kinase 1 (MAP4K1)/hematopoietic progenitor kinase 1, a kinase upstream of Jun 
N-terminal kinase (JNK). The cDNA microarray analysis of Pdcd4 overexpressing RKO 
human colon carcinoma cells revealed MAP4K1 as the sole target of Pdcd4 on the JNK 
activation pathway. Overexpression of either Pdcd4 or dominant negative MAP4K1 
mutant in metastatic RKO cells inhibited not only c-Jun activation but invasion as well.  
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2.3 Objectives and Rationale of the Study  
Pdcd4 is a novel gene originally identified as a gene upregulated during apoptosis 
(Shibahara et al., 1995), but later recognized as a tumor suppressor (Cmarik et al., 
1999). The molecular functions of Pdcd4 such as the role of RNA binding and 
translational regulation have not been characterized in detail.  The molecular 
mechanism by which Pdcd4 executes its function and the biological significance of its 
biochemical activities are yet to be unraveled. Apparently, the primary limitation for the 
further analysis of molecular functions of Pdcd4 is the lack of a well-characterized cell 
system, in which the Pdcd4 expression level can be modulated.  
2.3.1 Pdcd4 Models 
 
Gene-function studies require careful selection of representative models to ensure that 
the experimental findings do reflect the role of a gene in the organism. In molecular 
biology, based on the reverse genetic approach, generally two basic models are 
employed to study the function of a particular gene, viz., downregulation (knock-out or 
knock-down) and upregulation (overexpression) systems.  In the present work, three 
cell systems were developed and characterized: A Pdcd4 knock-down system, a Pdcd4 
knock-out system and a Pdcd4 overexpression system. The all three systems were 
employed to elucidate the molecular functions of the Pdcd4 gene. In particular, the 
primary aim was the identification of novel molecular targets for Pdcd4 by utilizing the 
three systems. Once identified, these novel targets of Pdcd4 could be used to further 
uncover the signaling pathways by which Pdcd4 functions as a tumor suppressor.  
2.3.2 Pdcd4 Downregulation System 
 
For studying the function of a gene, in particular, of a tumor suppressor gene, a 
downregulation cell system will be very useful as the gene of interest is completely or 
almost completely eliminated from the cell. This mimics the cancer cell in which the 
functional copies of tumor suppressor genes are inactivated during tumorigenesis.    
 
Pdcd4 Knock-down System 
The knock-down of Pdcd4 was attempted by RNA interference (RNAi) which is mediated 
through short double-stranded RNA molecules, known as small interfering RNA (siRNA). 
Formation of siRNA duplexes of 19-25 nt length followed by incorporation into the 
RNA-induced silencing complex (RISC) catalyzes cleavage of complementary mRNAs 
(Hammond, 2001). The knock-down system is preferred, due to two major advantages. 
First, silencing by siRNA is highly specific.  Second, RNAi knock-down efficiencies range 
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from the entire extinguishing of the gene function to a graded loss-of function (Sui, 
2002). It has been found after analyzing over 60 cancerous cell lines that inactivation 
of tumor suppressor genes occurs not only through gene mutation or deletion but 
alternatively also as a result of reduced gene expression (Jansen et al., 2004). For 
example, most of the non-small lung cancer cell lines and renal cancer cell lines 
showed less than mean Pdcd4 protein level (Jansen et al., 2004). As Pdcd4 showed 
altered gene expression in many cancers, knock-down system generated by RNAi 
mediated siRNA silencing is an apt tool for studying its function. The HeLa cell line was 
selected for developing the human Pdcd4 knock-down system. HeLa is an established 
cell line derived from cervical epithelial cells of adenocarcinoma origin. RNA and protein 
analysis of HeLa cells have shown that they express detectable amounts of Pdcd4 
(Boehm, 2005).   
 
Pdcd4 Knock-out System 
Generating a Pdcd4 knock-out cell system was also of interest, as it could simulate 
tumors, in which expression of Pdcd4 is entirely eliminated. Complete loss of Pdcd4 
protein was shown in several central nervous system tumors whereas their normal 
counterparts shown readily detectable Pdcd4 by immunohistochemical analysis (Jansen 
et al., 2004). The knock-out system was generated by homologous recombination, a 
procedure in which engineered targeting constructs are integrated into the genome and 
thereby disrupt the gene of interest. 
 
Exchange of sequence information between two homologous DNA molecules, referred 
to as homologous recombination, makes a major contribution to the repair of DNA 
damage and thereby contributes to the preservation of genome integrity (Modesti and 
Kanar, 2001). This natural phenomenon can be exploited in gene targeting to disrupt a 
gene of interest in a predetermined way. In classical homologous gene targeting, a 
fragment homologous to the locus to be modified is transfected in the cell. If one can 
select for insertion in the genome (with a selectable marker placed between flanking 
homologous DNA sequences), the majority of the insertion events in most organisms 
will be found at random locations all over the genome. A few events will result from the 
integration at the homologous locus by homologous recombination; however, one 
needs to screen extensively for such rare events. This is not the case in a limited 
number of organisms and cell types where homologous integration is predominant. As 
the avian DT40 lymphoid cell line has extremely high rate of homologous 
recombination, the DT40 cell line was chosen for creating Pdcd4 knock-out cell system. 
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2.3.3 Pdcd4 Upregulation System 
 
In addition to the downregulation system, cells overexpressing Pdcd4 were also 
generated. Although overexpression of a gene is an artificial condition, it might mimic 
the function of the gene in the normal cell. A549 is an epithelial human lung carcinoma 
cell line. A study has shown that Pdcd4 expression is widely lost in lung tumor cells. In 
addition, Pdcd4 might be a prognostic factor in lung cancer and may correlate with 
tumor progression (Chen et al., 2003). Therefore, the A549 cell line was chosen for the 
overexpression of Pdcd4 and thereby to revoke the normal functions of Pdcd4.  
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3 MATERIALS AND METHODS 
3.1 Materials  
3.1.1 Antibodies 
 
Antibody Catalog No. Firm/Company 
AKR1C2 Mouse Polyclonal IgG  A01 Abnova, Taipei, Taiwan 
AKR1C3 Goat Polyclonal IgG IMG-3773 Imagenex, CA, USA 
ATF-2  (N-96) Rabbit Polyclonal 
IgG 
Sc-6233 Santa Cruz BiotechnologY, CA, USA 
p-ATF-2 (F-1) Mouse Monoclonal 
IgG 
Sc-8398 Santa Cruz Biotechnology, CA, USA 
C/EBPβ Rabbit  Polyclonal  
Antiserum 
- Mink et al., 1996 
c-Jun (D) Rabbit Polyclonal IgG Sc-44 Santa Cruz BiotechnologY, CA, USA 
p-c-Jun (KM-1) Mouse Monoclonal 
IgG 
Sc-822 Santa Cruz Biotechnology, CA, USA 
c-Myc Rabbit Polyclonal IgG sc-764 Santa Cruz Biotechnology, CA, USA 
CK-8/18 Mouse Monoclonal IgG DLN-10749 Dianova, Hamburg, D 
CK-17 Mouse Monoclonal IgG C9179 Sigma-Aldrich, Missousri, USA 
GluProRS Rabbit Polyclonal IgG ab31531 Abcam, Hiddenhausen, D 
HA.11 Mouse Monoclonal IgG  Covance, CA, USA 
Human Pdcd4 Rabbit Polyclonal 
Antiserum 
- Eurogentec, Seraing, B 
β-tubulin Mouse Monoclonal IgG Sc-5274 Santa Cruz Biotechnology, CA, USA 
Anti-Mouse HRP Conjugated IgG P0260 Dako-Diagnostika GmbH, Hamburg, D 
Anti-Rabbit HRP Conjugated IgG P0217 Dako-Diagnostika GmbH, Hamburg, D 
Anti-Goat HRP Conjugated IgG A-5420 Sigm-Biochemicals, D 
3.1.2 Cell Culture Products 
 
Neubauer haemocytometer  Merck AG, Darmstadt, D 
Chicken serum PAA Laboratories GmbH, Linz, AU 
Dulbecco’s MEM-medium Biochrom KG, Berlin, D 
Fetal bovine serum Biochrom KG, Berlin, D 
Iscove’s modified Dulbecco’s medium Biochrom KG, Berlin, D 
L-Glutamine Biochrom KG, Berlin, D 
MEM-medium Biochrom KG, Berlin, D 
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Non-essential amino acids Biochrom KG, Berlin, D 
PBS Buffer Biochrom KG, Berlin, D 
Penicillin / Streptomycin Biochrom KG, Berlin, D 
RPMI 1640 medium Biochrom KG, Berlin, D 
Tissue culture flasks Greiner Labortechnik, Solingen, D 
Tissue culture dishes Greiner Labortechnik, Solingen, D 
Trypsin/EDTA solution Biochrom KG, Berlin, D 
3.1.3 Chemicals and Reagents 
 
The standard chemicals were purchased from Acros Organics, New Jersey, USA; 
Amersham Bioscience, Freiburg, D; AppliChem, Darmstadt, D; Baker, Deventer, NL; 
Becton Dickinson, Detroit, USA; Biomol Feinchemikalien GmbH, Hamburg, D; Difco 
Laboratories, Detroit, USA; Merck KGaA, Darmstadt, D; Sigma-Aldrich Chemie GmbH 
(including Fluka), München, D; Gibco BRL Life Technologies, Eggenstein; ICN 
Biomedical, Ohio, USA; Invitrogen, Groningen, NL; Merck AG, Darmstadt; Roche, 
Mannheim; Fermentas, St. Leon-Rot. Special chemicals were obtained from the 
following companies. 
 
[α-32P]-dCTP (10µCi/µl, ~3000Ci/mmol) Amersham Bioscience, Freiburg, D 
L-[35S] in vitro Cell Labeling Mix Amersham Bioscience, Freiburg, D 
2 K Acrylamide (30%)-Mix 37.5:1 AppliChem, Darmstadt, D 
Adenosine-5’-triphosphate (ATP) Amersham Bioscience, Freiburg, D 
Agar Sigma-Aldrich Chemie GmbH, München, D 
Agarose Gibco BRL Life Technologies, Eggenstein 
Ampicillin Sigma-Aldrich Chemie GmbH, München, D 
Ammonium per sulfate (APS) Merck KGaA, Darmstadt, D 
(β-D-arabinofuranosyl) cytosine Sigma-Aldrich Chemie GmbH, München, D 
Β-Gal-Elisa-lysis-buffer Roche, Mannheim, D 
Blasticidin S Invitrogen, Karlsruhe, D 
Cationic polymer transfection reagent Eurogentec, Belgium, DK 
Coomassie Brilliant Blue R250 Merck KGaA, Darmstadt, D 
Dithiothreitol Sigma-Aldrich Chemie GmbH, Steinheim, D 
D-Luciferin AppliChem, Darmstadt, D 
DNA-SmartLadder Eurogentec, Lige, B 
Doxycycline Sigma-Aldrich Chemie GmbH, Steinheim, D 
dNTP-Set Roche, Mannheim, D 
DryStrip pH 3-10, 13 cm Amersham Bioscience, Freiburg, D 
DryStrip pH 4-7, 13 cm Amersham Bioscience, Freiburg, D 
 
 
3 MATERIALS AND METHODS  22 
DryStrip pH 6-11, 13 cm Amersham Bioscience, Freiburg, D 
ECL western blotting detection reagent Amersham Bioscience, Freiburg, D 
EDTA Biomol Feinchemikalien GmbH, Hamburg,D 
Emerald enhancer Perkin Elmer, Weiterstadt, D 
Ethidium bromide  Sigma-Aldrich Chemie GmbH, Steinheim, D 
Ethyl methane sulfonate Sigma-Aldrich Chemie GmbH, Steinheim, D 
Film developing solution Dunker, Hattingen, D 
Film fixation solution Dunker, Hattingen, D 
Galacton Perkin Elmer, Weiterstadt, D 
HEPES  Sigma-Aldrich Chemie GmbH, Steinheim, D 
Immobiline drystrip cover fluid Amersham Bioscience, Freiburg, D 
IPG Buffer 3-10 Amersham Bioscience, Freiburg, D 
IPG Buffer 4-7 Amersham Bioscience, Freiburg, D 
IPG Buffer 6-11 Amersham Bioscience, Freiburg, D 
IPTG Biomol, Hamburg, D 
L-Histidinol dichloride Sigma-Aldrich Chemie GmbH, München, D 
Lysozyme  Sigma-Aldrich Chemie GmbH, München, D 
Mitomycin C Merck KGaA, Darmstadt, D 
NP-40 Fluka Chemie AG, Buchs, S 
Phenol-Chloroform-Isoamylalcohol 
(25:24:1) 
Merck AG, Darmstadt, D 
 
Phorphol-12-myristate-13-acetate Calbiochem, Darmstadt, D 
Prestained molecular weight marker 7B Sigma-Aldrich Chemie GmbH,Steinheim, D 
Puromycin dichloride Merck KGaA, Darmstadt, D 
Rapid-gel-acrylamide 40% USB corporation, OH, USA 
Skim milk powder for microbiology Merck AG, Darmstadt, D 
Staurosporine Sigma-Aldrich Chemie GmbH, München, D 
TEMED Sigma-Aldrich Chemie GmbH, Steinheim, D 
Triton X-100 Biorad, Hercules, USA 
Trypton Difco Laboratories, Detroit, USA 
X-Gal Biomol, Hamburg, D 
Yeast extract Difco Laboratories, Detroit, USA 
Zeocin Invitrogen, Karlsruhe, D 
3.1.4 Devices and Instruments 
 
Agfa Curix60 (Film Developer) Agfa AG, Leverkusen, D 
Auto Lumat LB953 EG & G Berthold, Bad Wildbach, D 
BASReader BAS-1800II Raytest, Stauberstadt 
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Blotting device Trans-Blot CELL Biorad, München 
Centrifuges  
         Avanti 300 Beckmann, München, D 
         Centrifuge 5810 R Eppendorf, Hamburg, D 
         Centrifuge 5415 D Eppendorf, Hamburg, D 
         Centrifuge 5417 R Eppendorf, Hamburg, D 
         Centrifuge IL-21 (Rotor JA-14, 10.5) Beckmann, München, D 
         TL-100 Ultracentrifuge Beckmann, München, D 
CO2 Incubator WTB Binder, Tuttlingen, D 
Electroporator Easyjekt Plus Peqlab, Erlangen 
FACScan Flow Cytometer Becton Dickinson, Heidelberg, D 
Films  
        BioMaX XAR Scientific Imaging Film Eastman Kodak Company, NY, USA 
        RX Scientific Imaging Films W.Plus Röntgen GmbH, Kamp-Lintfort, D 
Film developer Agfa CuriX60 Agfa AG, Leverkusen 
Gel dryer Biorad, München 
Heating Circulator MB-5 Julabo Labortechnik GmbH, Seelbach, D 
Laminar flow hood Zapf Instruments, Sarstedt, D 
IPG-Electroporesis System Amersham Biosc.,, Buckinghamshire, UK 
IPG-strip holder (ceramic) Amersham Pharmacia Biotech, Freiburg, D 
LiCOR Gene ReadIR 4200 MWG-Biotech, Ebersberg  
Mastercycler Gradient Eppendorf, Hamburg, D 
Nitrocellulose membrane (Protran) Schleicher & Schuell, Dassel,D 
Nylon membrane (Gene Screen Plus® ) Perkin Elmer, MA, USA 
pH-Meter CG840 Schott, Hofheim, D 
Phosphor-Imager BAS-1800 II FUJIFILM, Düsseldorf 
Power Pac 300 Biorad, München, D 
Power Supply ECPS 3000/150 Amersham Bioscience, Freiburg, D 
SDS-gel device (Hoefer SE 660) Amersham Bioscience, Freiburg, D 
UV-Spectrometers  
        Gene Quant II Pharmacia, Freiburg 
        UV-1602 SHIMADZU, Duisburg 
VorteX L46 Labinco BV, NL 
Whatman paper 3MM Schleicher & Schüll, Dassel, D 
3.1.5 Enzymes 
 
Dnase I Roche, Mannheim, D 
Klenow-Polymerase Roche, Mannheim, D 
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Proteinase K Roche, Mannheim, D 
Restriction Enzymes New England Biolabs, Schwalbach, D 
Rnase Roche, Mannheim, D 
Taq-DNA-Polymerase Gibco BRL Life Technologies, Eggenstein, D 
T4 DNA Ligase New England Biolabs, Schwalbach, D 
3.1.6 Genotype of Escherichia coli K12 strains 
 
Top10F´: F’ [lacIq, Tn10(TetR)] mcrA ∆(mrr-hsdRMS-mcrBC) Φ80 lacZ∆M15 ∆lacX74 
deoR recA1 araD139 ∆ (ara,leu)7697 galU galK rpsL (StrR) endA1 nupG 
3.1.7 Kits 
 
Complete Mammalian Protein Extraction Kit Calbiochem, Darmstadt, D 
Dual Luciferase Reporter Assay System Promega GmbH, Mannheim, D 
DYEnamic Direct cycle sequencing Kit  Amersham Bioscience, Freiburg, D 
Nucleobond Kit PC 500 Macherey-Nagel, Düren, D 
NucleoSpin Mini Plasmid Quick Pure Macherey-Nagel, Düren, D 
Megaprime DNA-labeling-Kit Amersham Bioscience, Freiburg, D 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden, D 
QIAprep Spin Miniprep Kit Qiagen, Hilden, D 
QIAquick Gel Extraction Kit Qiagen, Hilden, D 
Rapid-DNA-Ligation-Kit Roche, Mannheim, D 
TOPO TA Cloning Kit Invitrogen, Karlsruhe, D 
3.1.8 Plasmids and Constructs 
 
The following vectors and constructs were used in the present research work. 
 
Plasmid/Construct Description 
pCR®2.1-TOPO® ~3.9 Kb, Ampr, Kanr, PLac/LacZα, T/A-Cloning vector for 
cloning the PCR-products (Blue/White-Screening) 
(Invitrogen) 
pBlueScript KS ~3 Kb, Ampr, lacZ promoter, a cloning vector (Stratagene) 
pbl-pdcd4-targetHisD ~9.7 Kb, histidinol resistance under the control of β-actin 
promoter, the targeting construct flanked by the genomic 
DNA sequences from the major part of the chicken Pdcd4 
gene (Bitomsky, 2003)  
 
 
3 MATERIALS AND METHODS  25 
pbl-pdcd4-targetPuro ~8.7 Kb, puromycin resistance under the control of β-actin 
promoter, the targeting construct flanked by the genomic 
DNA sequences from the major part of the chicken Pdcd4 
gene (Bitomsky, 2003) 
pcDNA3 ~5.4 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for β-galactosidase, (Invitrogen) 
pcDNA3-CCR 
 
~6.6 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the chicken C/EBPβ without upstream region (Mink 
et al., 1997) 
pcDNA3-c-Jun ~6.6 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the human c-Jun (Schwarz et al., 2003) 
pcDNA3-i11/6HA  ~6.9 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the chicken Pdcd4-HA tagged (Schlichter et al., 
2001b)
pcDNA4/TO/myc-His 5.1 Kb, Ampr, CMV-promoter, eucaryotic tetracycline 
inducible expression vector (Invitrogen) 
pcDNA4TomycHis-
i11/6HA 
6.6 Kb, Ampr, Zeor, CMV-promoter, eucaryotic tetracycline 
inducible expression vector codes for the chicken Pdcd4-HA 
tagged (Schlichter et al., 2001b)
pcDNA4-Hpdcd4 6.6 Kb, Ampr, Zeor, CMV-promoter, eucaryotic expression 
vector codes for the human Pdcd4 
pcDNA6/TR ~6.7 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the tetracycline repressor protein (Invitrogen) 
pCI-neo ~5.5 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
pCI-neo WT β-Globin ~6.9 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the wild-type β-Globin (Neu-Yilik et al., 2001)   
pCI-neo NS39 β-
Globin 
~6.9 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the β-Globin having a nonsense mutation at 39 
(Neu-Yilik et al., 2001) 
pcMVβ 7.2 Kb, Ampr, CMV-promoter eucaryotic expression vector for 
β-galactosidase, (Clontech, GmbH, Hamburg) 
pCMVluc Ampr, CMV-promoter, eucaryotic expression vector for firefly 
luciferase (600 bp Nru/HindIII-fragment from pcDNA3 is 
cloned into the SmaI/HindIII restriction sites of pGL3 basic 
vector). pGL3 basic is a eucaryotic expression vector for 
firefly luciferase under SV40 promoter 
pCMV-RL Ampr, CMV-promoter, eucaryotic expression vector codes for 
firefly and renilla luciferase reporter genes. The CMV-
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promoter (654 bp) from pcDNA3 was cloned into phRnull 
(~3.3 Kb, Promega) vector (Ahlbory, 2005) 
pGL3’  ~5.3 Kb, Ampr, SV40-promoter, eucaryotic expression vector 
codes for firefly luciferase (Haines, UK) 
phc-jun(-1600/+740) 
–Luc 
Ampr, pXPI-eucaryotic expression vector codes for the human 
c-Jun promoter (-1600 to +740 bp) followed by luciferase 
gene 
phpL ~5.4 Kb, Ampr, SV40-promoter, eucaryotic expression vector 
codes for a RNA secondary structure followed by firefly 
luciferase gene (Haines, UK) 
pRF ~6.5 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the renilla and firefly luciferases 
pRApaf1F ~6.7 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the renilla and firefly luciferases, Apaf-1 IRES 
element of 233 bp is inserted in between the two luciferases 
(Coldwell et al., 2000) 
pRc-MycF ~6.9 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for the renilla and firefly luciferase, c-Myc IRES 
element of ~400 bp is inserted in between the luciferases 
(Stoneley et al., 1998) 
pRMntF ~6.7 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for renilla and firefly luciferases, Mnt IRES element of 
~200 bp is inserted in between the two luciferases (Stoneley 
et al., 2001) 
pRN-MycF ~6.9 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for renilla and firefly luciferase, N-Myc IRES element of 
~400 bp is inserted in between the two luciferases (Jopling 
and Willis, 2001) 
pRSVc-Jun 5.4 kb, Ampr, RSV-promoter, eucaryotic expression vector 
codes for the human c-Jun (~1.8 kb ) (Angel et al., 1988) 
pRXiapF ~8.1 Kb, Ampr, CMV-promoter, eucaryotic expression vector 
codes for renilla and firefly luciferase, Xiap IRES element of 
~1.6 bp is inserted in between the luciferases (Holcik and 
Korneluk, 2000) 
pSG5-NFM#16.3 ~5.4 Kb, Ampr, SV40-promoter, eucaryotic expression vector 
codes for full length C/EBPβ 
pTER+ ~5.3 Kb, Ampr, Zeor, H1 promoter (modified with tetracycline 
operator region), eucaryotic inducible expression vector. 
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Derived from the pTER vector (4.5 Kb) inserted with 750 bp 
spacer region between the BglII/HindIII restrinction sites 
(Watering et al.,2003) 
pUC18 ~2.7 Kb, Ampr , LacZ promoter, a cloning vector (Invitrogen) 
pUC19 ~2.7 Kb, Ampr , LacZ promoter, a cloning vector (Invitrogen) 
3.1.9 Primers 
 
Primer 5’               3’ sequence Tm/°C 
BGH_rev  
(modified 5’ IRD 800) 
TAG AAG GCA CAG TCG AGG 56.0 
human_pdcd4_cp_for CTG GAT CCG CCA CCA TGG ATG TAG AAA ATG 
AGC AG 
71.8 
human_pdcd4_cp_rev TCC TCG AGT TAG GCG TAG TCG GGC ACG TCG 
TAG GGG TAG TAG CTC TCT GGT TTA 
>75 
human_pdcd4_sense ATG GAT GTA GAA AAT GAG CAG 54.0 
human_pdcd4_antisen TCA GTA GCT CTC TGG TTT AA 53.2 
M13 Forward Primer GTA AAA CGA CGG CCA GT 52.8 
M13 Reverse Primer GGA AAC AGC TAT GAC CAT G 54.5 
siRNAhumpdcd4_603s GAT CCC CGT GTT GGC AGT ATC CTT AGT TCA 
AGA GAC TAA GGA TAC TGC CAA CAC TTT TTA 
>75 
siRNAhumpdcd4_603as AGC TTA AAA AGT GTT GGC AGT ATC CTT AGT 
CTC TTG AAC TAA GGA TAC TGC CAA CAC GGG 
>75 
siRNAhumpdcd4_1260s GAT CCC CCA TTC ATA CTC TGT GCT GGT TCA 
AGA GAC CAG CAC AGA GTA TGA ATG TTT TTA 
>75 
siRNAhumpdcd4_1260as AGC TTA AAA ACA TTC ATA CTC TGT GCT GGT 
CTC TTG AAC CAG CAC AGA GTA TGA ATG GGG 
>75 
T7 Primer 
(modified 5’ IRD 800) 
AAT ACG ACT CAC TAT AG 45.5 
T3 Primer 
(modified 5’ IRD 800) 
ATT AAC CCT CAC TAA AG 45.5 
3.1.10 Standard Buffers and Solutions 
 
Buffer Quantity Constituent 
Annealing Buffer pH 7.4 100 mM 
30 mM 
2 mM 
Potassium acetate 
HEPES 
Magnesium acetate 
DNA-Loading Buffer (5X)  20% (w/v) Ficoll-400 
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(Agarose gel ) 0.25% (w/v) Orange G 
DNA-Loading Buffer (5X)  
(Sequencing gel) 
96% 
20 mM  
0.05% (w/v) 
0.05% (w/v) 
Formamide, deionized 
EDTA 
Bromophenol blue 
Xylencyanol FF 
PBS-Buffer (10X) pH 7.4 137 mM 
2.7 mM 
4.3 mM  
1.4 mM 
Sodium chloride 
Potassium chloride 
Disodium hydrogen phosphate 
Potassium dihydrogen phosphate 
RIPA Lysis Buffer 10 mM 
50 mM 
0.5% (w/v) 
0.1% (w/v) 
1 mM 
Tris-HCl pH 7.8 
Sodium chloride 
Sodiumdeoxycholate 
NP-40 
SDS 
Sequencing Gel Buffer 336 g 
80 ml 
448 ml 
Urea 
TBE long run buffer (10X) 
Water 
SSC-Buffer (20X) 
pH 7.0 
3 M 
0.3 M 
Sodium chloride 
Sodium citrate-dihydrate 
TAE (50X) 
pH 7.6 
2 M 
2 M 
0.05 M  
Tris base 
Sodium acetate 
EDTA 
TBE-Buffer Long run (10X) 
pH ~ 8.3 
0.89 M 
0.89 M  
20 mM  
Tris base 
Boric acid 
EDTA 
TE-Buffer (1X) 10 mM 
1 mM 
Tris-HCl 
EDTA 
Plasmid DNA Isolation   
Resuspension Buffer 5 mM 
10 mM 
25 mM 
Sucrose 
EDTA 
Tris-HCl pH 8.0 
RNase (add freshly) 
Lysis Buffer 0.2 M 
1% (w/v) 
Sodium hydroxide 
Sodium dodecyl sufate (SDS) 
Neutralization Buffer 3M Potassium acetate 
Genomic DNA Isolation   
Lysis Buffer 100 mM 
10 mM 
Sodium chloride 
Tris-HCl pH 8.0 
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50 mM 
0.5% (w/v) 
20 µg/ml 
100 µg/ml 
EDTA 
SDS 
RNase A 
Proteinase K 
PolyA RNA Isolation   
Lysis Buffer 500 mM 
10 mM 
10 mM 
Sodium chloride 
Tris-HCl pH 7.2 
EDTA 
Binding Buffer 0.5 M 
10 mM 
0.1 mM 
0.2% (w/v) 
Sodium chloride 
Tris-HCl pH 7.2 
EDTA 
SDS 
Wash Buffer 100 mM 
10 mM 
0.1 mM 
0.2% (w/v) 
Sodium chloride 
Tris-HCl pH 7.2 
EDTA 
SDS 
Elution Buffer 10 mM 
0.1 mM 
0.2% (w/v) 
Tris-HCl pH 7.2 
EDTA 
SDS 
Southern Blotting   
DNA-Loading Buffer (5X) I 
(Southern Blotting) 
50% (v/v) 
0.25% (w/v) 
0.25% (w/v) 
Glycerol 
Bromphenol blue 
Xylencyanol FF in 0.5X TBE 
20X SSC 0.3 M 
3 M 
Sodium citrate pH 7.0 
Sodium chloride 
Denaturation Buffer I 0.5 M 
1 M 
Sodium hydroxide 
Sodium chloride 
Neutralization Buffer I 0.5 M 
1. 5 M 
Tris-HCl 
Sodium chloride 
Denaturation Buffer II 0.4 M Sodium hydroxide 
Neutralization Buffer II 0.2 M Tris-HCl in 1X SSC 
Hybridization Solution 5X 
20 mM 
5X 
1% (w/v) 
50% (v/v) 
15 µg/ml 
SSC 
Sodium phosphate buffer pH7.0 
Denhardt’s Solution 
SDS 
Formamide, deionised 
Denatured Salmon sperm DNA 
denatured by heat at 95°C, 10 min 
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Denhardt’s Solution (50X) 1% (w/v) 
1% (w/v) 
1% (w/v) 
Ficoll 
Polyvinyl pyrrolidone 
BSA 
Washing Solution I 5X 
0.1% (w/v) 
SSC 
SDS 
Washing Solution II 2X 
0.1% (w/v) 
SSC 
SDS 
Stripping Solution 0.1X  
1% (w/v) 
SSC 
SDS 
Northern Blotting   
RNA Loading  Buffer 50% (v/v) 
10% (v/v) 
18% (v/v) 
0.2% (w/v) 
Formamide, deionized 
10X MOPS pH 7.0 
37% Formaldehyde  
Bromophenol blue 
10X MOPS 0.2 M 
0.1 M 
0.01 M 
MOPS pH 7.0 
Sodium acetate 
EDTA 
20X SSPE 0.2 M 
3 M 
0.02 M 
Sodium dihydrogen phosphate pH 7.4 
Sodium chloride 
EDTA 
Hybridization Solution 5X 
5X 
50% (v/v) 
1% (w/v) 
10% (w/v) 
15 µg/ml 
SSPE 
Denhardt’s Solution 
Formamide, deionised 
SDS 
Dextran sulfate sodium salt 
Denatured Salmon sperm DNA,  
denatured by heat at 95°C for 10 min 
Transfection   
DNA-Precipitation Buffer 10 mM 
1 mM 
300 mM 
Tris-HCl pH 7.8 
EDTA 
Sodium chloride 
Glycerol-Shock Solution 15% (v/v) 
1X  
Glycerol 
HBS 
β-Galactosidase Assay   
Reaction Buffer  0.1 M 
1 mM 
0.001% (v/v) 
Sodium dihydrogen phosphate  pH 8.0 
Magnesium chloride 
Galacton 
Stop Buffer 0.2 M Sodium hydroxide 
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5% (v/v)  Emerald as enhancer 
Luciferase Assay   
Reaction Buffer  25 mM 
2.2 mM 
11.2 mM 
Glycyl-Glycine pH 7.8 
ATP 
Magnesium chloride 
Injection Buffer 25 mM Glycyl-Glycine pH 7.8 
Isoelectric Focusing   
Rehydration Buffer 8M 
2% (w/v) 
Pinch 
2.8 mg/ml 
0.5% (v/v) 
Urea 
Triton-X-100 
Bromophenol bule 
DTT 
IPG buffer 
Equilibration Buffer 50 mM 
6 M 
30% (v/v) 
2% (w/v) 
10 mg/ml 
25 mg/ml 
Pinch 
Tris-HCL pH 8.8 
Urea 
Glycerol 
SDS 
DTT 
Iodoacetamide 
Bromophenol blue 
SDS-PAGE   
Laemmli Buffer (3X) [-DTT] 
 
187 mM  
6% (w/v) 
30% (w/v) 
0.01% (w/v) 
5%  
Tris / HCl, pH 6.8 
SDS 
Glycerol 
Bromophenol blue 
1 M DTT (added freshly) 
SDS-PAGE Running Buffer 
(10X) 
250 mM 
1.92 M 
0.1% (w/v) 
Tris base 
Glycine 
SDS 
CBB-staining solution 45% (v/v) 
10% (v/v) 
0.25% 
Ethanol 
Acetic acid 
Coomassie Brillian Blue  
CBB-destaining solution 45% (v/v) 
10% (v/v) 
Ethanol 
Acetic acid 
Ponceau-S solution 1% (v/v) 
0.5% (w/v) 
Acetic acid 
Ponceau S 
Western Immunoblotting   
Blotting Buffer (1X) 192 mM 
25 mM 
Glycine 
Tris base 
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20% (v/v) Methanol 
Block Solution 5% (w/v) 
1X 
Skimmed milk powder  
PBS 
Primary Antibody Solution 10% (v/v) 
1X 
Primary antibody prepared in 
PBS 
Secondary Antibody Solution 0.1% (v/v) 
 
1X 
HRP-conjugated secondary antibody 
prepared in  
PBS 
Wash Buffer 1X 
0.05% (v/v) 
PBS 
Tween 
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3.2 The Molecular Biology Techniques 
3.2.1 Media and Agar plates 
 
LB0-medium 1% (w/v) Sodium chloride 
 1% (w/v) Tryptone 
 0.5% (w/v) Yeast extract 
For the plates 0.5% (w/v) Agar 
Antibiotics   
LBAmp-Agar plates + 100 µg/ml Ampicillin 
LBKan-Agar plates + 50 µg/ml Kanamycin 
YT-medium 0.5%  (w/v) Sodium chloride 
 0.8% (w/v) Tryptone 
 0.5% (w/v) Yeast extract 
3.2.2 Preparation of Competent E.coli cells 
 
The term “competent cells” is used for the bacterial cells with enhanced ability to take 
up exogenous DNA and thus to be transformed. Competence can arise naturally in 
some bacteria (e. g. Pneumococcus, Bacillus); a similar state can be induced in E. coli 
by chilling the cells in presence of divalent cations, such as calcium chloride prepares 
the cell walls to become permeable to the plasmid DNA.  
 
To produce competent E.coli cells 50 ml of LB-medium was inoculated with the bacterial 
strain of choice and incubated overnight at 37°C. The next day 100 ml LB-medium was 
inoculated with approximately 5 ml of the overnight culture to give a final optical 
density of OD650  = 0.1, and the bacterial suspension was grown at 37°C to 
OD650  = 0.7–1.0. 50 ml culture was centrifuged (5 min, 6500 rpm, 4°C), obtained pellet 
was resuspended in 20 ml of ice-cold 0.1 M magnesium chloride-solution and incubated 
on ice for 10 min. After a second centrifugation (5 min, 6500 rpm, 4°C) the cell pellet 
was resuspended in 20 ml ice-cold 0.1 M calcium chloride solution and kept on ice for 
further 25 min. Finally the suspension was centrifuged (5 min, 6500 rpm, 4°C), the 
pellet was resuspended in 2 ml ice-cold 0.1 M calcium chloride solution, and 550 µl of 
glycerol (87% (v/v)) was added. Aliquots of 100 µl were immediately freezed into the 
liquid nitrogen. Competent cells were stored at -70°C.  
3.2.3 Transformation of Competent Bacteria and Blue/White Screening 
 
The process of introducing naked DNA molecules into the competent bacterial cells is 
called bacterial transformation. The permeability of DNA into the competent cells is 
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achieved by subsequent, immediate heating and cooling at particular temperature for 
specific duration. During heat-shock the pores in the membrane of bacteria become 
wider and exogenous DNA can diffuse into the cells. 
 
pCR®2.1-TOPO® vector has an expression cassette for the regulatory part of the 
lac-operon including the 5’ part of the gene lacZ, which codes 
α-peptide-β-galactosidase. This peptide is able to complement in vivo the defective 
bacterial protein β-galactosidase, which lack amino acids 11-41 from the N-terminus of 
the protein (deletion lacZ∆M15). As a result, transformation of the cells that have such 
a deletion (e. g. TOP 10F’) by a vector carrying the beginning part of the lacZ change 
the phenotype of the bacteria form Lac- to Lac+. When a PCR product is inserted in the 
TOPO vector, the synthesis of the α-peptide is disrupted and bacteria have Lac- 
phenotype. When the plates are added with the chromogenic substrate, X-Gal and the 
inductor, IPTG for the lac-operon, Lac- colonies are colorless, while Lac+ colonies have a 
blue color.  
 
For transformation, one aliquot (100 µl) of competent cells was thawed on ice, 10 µl of 
ligation mix or 1 µg Plasmid DNA was added and the mixture was incubated in the ice 
for 5 min. To allow the DNA to permeate the cell membrane, the heat-shock procedure 
was applied for 2 min at 37°C. After incubation on ice for 5 min, 300 µl LB-medium was 
added and the cells were incubated at 37°C for 30 min. For the phenotypic selection of 
the antibiotic resistance, the cells were then plated onto LB-plates containing 100 
µg/ml ampicillin and incubated at 37°C until single colonies were grown (~18hr). In 
case of blue/white screenings with pCR®2.1-TOPO® Cloning vector (Invitrogen), 
additionally 40 µg/ml, 0.01% (w/v) X-Gal and 1 mM IPTG had been spread on the 
LB-plates before seeding the bacteria.   
3.2.4 Plasmid DNA Isolation  
 
Plasmid DNA was isolated from the E.coli cultures grown overnight in the ampicillin 
containing LB-medium. The medium was inoculated with the bacteria and transformed 
with the desired plasmid DNA. The plasmid DNA could be isolated by different methods, 
depending on the further experimental step. For checking the colonies formed by 
routine cloning procedures, alkaline lysis method is used. In order to prepare plasmid 
DNA for sequencing, either the QIAprep Spinminiprep Kit or the Nucleospin kit was 
used. For the preparation of larger amount of plasmid DNA for transient transfection 
experiments of eucaryotic cells, the corresponding QIAGEN Plasmid Maxi Kit or the 
Nucleospin Maxi kit was used according to the kit instructions.  
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The method of plasmid DNA isolation by the kits is also based on the principle of 
alkaline lysis of bacterial cells. It irreversibly denatures and further precipitates the 
genomic DNA, proteins and the cell debris by using alkali and an anionic detergent. But 
only the plasmid DNA can be selectively renatured to its original structure by providing 
the neutralization pH. Then the plasmid DNA is absorbed to the silica column in the 
presence of high salt concentrations. After removal of molecular contaminants by 
washing at pH 7.0, plasmid DNA is eluted by a low salt buffer at pH 8.5. Further the 
DNA was precipitated and purified by isopropanol and ethanol treatment, respectively. 
For the minipreparation, up to 10 µg of plasmid DNA can be obtained from 1-2 ml of 
bacterial culture, while maxi preparations were performed with 200 ml of bacterial 
culture yielding up to 500 µg-1 mg of plasmid DNA. 
 
For the minipreparation of plasmid DNA, overnight E.coli culture of 1.5 ml was pelleted 
by 1 min centrifugation at 13000 rpm. The pellet was suspended in 100 µl of 
resuspension buffer and kept at the RT for 5 min. Then 200 µl of lysis buffer was 
added, and the complete mixing was ensured by inverting the tubes. After the lysate 
has become clear, 150 µl of the neutralization buffer was added and mixed again by 
inversion. The mixture was centrifuged for 5 min at 13000 rpm, the supernatant was 
collected into a fresh 1.5 ml microfuge tube and the DNA was precipitated by adding 
equal volume of isopropanol. DNA pellet was formed by centrifugation for 20 min at 
14000 rpm in a cold centrifuge and then washed with 500 µl of 80% ethanol. The pellet 
was suspended in 50 µl of TE buffer.   
3.2.5 Quantification of DNA 
 
UV spectrophotometer is used to measure the concentration of nucleic acids at the 
wavelength maximum of 260 nm. The pi electrons present in the aromatic ring system 
of the purine and pyrimidine bases absorb the UV light and make it suitable for the 
quantification of DNA/RNA. The absorption of 1 OD, using a 1 cm cuvette is equivalent 
to approximately 50 µg/ml dsDNA. The purity of the isolated nucleic acids is 
determined by measuring the optical density at 280 nm where aromatic amino acids of 
proteins show the highest absorbance. The ratio of OD260/OD280 is about 1.8 for the 
pure DNA solutions. Lower values are a sign of protein contamination. The formula for 
the final concentration is: DNA concentration [µg/µl] = OD260 X dilution factor X 0.05 
3.2.6 Modification of DNA by Enzymes 
 
Restriction endonucleases are the enzymes, purified from the bacteria, which recognize 
and cut inside the double-stranded DNA at specific palindromic sites. After cutting, they 
produce DNA fragments with sticky ends having overhangs or blunt ends.  Restriction 
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digests were performed at appropriate temperature and buffer conditions for each 
specific enzyme according to the information in the manufacturers’ manual. For the 
cleavage of DNA the following reaction mixture was prepared and incubated for 60-90 
min at required temperature in a water bath. 
 
1 µg DNA 
1 µl Enzyme 1 (10 U/µl) 
0.5 µl Enzyme 2 (20 U/µl) 
2 µl 10X Buffer (1,2,3 or 4)  
2 µl 10X BSA (optional) 
Add to 20 µl dd water 
3.2.7 Agarose Gel Electrophoresis  
 
Nucleic acids can be separated with respect to their size in an agarose matrix by gel 
electrophoresis. In order to obtain optimal separation of nucleic acid fragments, the 
concentration of agarose was varied according to the expected fragment sizes. The 
concentration of agarose in TAE buffer varied from 0.8% (w/v) for large fragments 
(>500 bp) and 2% (w/v) for smaller fragments. The electrophoresis was carried out for 
the separation of DNA fragments at 30-100V in 1X TAE buffer. Prior to electrophoresis 
DNA-loading buffer was added to the samples, and the DNA-SmartLadder (Eurogentec) 
was used as a reference for the size determination. For detection of the DNA 
fragments, gels were stained for 15-30 min in an ethidium bromide containing solution 
(0.5 µg/ml in 1X TAE buffer) and visualized under the UV-light at 256 nm excitation 
wavelength. 
3.2.8 Extraction of DNA Fragments from Agarose gels 
 
Extraction of the DNA fragments from the agarose gel was performed using the 
QIAquick Gel Extraction Kit according to the manufactures instructions. The DNA band 
was visualized under the UV-light and was cut out from the agarose gel. The piece was 
melted at 50°C in QG buffer, having appropriate high salt concentration and pH value ≤ 
7.5 to allow the DNA to bind to the silica membrane. After washing, DNA was eluted 
from the membrane with elution buffer (pH > 7.5). The final volume for DNA fragment 
usually was 30 µl for PCR products and 50 µl for the digested vector. 
3.2.9 Ligation 
 
For the ligation of the restricted DNA fragments into the linearized vector, the Rapid 
DNA Ligation Kit was used according to the manual instruction. The buffers in the kit 
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allow the reaction to occur in 20 µl volume for 5 min at RT. The optimal molar ratio of 
vector/insert is 1/5 for best ligation.  
3.2.10 Polymerase Chain Reaction (PCR) 
 
PCR is a molecular biological technique, which allows to enzymatically amplify specific 
DNA fragments in vitro. Two synthetic oligonucleotide primers, which are 
complementary to two regions of the target DNA (one for each strand) to be amplified, 
are added to the target DNA, in the presence of excess of all 4 deoxynucleotides and 
heat-stable DNA polymerase (e. g. Taq, Pfu polymerases). In a series of temperature 
cycles, the target DNA is repeatedly denatured, annealed to the primers and a 
daughter strand extended from the primers. As the daughter strands themselves act as 
templates for subsequent cycles, DNA fragments matching both primers are amplified 
exponentially. The PCR allows insertion of desirable restriction sites into the end(s) of 
amplified fragments, which will be used in subsequent cloning of DNA into any required 
vector. Reaction components are mixed in 20 or 50 µl PCR microfuge tubes and placed 
into the PCR thermal cycler, where the required parameters for the reaction can be 
programmed. The following reaction mix was used: 
 
5 µl 10 X PCR Buffer 
2.5 µl  MgCl2
0.5 µl dNTP-Mix (20 mM) 
1 µl Template DNA (10 ng/µl) 
2 µl 5’ primer (10 pMol/µl) 
2 µl  3’ primer (10 pMol/µl) 
1 µl Taq-polymerase (1 U/µl) 
36 µl dd water 
The following PCR program or small modified versions were used 
Step Time Temperature Cycle 
1 5 min 95°C      1 X 
2 1 min 95°C     
3 1 min (Tm*-2)°C 30 X (steps 2-4) 
4 1 min 30 sec 72°C  
5 10 min 72°C 1 X 
Tm* is the lowest Tm of the two primers. 
 
After the PCR reaction, 20 µl of the PCR products were loaded onto the 1.5% agarose 
gel for purification of the amplified fragments from the free nucleotides. The fragments 
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were cut and extracted from the gel. Then the fragments were ligated to the 
pCR®2.1-TOPO® vector for further sequencing analysis. 
3.2.11 T/A-cloning of PCR products with TOPO TA System 
 
The cloning vector pCR2.1-TOPO is supplied linearized with single 3´-thymidine (T) 
overhangs and topoisomerase I covalently bound to the vector. The Taq polymerase 
has a nontemplate-dependent terminal transferase activity that adds a single 
deoxyadenosine (A) to the 3´ ends of the PCR products. As the vector supplied in the 
kit has overhanging 3´ deoxythymidine (T) residues, it allows PCR inserts to ligate 
efficiently with the vector. The topoisomerase I from Vaccinia virus binds to the duplex 
DNA at specific sites and cleaves the phosphodiester backbone after 5′-CCCTT in one 
strand. The energy from the broken phosphodiester backbone is conserved by 
formation of a covalent bond between the 3′ phosphate of the cleaved strand and a 
tyrosyl residue (Tyr-274) of topoisomerase I. The phospho-tyrosyl bond between the 
DNA and enzyme can subsequently be attacked by the 5′ hydroxyl of the original 
cleaved strand, reversing the reaction and releasing topoisomerase. For the ligation, 
0.5 µl of the pCR2.1-TOPO vector was mixed together with 4.5 µl of the gel purified 
PCR product and 1 µl of salt solution. The mixture was incubated for 5 min at RT and 
added to an aliquot of competent bacterial cells for transformation. 
3.2.12 DNA Sequencing 
 
The sequencing of the DNA is based on dideoxy method, where in vitro DNA synthesis 
is performed in the presence of chain-terminating dideoxyribonucleoside triphosphates 
(ddNTPs). If the primer is labeled with a fluorescent dye, it is possible to detect the 
DNA fragments generated by PCR automatically while they are running through a 
polyacrylamide gel.  This strategy is followed by using Thermo Sequenase fluorescent 
labeled primer cycle sequencing Kit to create the fluorescently labeled PCR products 
and the automatic Sequencer Gen Read IR4200 to detect them by IR-laser (800 nm), 
while they are passing through the sequencing gel. The sequences obtained this way 
are analyzed using the supplied software. For the reaction, fluorescently labeled 
universal primers were used: T7 and T3 for pCR®2.1-TOPO® vector and M13 for pTER+ 
plasmids. The following mixtures were made for each “nucleotide”: 
0.5 µl A, T, G or C labeling-mix 
1 µg Template to be sequenced 
0.5 µl Fluorescent labeled primer (1 pmol/µl) 
5.5 µl dd water 
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The PCR program 
Step Time Temperture Cycle 
1 5 min 95°C      1 X 
2 30 sec  95°C     
3 40 sec  (Tm*-2)°C 40 X (step 2-4) 
4 1 min 30 sec 72°C  
5 10 min 72°C 1 X 
 
When the PCR was finished, 4 µl of the loading dye was added to each sample, and 2 µl 
of each sample was loaded onto the sequencing gel (section 3.2.13). 
3.2.13 Sequencing Gel 
 
For the sequencing of the DNA fragments with universal fluorescent-labeled primers, 
the following sequencing gel mixture was used. 
5.3% (v/v) Rapid-Gel-Acrylamide 40%  
10% (v/v) 10 X TBE (long run) 
0.625% (v/v) APS (10% (w/v)) 
0.13% (v/v) TEMED 
The gel was pre-run for ~15 min and then samples were loaded. The gel was run 
overnight at 1500 V.  
3.2.14 Isolation of Genomic DNA from the Eucaryotic cells 
 
For the isolation of genomic DNA, the cells are placed in a solution of proteinase K and 
SDS and incubated until most of the cellular protein is degraded. The digest is 
deproteinized by successive phenol-chloroform-isoamylalcohol extractions, recovered 
by ethanol precipitation, DNA pellet was dried and resuspended in buffer. Phenol 
efficiently denatures proteins and probably dissolves the denatured protein. Chloroform 
is another protein denaturant and isoamylalcohol is an antifoaming agent. The DNA is 
effectively precipitated by absolute ethanol at high salt concentration and 70% ethanol 
subsequently desalts the genomic DNA. 
  
Genomic DNA was isolated from the DT40 WT and knock out clones. When the cells 
were confluent (~ 1x107/ml), 2 flasks of suspension cells were spinned at 1500 rpm, 
4°C for 5 min. The cell pellet was washed with ice cold PBS twice. The cell pellet was 
resuspended in 1 ml of genomic DNA lysis buffer, and Proteinase K and RNAse were 
added to a final concentration of 100 µg/ml and 20 µg/ml, respectively. The cells were 
lysed and incubated in a water bath at 50°C for 6 hr to overnight. The lysate was 
transferred to a 2 ml microfuge tube and extracted with equal volume of 
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phenol-chloroform-isoamylalcohol (25:24:1) mixture followed by centrifugation 
(3000-5000 rpm, 10-15 min, 4°C). The upper phase was recovered and repeatedly 
extracted with the solvent mixture. Half volume of 5M lithium chloride and 1 volume of 
absolute ethanol were added to the upper phase and vigorous shaking followed by 
centrifugation (14000 rpm, 15 min, 4°C) precipitated the genomic DNA. Finally the DNA 
pellet was washed, dried and dissolved in 200 µl of TE buffer by placing in a water bath 
upto 67°C. The DNA concentration was measured.  
3.2.15 Isolation of PolyA RNA from the Eucaryotic cells 
 
For handling RNA, all solutions and devices as well as pipette tips and reaction tubes 
were sterilized by routine sterilization techniques. Gloves were worn throughout the 
procedure, glassware was treated at 200°C for at least 4 hr and solutions were treated 
additionally with 0.1% (v/v) diethylpyrocarbonate (DEPC) to inactivate RNAses. 
 
The nascent mRNA in eukaryotic systems is modified by adding adenine (~250, Poly 
AMP nt) at the 3’ end. The PolyA enhances both the lifetime and translatability of 
mRNA. These polyA tails are exploited in their extraction and purification. In 
chromatography, oligo dT are attached to the cellulose matrix. The Oligo dT are short 
segments of deoxyribose thymidine nt, which could anneal to complementary 
sequences, polyA. When the cell extract is run through the column the mRNA with 
polyA tail get attached to the oligo dT bound to cellulose matrix of the column and are 
eluted by either slightly changing the pH or ionic strength. 
 
For one sample 3-5 petri dishes (1.0-1.5x107 cells) of untransfected or transfected cells 
were harvested in ice cold PBS and washed once with 5 ml PBS. The cells were 
suspended in 3 ml of cold lysis buffer and proteinase K was added to a final 
concentration of 200 µg/ml. After a min, SDS was added to a final concentration of 
10% (w/v), followed by shearing of the DNA by passing the cell suspension first 
through a 50 mm, later through a 25 mm needle. The proteinase K concentration was 
raised to 300 µl/ml and cells were incubated at 37°C for 2-3 hr. In between the oligo dT 
cellulose was washed for 3 times with 0.1 M sodium hydroxide (centrifugation: 3 min, 
2000 rpm, 4°C) and several times with water until the pH of the solution is neutral. 
After washing for three times with binding buffer oligo dT cellulose in binding buffer 
(~1-2 ml packed volume dT cellulose) was applied to the cell extracts. Solutions were 
stirred overnight at RT. After pelleting of the cellulose (3 min, 2000 rpm, 4°C) it was 
resuspended twice in 10 ml binding buffer and finally resuspended in 5 ml binding 
buffer and loaded onto the column. The columns were also treated with 0.1 M sodium 
hydroxide and washed with water before loading. Loaded columns were washed three 
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times with 5 ml wash buffer and finally polyA RNA was eluted with 3 ml elution buffer. 
The concentration was determined by measuring the OD260 and for storage at -20°C, 
RNA was precipitated by adding 0.3 M sodium acetate and 3 volumes of absolute 
ethanol. 
3.2.16 Genomic DNA-Agarose gel Electrophoresis and Southern Blotting  
 
In Southern blotting, the DNA fragments are transferred from an agarose gel to a nylon 
or nitrocellulose membrane by capillary action, preserving the spatial arrangement. The 
DNA molecules are immobilized on the membrane, either by heating or by ultraviolet 
irradiation and can be detected by hybridization with a radioactive DNA probe.  
 
Southern blotting was used to analyze the DT40 knock-out clones generated by 
homologous recombination. 10 µg of prepared genomic DNA from the WT and the 
clones were digested by using 10 U of ApaI enzyme in a 50 µl digest for overnight at 
RT. The next day 10 µl loading buffer was added to the digest. Then 50 µl of each DNA 
sample were loaded to a thick 0.9% agarose gel and the gel was run for 3-4 hr at 120 
V. The gel was denatured by incubating with denaturation buffer for 30 min followed by 
incubation with the neutralization buffer for 30 min by placing on a shaker at RT. DNA 
was then blotted onto a nylon membrane, where the mobile phase was 10X SSC buffer. 
 
Here, the upward capillary transfer method was used to transfer the DNA from the gel 
to the nylon membrane. The transfer pyramid set up stacks the following materials in 
the given order. A clean glass tank containing 10X SSC was overlaid by a clean glass 
plate. Over the glass plate, the 3MM whatman filter paper wick is placed and both ends 
of the whatman filter paper were submerged into the tank buffer. The gel was placed 
over the whatman filter paper followed by the nylon membrane over the gel at once. 
The whatman filter papers were cut to the same size of the membrane and covered the 
membrane. Then, filter paper towels were cut and stack over the whatman filter paper 
upto 4-5 cm height. Above this set up, a glass plate and a weight was placed. This 
pyramid structure was left overnight. The next day membrane was washed with 2X 
SSC to remove the agarose particles, again treated with denaturation and 
neutralization buffer each for 1 min and irradiated for 100 sec with UV-light (254 nm) 
for immobilizing the DNA non-covalently on the nylon membrane.  
3.2.17 RNA-Agarose gel Electrophoresis and Northern Blotting 
 
RNA samples were separated on a 1% denaturing agarose gel. For 10 ml gel solution 
1% (w/v) agarose was dissolved in 1 ml 10X MOPS and 7.2 ml DEPC treated water 
using a microwave oven. For small gels (8 samples) 35 ml were needed and for bigger 
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gels (upto 20 samples) 180 ml of gel solution were prepared. After cooling down to 
60°C, 18% (v/v) formaldehyde was added to the gel solution and the solution was 
poured into the gel running device. From the RNA preparations a volume containing 
around 2 µg of RNA was taken for each sample, RNA was precipitated (30 min, 14000 
rpm, 4°C) and air died. The pellet was resuspended in 20 µl RNA loading buffer and 
heated for 10 min at 65°C. The composition of the loading buffer is given below. Gel 
electrophoresis was performed in 1X MOPS running buffer at 100-120 V for 3 hr. It is 
an optional step that the gel is stained in ethidium bromide for 15 min and visualized 
under UV-light (320 nm). The northern blotting was done as shown in the section 
3.2.16 by upward capillary transfer method. 
3.2.18 Radioactive Labeling of DNA with α32P-dCTP and with 3H-dUTP  
 
Radioactive labeling of DNA for Southern and northern blotting (section 3.2.16 and 
3.2.17) experiments was performed with α32P-dCTP, using the Klenow fragment of the 
DNA polymerase I. Radioactive labeling of DNA probes was performed using the 
‘Megaprime DNA labeling system’. This system uses random sequence nanomer as 
primers for DNA synthesis on denatured template DNA at numerous sites along its 
length. The primer-template complex is a substrate for the Klenow fragment of DNA 
polymerase I. By substituting a radiolabeled nucleotide for a non-radioactive equivalent 
in the reaction mixture, makes the newly synthesized DNA, radioactive. The absence of 
the 5’-3’ exonuclease activity associated with the DNA polymerase I ensures that 
labeled nucleotides incorporated by the polymerase are not subsequently removed as 
monophosphates. 
 
For this procedure 25-35 ng of DNA were taken, denaturated for 5 min at 95°C with 5 
µl of primer solution. Then 10 µl of labeling buffer, 2 µl of Klenow enzyme (1 U/µl) and 
5 µl of α32P-dCTP (10 mCi/µl, ~3000Ci/mmol) were added and incubated for 30 min at 
37°C. Purification from the non-incorporated radioactive nucleotides was performed 
with centrifugation for 3 min at 3000 rpm through MicroSpinTMG-50 Columns. After this 
procedure the pure radiolabeled DNA probe denatured and directly added to the 
Southern hybridization solution. 
3.2.19 Hybridization and Washing 
 
The hybridization experiment can be divided into three steps. First, the membrane is 
incubated in a prehybridization solution containing reagents that block nonspecific DNA 
binding sites on its surface, thereby reducing the background hybridization. Denhardt’s 
solution and sperm DNA are the blocking agents. In the second step, the 
prehybridization solution is replaced by fresh buffer containing the labeled probe and 
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an overnight incubation is carried out to allow the probe to bind to the target 
sequences in the immobilized DNA. In the final stage of the experiment, the membrane 
is washed with a series of solutions that gradually remove the non-specifically bound 
probes. The membrane was placed in a hybridization flask and prehybridized with 10 
ml of the hybridization mixture containing denaturated Salmon-sperm for 2-3 hr in 
hybridization oven at 42°C. Afterwards the prehybridization solution was changed and 
10 ml of fresh hybridization solution containing the denaturated-labeled probe was 
added for hybridization.  
 
Washing, Exposure and Stripping 
After hybridization the membrane was washed first with washing solution I for 20 min 
and then with washing solution II 2-3 times for 20 min each with shaking at 55°C. 
Finally the membrane was wrapped with polyethylene and exposed to the 
phosphorimager screen. The screen was developed by phosphorimager. For the 
hybridization of a northern blot with different probes previously hybridized probes were 
removed by heating the membrane in stripping solution for 20 min at 100°C. 
3.2.20 Cell Cycle Analysis by FACS Method   
 
Flow cytometry is a technique for counting, examining and sorting microscopic particles 
suspended in a stream of fluid. The measurement of the DNA content of cells was one 
of the first major applications of flow cytometry. The DNA content of the cell can 
provide a great deal of information about the cell cycle, and consequently the effect of 
the added stimuli on the cell cycle. e.g. downregulated genes or UV treatment. 
Fluorescence-activated cell sorting (FACS) is a type of flow cytometry, a method for 
sorting a suspension of biologic cells into two or more containers, one cell at a time, 
based on the specific light scattering and fluorescence characteristics of each cell. The 
most commonly used dye for DNA content/cell cycle analysis is propidium iodide (PI). It 
can be used to stain whole cells or isolated nuclei. The PI intercalates into the major 
groove of double-stranded DNA and produces a highly fluorescent adduct that can be 
excited at 488 nm with a broad emission centered around 600 nm. Since PI can also 
bind to double-stranded RNA, it is necessary to treat the cells with RNAse for optimal 
DNA resolution.  
 
In the present work, the adherent or suspension cells were harvested and washed with 
PBS for twice. The cells were fixed with 70% methanol at 4°C for few hr to overnight. 
After fixation, the cells were washed with PBS and eluted in 425 µl PBS and 50 µl 
RNAse followed by incubation for 20 min at 37°C. Finally, 25 µl of PI was added to the 
cell suspension and fluorescently labeled cells were measured by FACS.  
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3.3 The Cell Culture Techniques 
3.3.1 Cell lines and Medium 
 
Name Nature of the Cell line Medium 
A549 Human, small cell lung 
carcinoma, adherent cell line 
derived from epithelial cells  
MEM Medium 
10% (v/v) Fetal bovine serum (FBS) 
1% (v/v) L-Glutamine 
1% (v/v) Penicillin/Streptomycin (P/S) 
DT40 Chicken, borsa lymphoma 
suspension cell line derived 
from lymphoblast cells 
ISCOVE’S Medium 
8% (v/v) FBS 
2% (v/v) Chicken serum  
1% (v/v) L-Glutamine 
1% (v/v) P/S 
0.001% (v/v) β-Mercaptoethanol  
HeLa Human, cervical carcinoma, 
adherent cell line derived 
from epithelial cells 
DMEM/RPMI Medium 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1% (v/v) P/S 
HTB-133 Human, breast ductal 
carcinoma, adherent cell line 
derived from epithelial cells 
DMEM/RPMI Medium 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1% (v/v) P/S 
QT6 Japanese Quail, 
fibrosarcoma, adherent cell 
line derived from fibroblasts 
DMEM Medium 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1% (v/v) P/S 
3.3.2 Passage and Cultivation of cells 
 
Cells were cultured in 10 cm sterile petri dishes or T75 culture flasks with the 
appropriate medium (section 3.3.1) and grown in a CO2-incubator, at 37°C in a water 
saturated atmosphere with 5% (v/v) CO2. Confluent cells were passaged and plated at 
1:5 to 1:40 dilutions in new culture flasks. For passaging, adherent cells were washed 
with 1X PBS after removal of the medium and treated with 0.5-1 ml trypsin/EDTA 
(0.2%-0.5% (w/v)) solution at 37°C for 2 min. They were plated after resuspension in 
fresh culture medium. Suspension cells were passaged by taking the appropriate 
volume aliquots according to the desired dilutions from the dish with confluent cells and 
transferring them to fresh medium in the new dishes.   
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3.3.3 Cell Counting 
 
The number of cells for the transfection experiments was determined using a Neubauer 
haemocytometer, and the cell suspension was diluted with growth medium in order to 
obtain the desired concentration. 10 µl of the cell suspension was loaded onto the 
haemocytometer and counted under the microscope. 
3.3.4 Transfection and Harvesting of Adherent and Suspension Cell lines 
 
During transfection, foreign DNA is introduced into the eucaryotic cells. A part of it 
enters the nucleus during the cell division and is transcribed. In the transient 
transfection, most of the DNA is not integrated in the chromosomes of the cell and 
therefore will be degraded after some time. The transfected DNA is integrated into the 
genome in the stable transfection method. 
 
Transfection and Harvesting of Adherent cells 
In this work, A549, HeLa, HTB-133 and QT6 cells were transfected using the calcium 
co-precipitation method, wherein co-precipitation of calcium phosphate and DNA cause 
their adsorption on the cell surface, from where it can be taken up by the cells via 
phagocytosis. To increase the transfection efficiency a glycerol-shock is applied 3-4 hr 
after transfection, which facilitates the uptake of the foreign DNA.  
 
One day prior to the transfection, 1.5x105/ml cells were seeded on 10 cm petri dishes 
described in 3.3.2. The plasmid DNA to be transfected was precipitated at -20°C 
overnight by adding 144 µl of DNA precipitation buffer and 600 µl of absolute ethanol. 
Immediately before the transfection DNA was pelleted (13000 rpm, 20 min, 4°C), and 
supernatant was removed. The pellet was dried in the laminar-flow hood and 
resuspended in 438 µl of sterile water and 62 µl of 2 M sterile calcium chloride-solution. 
This mixture was added to 500 µl of sterile 2X HBS buffer with vortexing. This solution 
was then pipetted drop wise onto the cells in the petri dish and incubated for 3-4 hr in 
the CO2-incubator. To apply the glycerol shock, the culture medium was removed, cells 
were treated with 2 ml of shock solution for 2 min, washed twice with PBS and fresh 
culture medium was added. The cells were harvested after 24 or 48 hr of the 
transfection. The culture medium was removed and cells were washed twice with ~5 ml 
of PBS at RT, scraped in 1 ml of PBS and transferred to a microfuge tube. Cells were 
then pelleted (1500 rpm, 5 min, at 4°C) and used either for reporter gene assays or 
boiled with Laemmli buffer for SDS-PAGE (section 3.4). 
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Transfection and Harvesting of DT40 cells  
To transfect the suspension cells, an electrophysical method was used by employing a 
short electric pulse to increase permeability of the cell membrane. DNA can penetrate 
into the cells through the pores generated by such electric impulse. Membranes restore 
their properties after the termination of the applied electrical pulse. The DT40 cells 
were counted, pelleted (750 rpm, 10 min, RT), washed once with PBS, and suspended 
in PBS at a concentration of 1.5x107 cells/ml. 300 µl of the cell suspension containing 
1.5x107 cells/ml were taken in an electroporation cuvette (0.4 cm) and then the 
plasmid DNA was added. The cuvette was placed on ice for 10 min prior to the 
electroporation. The following electroporation programs were used in the 
electroporation device. After the electroporation, the cells were incubated on ice for 5 
min before culturing in the dishes. 
 
Transient tranfection 330 V 
 900 µF 
 86 ms 
 99 ohms 
Stable transfection (2 consecutive pulses) Pulse I Pulse II 
 1200 V 160 V 
 25 µF 1500 µF 
 2.47 ms 148 ms 
 99 ohms 99 ohms 
 
For transient transfection, the electroporate was suspended in 10 ml of the culture 
medium in 10 cm petri dishes and incubated for 24 hr and harvested by centrifugation 
(1500 rpm, 5 min, at 4°C) in the next day. The pellet was transferred to a microfuge 
tube, washed twice with PBS, and lysed in respective lysis buffer either for reporter 
gene assay or SDS-PAGE analysis. For stable transfection, the electroporate was 
suspended in 10 ml medium, distributed as 100 µl/well into a 96 well plates. The 
following day the required amount of antibiotics were diluted in 10 ml medium and 
distributed as 100 µl per well. In 2-3 weeks, the stable clones were developed, the cells 
from single well/single clone were transferred into the 24/6 wells plates and further 
grown for analysis.  
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3.4 The Protein Biochemical Techniques 
3.4.1 Reporter-gene Assays 
 
A reporter-gene encodes an easily assayable product that is coupled to the regulatory 
sequences and a promoter of interest. Upon transfection into suitable cells 
reporter-gene can then be used to determine the functional efficiency of the promoter 
or the factors that affect the promoter or the regulatory sequence. In this work renilla 
and firefly luciferase dual reporter gene constructs were generated by inserting DNA 
fragments of the untranslated region from different genes associated with apoptosis 
and cancer. The activity of the reporter-gene is determined by the emission of light. 
The second reporter vector used in most experiments as a reference for the 
transfection efficiency is the pCMVβ expression vector. It contains the lacZ gene coding 
β-galactosidase expressed under the SV40 early promoter and enhancer. Cell pellets 
obtained after harvesting (3.3.4) were lysed in 100 µl of β-gal lysis buffer, incubated 
on ice for 15 min and centrifuged (15 min, 14000 rpm, 4°C). Then, the supernatant 
was used in luciferase or β-galactosidase assays.  
 
β-Galactosidase assay 
Glycoside bonds of lactose and its derivatives can be cleaved by β-galactosidase. The 
commercially supplied substrate galacton is a 1,2-dioxetane-based derivative, which 
emits visible light upon enzyme-catalyzed decomposition. For measuring β-
galactosidase activity, 8 µl of cell extract was pipetted into the sample tubes. These 
tubes were placed into the luminometer and buffers were automatically added. First 
100 µl of reaction buffer was added. After 30 min of incubation, 300 µl of stop buffer 
was injected into the tubes.   
 
Luciferase assay 
Firefly luciferase protein catalyzes ATP- and Mg2+-dependent oxidation of the firefly 
specific substrate, D-luciferin, to oxy-luciferin that causes the generation of light, which 
can then be detected and quantified by luminometer. To measure the luciferase 
concentration 20 µl of the cell extracts were pipetted into the sample tubes, which were 
placed into the luminometer, where the reaction and injection buffers were 
automatically added. At first 300 µl of the reaction buffer was injected into the tubes 
followed by 100 µl of the injection buffer.   
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3.4.2 2-Dimensional-Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis  
 
The 2-dimensional-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(2D-SDS-PAGE) is a widely used method for the analysis of complex protein mixtures 
extracted from cells, tissues or other biological samples. This technique sorts protein 
according to two independent properties in two discrete steps: the first-dimension (1D) 
step, isoelectric Focusing (IEF), separates proteins according to their isoelectric points 
(pI); the second dimension step, SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
separates proteins according to their molecular weights (MW).  
 
Sample Preparation 
For the complete analysis of all the cellular proteins, the cells must be effectively 
disrupted. The liberated proteases upon cell disruption have to be inactivated or 
inhibited. Precipitation of the non-protein impurities is important as they can interfere 
with the resolution of the 2D results. Sample proteins must be completely 
disaggregated and fully solubilized. It is achieved by denaturants including urea and a 
zwitterionic detergent. The protein modifications during the sample preparation can be 
avoided by storing the samples always on the ice. In particular after urea treatment, 
the samples are maintained below 30°C. In the present work, the total protein extract 
was prepared by using the complete mammalian proteextract kit (C-PEK). It includes a 
hypotonic buffer for cell resuspension and lysis and a denaturing extraction reagent for 
the solubilization of proteins. The nucleic acid impurities are degraded and a 
non-viscous protein solution is obtained by DNAse treatment. Protease inhibitors 
prevent proteolysis.  
 
Isoelectric Focusing (IEF) 
IEF is an electrophoretic method that separates proteins according to their isoelectric 
points (pI). Proteins are amphoteric molecules; they carry either positive or negative or 
zero net charge, depending on the pH of their surroundings. The net charge of a 
protein is the sum of all the negative and positive charges of its amino acid side chains 
and amino- and carboxyl-termini. The isoelectric point is the specific pH at which the 
net charge of the protein is zero. Proteins are positively charged at pH values below 
their pI and negatively charged at pH values above their pI. In a pH gradient, under 
the influence of an electric field, a protein will move to the position in the gradient 
where its net charge is zero. A protein with a positive net charge will migrate toward 
the cathode, becoming progressively less positively charged as it moves through the pH 
gradient until it reaches its pI. A protein with a negative charge will migrate toward the 
anode, becoming less negatively charged until it also reaches zero net charge. If a 
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protein should diffuse away from its pI, it immediately gains charge and migrates back. 
This is the focusing effect of IEF, which concentrates proteins at their pIs and allows 
proteins to be separated on the basis of very small charge differences. Immobilized pH 
gradients (IPG) is created by covalently incorporating a gradient of acidic and basic 
buffering groups into a polyacrylamide gel at the time it is cast.  
 
IPG Strip Equilibration 
The equilibration step saturates the IPG strip with the SDS buffer system required for 
the second dimension separation. The equilibration buffer contains many reagents to 
maintain the pH of the IPG strip. Urea is added together with glycerol, reduces the 
effects of electroendoosmosis by increasing the viscosity of the buffer. Glycerol 
together with urea improves transfer of protein from the first to the second dimension. 
DTT preserves the fully reduced state of denatured unalkylated proteins. SDS 
denatures proteins and forms negatively charged protein-SDS complexes.  
 
Second Dimension SDS-PAGE  
SDS-PAGE alone is used to detect/quantitate and check the purity of the proteins 
expressed in prokaryotic and eucaryotic systems by either staining with Coomassie 
brilliant blue or by immunoblotting. SDS-PAGE is a method that allows separation of 
the proteins according to their molecular weight but not by charges. Besides, first 
dimensional IEF followed by the SDS-PAGE separates the isoelectrically focused 
proteins based on their molecular weight in the second dimension. 
 
Proteins usually possess positive or negative charge depending on their amino acid 
composition and have different native three dimensional structures. To make different 
proteins similar in shape and charge, they are subjected to denaturation in Laemmli 
sample buffer at high temperature (95°C) for 10 min. This buffer contains a powerful 
negatively charged detergent, sodium dodecyl sulfate (SDS). SDS binds to the 
hydrophobic regions of the protein molecules (1.4 g SDS/g protein) and disrupting all 
non-covalent bonds, thereby causing them to unfold into extended polypeptide chains. 
The individual proteins are released from their associations with other proteins and 
rendered freely soluble in detergent solution. The β-mercaptoethanol is a reducing 
agent which reduces the disulphide bonds and makes the multiple unit proteins into 
single units. In addition, each protein in the mixture binds a large number of detergent 
molecules which mask their intrinsic charge and causes it to migrate towards the 
positive electrode when a voltage is applied. Tetramethylethylene diamine (TEMED) 
initiates the free radical polymerization and ammonium persulfate (APS) enhances it.  
During the discontinuous gel electrophoresis, proteins are first focused by running 
through a short stacking gel prior to entering the resolving gel.  
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Separating gel (12.5%) 6.25 ml lower Tris (1.5 M Tris-HCl, pH 8.8; 0.4% (w/v) 
SDS) 
 8.1 ml dd water 
 10.4 ml Acrylamid/Bisacrylamide (30%) 37.5:1 mix 
 250 µl APS 
 10 µl  TEMED 
Stacking gel (4.3%)  upper Tris (1 M Tris-HCl, pH 6.8; 0.4% (w/v) SDS) 
 3 ml dd water 
 717 µl Acrylamide/Bisacrylamide (30%) 37.5:1 mix 
 50 µl APS 
 5 µl  TEMED 
 
2D-SDS-PAGE Protocol 
1x105 cells/ml were seeded in 10 cm petri dishes, the cells were harvested the next 
day and washed with PBS and wash buffer each twice (1000 rpm, 5 min, 4°C). The 
total protein extract was prepared as directed in the C-PEK. The sample was prepared 
as mentioned below and loaded in the IPG strip holder. The IPG strip was carefully 
placed over the sample without capturing air bubbles. The strip holder was placed in 
the IPGphor electrophoresis system and IEF program was run for overnight.  
 
 Sample Preparation 250 µl Total protein extract 
 1000 µl Rehydration buffer 
 2 µl DTT 
 IPG Buffer 1.5 µl 
IEF Program   
Rehydration Passive 1-4 hr  
 Active 12 hr 30V 
IEF 1 hr  500V 
 1 hr 1000V 
 30 min 5000V 
 30 min 8000V 
 2 hr 8000V 
 
On the next day, the strip was removed from the chamber and equilibrated with 5 ml of 
equilibration buffer added with 333.3 µl of 1M DTT by shaking for 10 min at RT followed 
by 676 µl of iodoacetamide was added and placed on a shaker for another 10 min at 
RT. A 10% SDS-PAGE was prepared and the equilibrated IPG strip was placed 
horizontally over the SDS-PAGE. Over the IPG strip the melted 0.5% low melting point 
agarose was pipetted and allowed to cool for 45 min. Then, the SDS-PAGE was pre-run 
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for 20 min at 10 mA and later at 35 mA for 4 hr. The gels were stained or transferred 
to a membrane for different purposes. 
3.4.3 Coomassie Brilliant Blue Staining  
 
Coomassie Brilliant Blue (CBB) dye can bind nonspecifically to the proteins, and is used 
for the detection of proteins and estimation of protein concentration on the gels. 
Staining with the dye allows detecting the sufficient amount of the protein (>0.3 µg). 
The fractionated proteins in the SDS-PAGE were precipitated using a fixing solution 
containing methanol/acetic acid. The location of the precipitated proteins was then 
detected using CBB (which turns the entire gel blue). After destaining, the blue protein 
bands appeared against a clear background. For staining, the gels were kept for 30 min 
in CBB-staining solution with shaking and then destained with CBB-destaining solution 
until an appropriate signal/background ratio was reached.  
3.4.4 Western Blotting and Immunodetection 
 
In western blotting, proteins are transferred from an acrylamide gel to a nitrocellulose 
membrane by an electric field, preserving their spatial arrangement. When the 
molecules are immobilized on the membrane they can then be detected with high 
sensitivity by labeling with specific antibodies.  
 
Blotting was performed at 80 V for 1 hr in blotting buffer, and then non-specific, 
reversible Ponceau-S staining of the proteins was performed to confirm the transfer of 
proteins. Unoccupied binding sites on the membrane were blocked by incubation for 1 
hr at RT in the block solution. The membrane was then kept for 1 hr at RT in the 
solution with the protein specific primary antibody (dilution 1:1000). To remove the 
nonspecifically bound primary antibody, the membrane was washed thrice with the 
wash buffer each for 6-10 min followed by incubation for 45 min at RT with the 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibody (dilution 
1:1000). Afterwards, the membrane was washed thrice with the wash buffer each for 
6-10 min, and the proteins were detected using the ECL chemiluminescence detection 
system. For that purpose, the membrane was incubated for 1 min in a 1:1 mixture of 
the ECL solution A and B. Then the solution was removed, and X-ray film was exposed 
to the membrane. The exposition time had to be adjusted to the signal intensity for 
every protein.   
3.4.5 35S-Methionine Labeling 
 
Protein biosynthesis in mammalian cells relies on the continuous uptake of essential 
amino acids from the environment. Acute amino acid restriction leads to block in the 
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protein synthesis and when radioactive amino acids are provided, they are incorporated 
into the newly synthesized proteins. Because of its high specific activity and ease of 
detection, 35S-methionine is the amino acid of choice for the biosynthetic labeling of 
proteins. 1x105 cells/ml was seeded in the dishes and the next day the serum 
containing medium was removed and medium without methionine was added to starve 
the cells for 30 min. Then the cells were provided with medium containing 
35S-methionine for labeling the cells. After labeling for different times, the cells were 
harvested and washed three times with 1X PBS. Then the cell pellet was either lysed in 
1X Laemmli buffer for SDS-PAGE or 10 µl of the cell pellet was loaded on a whatman 
filter paper as spots. The SDS-PAGE was followed by fixing, washing and drying the gel. 
The composition of the fixing solution is given below. The cell pellet loaded on the 
whatman paper were fixed and washed by trichloro acetic acid. Then the filter paper is 
air-dried, followed by exposed to the phosphor imager screen for detection and 
quantification.  
 
Fixing Solution 25% (v/v) Methanol 
 10% (v/v) Acetic acid 
  Fixing followed by shaking with  
 0.5 M Sodium salicylate 
3.4.6 Immunoprecipitation 
 
The Pdcd4 knock-down stable clones were analyzed for the siRNA mediated silencing of 
Pdcd4 by immunoprecipitation experiment. The basic principle is that the endogenous 
proteins can be isolated from a protein extract as a complex via an antibody specific to 
the protein. After coupling of the constant region of the antibody onto a matrix (e.g. 
protein A or protein G sepharose) non-interacting proteins can be washed away and all 
interacting proteins can be analyzed by SDS-PAGE and western blotting or used for 
further experiments. The 35S-methionine labeled cells were harvested, lysed by the 
stringent RIPA lysis buffer and 3µl of Pdcd4 specific antibody was applied to 1 ml of 
cellular extract followed by incubation on a rotating device for 1 hr at 4°C. Depending 
on the antibody used, protein A (for rabbit antibodies) was washed three times with the 
corresponding lysis buffer and about 15 µl of bed volume was applied to each sample, 
with and without block peptide. After incubation under rotation for 1 hr at 4°C, the 
samples were washed thrice with ice cold lysis buffer and then boiled for 10 min at 
95°C in 100 µl of 1X Laemmli buffer. The immunoprecipitate was analyzed by 
SDS-PAGE. The gels were fixed by shaking with fixing solution followed by sodium 
salicylate and finally dried. Then, the dried gel was exposed to the phosphorimager 
screen. 
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4 RESULTS 
4.1 Downregulation of Pdcd4 – A Knock-Down System 
4.1.1 Targeted Silencing of the Human Pdcd4 gene 
 
Pdcd4 is a highly conserved gene among the vertebrates as well as in distantly related 
organisms such as the fruit fly Drosophila melanogaster (referred to as CG10990) or 
the marine sponge Suberites domunculata (Wagner et al., 1998). Although growing 
experimental evidence identifies Pdcd4 as a tumor suppressor gene, the molecular 
mechanism behind the tumor suppressor function is yet to be understood. Eventually, 
developing a well-characterized cell system is inevitable to elucidate the molecular 
functions of Pdcd4.  
 
In general, a knock-down cell system is preferred for studying the function of a gene, 
as the activity of the gene is completely or almost completely eliminated which 
facilitates the search for the phenotypic changes in a cell. RNA interference (RNAi) was 
chosen to silence the Pdcd4 gene as it is a novel technique that has recently emerged 
as a reverse genetic approach to study new genes when the sequence is available. 
RNAi, an evolutionarily conserved phenomenon, represents a unique form of 
posttranscriptional silencing (PTGS). RNAi was first identified in plants and fungi, which 
is mediated by generating siRNA of 19-25 nt with characteristic 3’ dinucleotide 
overhangs (Jorgenesen, 1990). The siRNA is incorporated into the RNA-induced 
silencing complex (RISC), whereupon a RISC-associated, ATP-dependent helicase 
activity unwinds the duplex, thus enabling the two strands of siRNA to target mRNA 
recognition. The degree of complementarity between the siRNA and target mRNA 
determines the silencing via site-specific cleavage of the message in the region of the 
mRNA-siRNA duplex. The cleaved mRNA products are released and degraded and 
thereby silenced (Hammond et al., 2001). The mechanism of generation and activation 
of siRNAs inside the cell is explained in the figure 3 (Elbashir et al., 2001b; Bernstein et 
al., 2001; Ishizuka et al., 2002). 
 
siRNA Expression Construct 
In order to produce a human Pdcd4 (Hpdcd4) knock-down system, HeLa cells were 
chosen as they were found to express Pdcd4 and are easy to transfect (Boehm, 2005). 
For this purpose, two different siRNA duplexes targeting at two different regions of 
Hpdcd4 gene (Hpdcd4) were designed with the help of siRNA design software from 
OligoEngine. It designs the siRNA according to the following criteria (Brummelkamp et 
al., 2002): first AA dimer 75 bases downstream from the start codon should be located 
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and the next 19 nucleotides (nt) are extracted as a target sequence. The target 
sequence should have a GC content of 30-50%, should be flanked in the mRNA with TT 
at the 3’ end and must not contain a stretch of four or more A’s or T’s to avoid 
premature termination of the transcript. Finally a Blast search was performed against 
NCBI Unigene/EST library to ensure that only one gene is targeted.  
 
 
 
 
 
 
 
Figure 3: RNA interference mediated by sequence specific siRNA silencing   
 
The transfected pTER+ vector expresses siRNA with a stem loop structure, which are recognized by Dicer. 
Subsequently the dsRNA is cleaved resulting in 21 nt RNA duplexes, called the siRNAs. These siRNAs 
incorporated into the RISC where they are unwound by an ATP-dependent process, transforming the complex 
into an active state. Activated RISC uses one strand of the RNA as bait to bind homologous RNA molecules, 
then the target mRNA is cleaved and degraded.  
 
The engineered two siRNAs following the positions 603 and 1260 of Hpdcd4 mRNA were 
recommended for silencing of Hpdcd4. Within the 60-mer siRNA oligos, the 20 nt target 
appears in both sense and antisense orientation, separated by a 9 nt spacer sequence. 
The resulting transcript is predicted to fold back on itself to form a stem-loop structure, 
which is later cleaved to produce a functional siRNA inside the cell. The siRNA oligos 
were annealed and cloned into the pTER+ vector (Fig.4). A single nucleotide mismatch 
in the siRNA sequence abrogates the ability to suppress gene expression 
(Brummelkamp et al., 2002). Therefore, the positive clones were sequenced and the 
clones with the correct siRNA sequence were chosen for further knock-down 
experiment.  
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Figure 4: The siRNA expression construct  
 
The siRNA oligos were annealed and cloned between the BglII/HindIII restriction sites of the pTER+ vector. 
The clones were selected using zeocin antibiotic. The positive clones were sequenced by using BGH reverse 
primer. The siRNA expression is controlled from the H1 promoter of the RNA Polymerase III gene. The H1 
promoter is modified by inserting the tetracycline operator (TO), thereby enabling the binding of tetracycline 
repressor to this region and the regulation of siRNA expression by the addition of doxycycline. 
 
Transient Transfection 
For checking the integrity and functionality of the siRNA constructs, they were 
transiently transfected into QT6 cells. A eucaryotic expression vector overexpressing 
Hpdcd4 under the control of CMV-promoter was cotransfected with the siRNAs to see 
the siRNA effect. The 3’ end of the Hpdcd4 was tagged with hemagglutinin (HA) epitope 
and could be detected by mouse monoclonal anti-HA antibody. Figure 5 shows that 
both siRNAs downregulate the externally transfected Hpdcd4 and that the effect was 
increasing with increasing concentration of siRNA. 
 
55 KDa Hpdcd4
(10 µg)+----+----pTER+
(5, 10, 15 µg)-+++------siRNA B
(5, 10, 15 µg)------+++-siRNA A   
(5 µg)++++++++++pcDNA3.1-Hpdcd4
(0.5 µg)++++++++++pCMV β-gal
 
 
 
 
  
 
 
 
 
Figure 5: Downregulation of Hpdcd4 by siRNAs 
 
QT6 cells were transiently co-transfected with increasing concentrations (5, 10 & 15 µg) of pTER+-siRNA A & B 
and the Hpdcd4 overexpression construct (pcDNA3-Hpdcd4-HA 5 µg). To measure the efficiency of transfection, 
the cells were additionally transfected with pCMV β-gal (0.5 µg). 24 hrs after transfection, the cells were 
harvested, lysed, and part of the cells was used for measuring the β-galactosidase activity. Samples were 
electrophoresed on a 10% SDS-PAGE followed by western blotting. The blot was incubated with mouse 
monoclonal anti-HA antibody as primary antibody (Ab) and Horse Radish Peroxidase (HRP) conjugated 
polyclonal rabbit anti-mouse antibody as secondary antibody. Hpdcd4 bands are highlighted by an arrow at 55 
KDa. 
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Stable Transfection 
After confirming the proper functioning of the siRNA constructs, both the siRNA 
constructs were together stably transfected into HeLa wild-type (WT) cells and selected 
by their resistance to zeocin. The clones were analyzed for the downregulation of 
Hpdcd4 by immunoprecipitation (Fig.6) and western blotting (Fig.20). Among the 
identified clones downregulating Hpdcd4, K11 and K12 were further used for the 
functional analysis of Hpdcd4.    
 
Block Peptide
Clone 
+-+-+-+-+-+-+-
WT272221131211
55 KDa
Hpdcd4
 
 
 
 
 
 
Figure 6: Analysis of HeLa stable clones by immunoprecipitation 
Six HeLa stable clones (11, 12, 13, 21, 22 and 27) were analyzed by immunoprecipitation. The cells were 
starved without methionine, and then labeled for 1 hr using 35S-methionine. Then harvested, lysed, 
incubated with rabbit polyclonal antiserum raised against mouse-pdcd4 and treated with and without 
recombinant Pdcd4 to control the specificity of the immunoprecipitation. HeLa WT cells were used as a 
negative control. Hpdcd4 bands are indicated by an arrow at 55 KDa. The clones 11, 12 and 22 were 
identified as positive clones.  
4.1.2 The effect of Hpdcd4 on Cap-Dependent Translation 
It has been previously shown that Pdcd4 overexpression inhibits translation of a 
luciferase transcript containing a structured 5’ untranslated region (UTR) in primary 
keratinocytes (Jansen et al., 2004). The secondary structured region in the mRNA 
hinders the cap-dependent ribosomal scanning mechanism during the translation. Thus, 
in order to check the effect of Hpdcd4 on translation of 5’ structured mRNAs, luciferase 
constructs containing or lacking 5’ secondary structures (Fig.7) were transiently 
transfected into the HeLa WT and K12 cells. 
 
NcoI
EcoRI XbaI
pGL3’AmpFirefly Luciferase
XhoI BamHI
SV40
phpL
Hairpin Region
EcoRI XbaI
NcoI
AmpFirefly Luciferase
XhoI BamHI
SV40
 
 
 
 
 
Figure 7: Schematic diagram of reporter gene constructs 
 
The pGL3’ vector expresses firefly luciferase immediately after the SV40 promoter. The phpL vector codes for 
a RNA secondary structure and then expresses firefly luciferase.  
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The pGL3’ vector expresses firefly luciferase immediately after the promoter but the 
phpL expresses the luciferase after reading a RNA secondary structure which is 
believed to be hindering the normal cap-dependent translation. The experiment showed 
that there was no difference in the cap-dependent translation between WT and K12 
cells when pGL3’ was transfected (Fig.8a). The introduction of secondary structure 
reduced the cap-dependent translation in both WT and K12 cells but the fold of 
reduction was less in the K12 cells compared to the WT cells (Fig.8b).  However, this 
experiment showed that the translation of secondary structured-mRNA was higher in 
the absence than in the presence of Hpdcd4 (Fig.8a). It suggests that the Hpdcd4 
inhibits the translation of mRNAs with RNA secondary structure. 
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Figure 8: Effect of Hpdcd4 on RNA secondary structure 
  
10 µg each of pGL3’ and phpL were transiently transfected into the HeLa WT and K12 cells. To measure the   
efficiency of transfection, the cells were additionally transfected with pCMV β-gal (0.5 µg).  24 hrs after 
transfection the cells were harvested, lysed and assayed for β-galactosidase and luciferase activity. The 
luciferase activity was normalized to β-galactosidase activity. Average normalized values from triplicate 
experiments are shown in the figure. 
4.1.3 The effect of Hpdcd4 on IRES-Dependent Translation 
 
Cellular Internal Ribosome Entry Site (IRES) elements were preferentially found in the 
mRNAs of genes involved in the control of cellular proliferation, survival and death 
(Hellen and Sarnow, 2001). For example PDGF, VEGF, IGFII, c-Myc, c-Jun, PITSLRE, 
XIAP, DAP5, Apaf-1, Mnt and bag-1 mRNAs contain the IRES elements (Tara et al., 
2003). In order to study the effect of Hpdcd4 on IRES elements, IRES elements of 
genes related to apoptosis and cancer were chosen (Apaf-1, c-Myc, Mnt, and N-Myc) 
and the respective dual reporter gene constructs were obtained.  
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Though the firefly luciferase gene is widely used as a reporter gene for studying the 
promoter function and gene expression, normally a second reporter gene (e.g., 
beta-galactosidase) is used as an internal experimental standard to normalize for the 
differences in transfection efficiencies and other experimental variations. Dual reporter 
refers to the simultaneous expression and measurement of two individual reporter 
enzymes within a single system and it is commonly used to improve the experimental 
accuracy. Here, we used a dual luciferase system having two non-overlapping open 
reading frames (ORFs) for firefly (Photinus pyralis) and renilla (Renilla reniformis) 
luciferases. The renilla luciferase is expressed under the control of the SV40 promoter 
and enhancer region and the IRES element can be cloned upstream of the firefly 
luciferase gene (Fig.9). The firefly luciferase is expressed as a result of IRES-dependent 
translation. The bicistronic constructs with specific IRES elements were transiently 
transfected into the HeLa WT and K12 cells and both luciferase activities were 
measured sequentially from a single sample using dual luciferase assay kit (Fig.10). 
 
MCS
pRFFirefly Luciferase AmpRenilla Luciferase
MCS
SV40
C-Myc IRES
pRc-MycFFirefly Luciferase AmpRenilla Luciferase
MCS
SV40
 
 
 
 
 
 
Figure 9: Schematic diagram of dual luciferase constructs  
  
pRF is originally derived from pGL3 vector modified by inserting the renilla and firefly luciferases. The renilla 
luciferase is expressed from the SV40 promoter/enhancer region and the firefly luciferase is expressed from 
the IRES element. Various IRES elements could be cloned in between the two luciferases to assess their 
functional efficiency. (e.g.) pRc-MycF is cloned with c-Myc IRES using the multiple cloning sites in between 
the renilla and firefly luciferases.  
 
All different IRES elements show more firefly luciferase activity in the K12 cells 
compared to the WT cells. This demonstrates that the absence of Hpdcd4 increases the 
IRES element-dependent translation. Thus, this experiment shows that Hpdcd4 may 
have a direct or indirect inhibitory control over the IRES elements during normal 
physiological conditions. 
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Figure 10: Effect of Hpdcd4 on IRES elements 
 
Each 3 µg of pRApaf-1F, pRc-MycF, pRMntF and pRN-MycF dual luciferase constructs were transiently transfected 
into the HeLa WT and K12 cells. After 24 hrs cells were harvested, lysed and protein extract was prepared using 
promega dual luciferase kit. The firefly and renilla luciferase activities were measured sequentially in automated 
luminometer. Renilla luciferase activity was used for normalizing the firefly luciferase activity. The average 
normalized values from three independent experiments are shown in the figure.  
The effect of Hpdcd4 on c-myc IRES  
The proto oncogene c-myc is required for both cell proliferation and programmed cell 
death and deregulated c-myc expression is associated with a wide range of cancers 
(Henriksson and Luscher, 1996; Prendergast, 1999). The predominant mRNA of c-myc 
contains an IRES (~400 nt) in the 5´UTR region (Nanbru et al., 1997; Stoneley et al., 
1998). Thus, the initiation of translation of c-myc can occur by either a cap-dependent 
scanning mechanism or by internal ribosome entry. It has been shown that the IRES 
element was required to maintain the c-Myc protein synthesis under conditions when 
the cap-dependent translation initiation is compromised; for example during apoptosis 
(Stoneley et al., 2000a). Since Pdcd4 was shown to be involved in apoptosis and tumor 
suppression, the effect of knock-down of Pdcd4 on the c-Myc IRES was selected. The 
effect of Hpdcd4 on c-myc IRES was reproducible and the IRES activity was increased 
2.5 times more in the K12 cells compared to the WT cells as shown in figure 10. 
 
The effect of Hpdcd4 on c-myc IRES during Stress Conditions 
Previous studies have shown that c-myc IRES was active and c-Myc protein expression 
was maintained although a large reduction in total protein synthesis was observed 
during genotoxic stress (Subkhankulova et al., 2001). Therefore, in the next 
experiment the effect of Hpdcd4 on the c-myc IRES was assessed when stress was 
induced by UV treatment (Fig.11). The UV-irradiation is a nonreceptor-mediated 
induction of apoptosis (Spriggs et al., 2005; Latonen and Laiho, 2005).  
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Figure 11: Effect of Hpdcd4 on c-myc IRES during UV-induction 
 
Five µg of pRc-MycF was transiently transfected into the HeLa WT and K12 cells. 24 hrs later the 
transfection, cells were split and treated with UV 100 J/m2 (10 sec) or left untreated. 6 hrs later, cells were 
harvested, lysed and assayed for both, firefly and renilla luciferase activity using the promega dual luciferase 
assay kit. The figure shows the average normalized values from triplicate experiments.  
In the WT cells, the c-myc IRES activity is increased when the stress is induced 
compared to the untreated WT cells, however, the K12 cells did not show any 
difference in the IRES activity due to the UV treatment. Moreover, there was no 
significant difference in the IRES dependent translation between the UV treated WT and 
K12 cells.  
 
AraC, EMS, MMC, SSP, and TPA are known to induce genotoxic stress and thereby 
apoptosis (Subkhankulova et al., 2001). Cytosine arabinoside (AraC) is an analog of 
cytidine used as antineoplastic agent by selectively inhibiting DNA synthesis (DBR, 
1986). Ethylmethane sulfonate (EMS) is an alkylating agent which produces reactive 
electrophiles, which in turn causes single strand breaks in the DNA and induces cells to 
undergo apoptosis (Alderson, 1965). Mitomycin C (MMC) inhibits DNA synthesis. It 
reacts covalently with DNA, forming cross links between the complementary strands of 
DNA thereby preventing the separation of DNA strands. Thus, it inhibits DNA replication 
(Ueda and Komano, 1984). Staurosporine (SSP) is an alkaloid, a potent inhibitor of 
cap-dependent translation, and acts via inhibition of the phospholipid/Ca2+-dependent 
protein kinase (Tamaoki et al., 1986). Tetradecanoylphorbol acetate (TPA) is the most 
commonly used potent tumor promoter via activation of protein kinase C (Powell, 
2003).  In the present work, HeLa WT and K12 cells were treated with specific 
concentrations of these different chemicals to check the effect of Hpdcd4 on the c-myc 
IRES while the cells were undergoing stress (Fig.12). There was no significant 
difference in the IRES-dependent translation in the K12 cells compared to the WT cells.  
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Figure 12: Effect of Hpdcd4 on c-myc IRES during stress conditions 
 
2 µg of pRc-MycF was transiently transfected into the HeLa WT and K12 cells. After 24 hrs, cells were split 
and parallel culture were treated with 10 µM AraC, 50 mM EMS, 50 µM MMC, 500 µM SSP, and 10 nM TPA 
and harvested after 6 hrs. One culture was treated with UV 100 J/m2 (10 sec). The cells were harvested 24 
hrs later, lysed and assayed for firefly and renilla luciferase activity. The average normalized values of 
triplicate experiments are shown in the figure.  
4.1.4 The search for Novel Molecular Targets of Hpdcd4 – Transcription 
Factors 
 
Initially, a few transcription factors were identified as potential molecular targets of 
Hpdcd4. These factors are: ATF-2, c-Jun, c-Myc and C/EBPβ. The following table 2 
briefly describes their molecular functions.   
 
Table 2: The transcription factors as molecular targets of Hpdcd4 
 
Targets Mol.Wt (KDa) Molecular Functions 
ATF-2 70 Forms homo or hetero dimers with c-Jun to initiate CRE 
dependent transcription 
C/EBPβ 50 C/EBP family of transcription factor, control cell 
proliferation, differentiation and metabolism 
c-Jun 44 Major component of the leucine-zipper-dependent, 
heterodimeric AP-1 transcription factor 
c-Myc 67 Function in cell proliferation, differentiation and 
neoplastic diseases 
 
The effect of Pdcd4 on Phosphorylation of Transcription Factors 
One way to alter protein activity in response to extra- or intracellular signals is the 
modification of certain amino acid residues. The most prevalent covalent modification 
of proteins is the phosphorylation of certain amino acid residues. Approximately 30% of 
all cellular proteins contain covalently bound phosphate (Cohen et al., 2000). In 
general, the terminal (γ-) phosphoryl group of an ATP molecule is transferred to a 
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hydroxyl group of a serine, threonine or tyrosine residue of the protein and protein 
kinases catalyze the phosphorylation. Upon phosphorylation the chemical properties of 
the protein are influenced primarily by the introduction of two additional negative 
charges of the phosphoryl group and the ability to form three supplementary directed 
hydrogen-bonds (Hunter and Karin, 1992). Conformational changes of the protein 
might occur and result in different protein-protein interactions.  
 
The phosphorylation status of a few proteins was also of interest when studying the 
molecular targets of Hpdcd4.  When the cells were treated with UV, the cells undergo 
nonreceptor-mediated apoptosis due to stress (Spriggs et al., 2005; Wang et al., 
2006). In that process, many critical proteins involved in the cell survival and cell death 
get activated or deactivated by phosphorylation. To check the effect of Hpdcd4 on the 
phosphorylation status of the targets identified by 1D-SDS-PAGE, cells were UV induced 
and analyzed by immunoblotting. 
 
Activating transcription factor 2 (ATF-2) is a member of the ATF/cyclic AMP-responsive 
element binding protein family of transcription factors, found to possess growth 
factor-independent proliferation and transformation capacity (Papassava et al., 2004). 
It has been shown that UV and MMS stimulate ATF-2-dependent transactivation, which 
requires the presence of threonines 69 and 71 located in the transactivation domain. 
These sites were the targets of p54 and p46 stress-activated protein kinases (SAPKs), 
which phosphorylate ATF-2 (Van Dam et al., 1995). JNK1 is also a member of SAPK 
family, which is activated by many forms of stress including UV-irradiation, resulting in 
the phosphorylation of c-Jun, ATF-2, Elk-1 and p53 (Ramaswamy et al., 1998). 
Furthermore, another study has confirmed the phosphorylation of ATF-2 and c-Jun by 
JNK and p38 when induced by UV (Fisher et al., 1998).  
 
Therefore, UV-irradiation was chosen to study the phosphorylation profile of ATF-2, 
c-Jun and c-Myc transcription factors in the presence and absence of Hpdcd4. In the UV 
untreated cells, ATF-2 expression is barely observed. ATF-2 was expressed in 
detectable amounts only after the UV treatment. WT cells showed higher expression 
compared to the K12 cells (Fig.13).  The phosphorylation of ATF-2 was very well seen 
after UV-induction by both ATF-2 and P-ATF-2 immunoblotting. The degree of 
phosphorylation of ATF-2 was lower in K11 and K12 cells compared to the WT cells 
(Fig.13).   
 
The Jun proto-oncogene codes for the major 44 KDa form of the transcription factor 
AP-1 and it appears to occupy a central role in cellular signal transduction and 
regulation of proliferation (Angel et al., 1988). The c-Jun was slightly overexpressed in 
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knock-down cells compared to the WT cells (Fig.14). After the UV-induction, the 
expression level of c-Jun was higher compared to the untreated cells, but this increase 
was found to be similar in both WT and K12 cells (Fig.14). Phosphorylated c-Jun was 
seen as two major bands at ~40 KDa and less than 40 KDa connected by puffy signal; 
its expression was similar in all the three (WT, K11 and K12) untreated cells and was 
found to increase after UV treatment in all the cells (Fig.13). The lower band is more 
intense in untreated cells and the upper band is more intense in the UV treated cells. 
Although there is no difference in the phosphorylated c-Jun of the WT and the 
knock-down clones (K11, K12) (Fig.13), in comparison to the unphosphorylated c-Jun 
as input control (Fig.14), the phosphorylation of c-Jun was considered to be lower in 
the K12 cells compared to the WT cells. 
 
Deregulation of Myc expression is a common feature in cancer and leads to tumor 
formation in experimental model systems (Hooker and Hurlin et al., 2006). The potent 
oncoprotein plays a pivotal role as a regulator of tumorigenesis in numerous human 
cancers of diverse origin (Ponzielli et al., 2005) and this prompted us to check c-Myc 
expression. The c-Myc showed decreased levels of expression in the K11 and the K12 
cells compared to the WT cells under normal conditions. When UV induced, the 
expression of c-Myc has gone down in the WT as well as in the K12 cells (Fig.14).  
 
CBB staining
P-c-Jun
1:2000
P-ATF-2
1:2000
ATF-2
1:2000
Protein/KDa
Dilution+UV-+UV-+UV-
K12K11WT
 
 
 
 
 
 
Figure 13: The effect of Hpdcd4 on phosphorylation of the transcription factors   
 
HeLa WT, K11 and K12 cells were treated with UV 100 J/m2 (10 sec), incubated for 6 hrs, harvested, lysed 
in SDS-Laemmli buffer, samples were electrophoresed on 10% SDS PAGE followed by western blotting 
using specific mouse or rabbit mono/polyclonal antiserum as 1°Ab at specified dilution. Respective HRP 
conjugated 2° Ab was used. Loading of the cell lysates was normalized using the most abundant protein in 
the CBB staining. 
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Figure 14: The effect of Hpdcd4 on transcription factors during UV-induction 
HeLa WT and K12 cells were treated with UV 100 J/m2 (10 sec), incubated for 6 hrs and harvested. Then 
cells were lysed in SDS-Laemmli buffer, were electrophoresed on 10% SDS-PAGE followed by western 
blotting. The blot was probed with specific mouse or rabbit mono/polyclonal antibody as 1° Ab at specified 
dilution. Respective HRP conjugated 2° Ab was used. β-Tubulin was used as a loading control.  
4.1.5 The effect of Hpdcd4 on Transcription Factor C/EBPβ 
 
The transcription factor C/EBPβ belongs to CCAAT/enhancer-binding protein (C/EBP) 
family of transcription factors. This family consists of six transcriptions factors and 
C/EBPβ gene controls differentiation and proliferation in a variety of tissues. The 
C/EBPβ gene is intronless, but various isoforms are produced by alternative use of 
translation initiation codons from the same mRNA molecule through a leaky ribosomal 
scanning mechanism (Kozak, 1989). In addition, amino-terminal truncated isoforms are 
produced by limited proteolytic cleavage (Baer et al., 1998). C/EBPβ mRNA can 
produce the three isoforms (Fig.15) LAP*, LAP and LIP with the LAP and LIP forms 
being the major polypeptides produced in the cells (Descombes and Schibler, 1991).  
 
These isoforms retain different parts of the amino terminus and therefore display 
different functions in gene regulation and proliferation control.  An evolutionarily 
conserved upstream open reading frame in C/EBPβ mRNA is a prerequisite for 
regulated initiation from the different translation initiation sites and integrates 
translation factor activity. Deregulated translational control leads to aberrant C/EBPβ 
isoform expression which determines the cell fate. For example the LIP isoform consists 
only of the negative regulatory domain and is therefore capable of acting as a dominant 
negative inhibitor of C/EBPβ function by forming non-functional heterodimers (Ossipow 
et al., 1993). Expression of such truncated isoforms disrupts terminal differentiation 
and induces a transformed phenotype (Calkhoven and Ab, 1996).  
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In the present experiment the question addressed was whether Hpdcd4 influences the 
ratio of C/EBPβ isoform expression and thus the transformation of cells by affecting 
their cell growth. Figure 16 shows the schematic diagram for various C/EBPβ constructs 
used for the transfection.  
1 2 3 4 5 6 7 BR LZ
1    13 18          38           42       63              99   113118 131     145         179 184               222 243         328      
LAP*
3 4 5 6 7 BR LZ
22          
LAP
7 BR LZ
184       
LIP
TAD NRD
 
 
 
 
 
 
 
Figure 15: The schematic diagram of C/EBPβ isoforms (Descombes et al., 1991 and 
Leutz et al., 1994)  
 
Three different C/EBPβ isoforms can be produced by a leaky ribosomal scanning mechanism from the same 
mRNA. The numbers inside the scheme represent conserved regions; the numbers on top are amino acid 
residues; other abbreviations are: TAD: transactivation domain; NRD: negative regulatory domain; BR: basic 
region; LZ: leucine zipper; LAP: liver enriched protein; LIP: liver inhibitory protein 
EcoRI EcoRINcoI
Full length SV40-C/EBPβ (1328 bp)SV40 AmpC/EBPβ CDSUTR
Utrless SV40-CEBPβ(1137 bp)SV40 Amp
EcoRINcoI
C/EBPβ CDS
Utrless CMV-C/EBPβ (1012 bp)CMV Amp
XbaIEcoRI
C/EBPβ CDS
 
 
 
 
 
 
Figure 16: The C/EBPβ constructs used for transfection  
 
pSG5/NF-M#16.3 is the full length SV40-C/EBPβ of 1328 bp length. C/EBPβ is expressed under the control of 
SV40 promoter in this vector. Utrless-pSG5-C/EBPβ (~1.1 Kb) is deprived of the upstream region, expressed 
from SV40 promoter and termed as Utrless SV40-C/EBPβ. pcDNA3-CCR is C/EBPβ without the upstream 
region; length 1012 bp expressed from pCMV-promoter, termed as Utrless pCMV-C/EBPβ. Abbreviations: 
UTR:Untranslated Region; CDS: Coding Sequence. 
 
The effect of Hpdcd4 on C/EBPβ was analyzed by transiently transfecting the full length 
C/EBPβ (Full length SV40-C/EBPβ) into HeLa WT and K12 cells (Fig.17). The full length 
and truncated version of the C/EBPβ are corresponding to the molecular weight of 46 
KDa and 40 KDa, respectively. There were two bands observed both in the WT and K12 
cells which correspond to the transfected C/EBPβ. In addition, a middle band between 
these two bands was also seen in the transfected as well as untransfected cells. This 
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band might correspond to endogenous C/EBPβ or to non-specific protein. In both cells, 
the full length isoform was less intense than the truncated isoform. The expression of 
both the isoforms was found to be increased in the K12 cells compared to the WT cells.  
 
K12WTK12WTK12WTK12WT
No 
Transfection
Utrless 
CMV-C/EBPβ
Utrless
SV40-C/EBPβ
Full length
SV40-C/EBPβ
Full length C/EBPβ
Shorter length C/EBPβ
46 KDa
40 KDa
 
 
 
 
 
 
 
Figure 17: The effect of Hpdcd4 on C/EBPβ  
 
HeLa WT and K12 cells were transiently transfected with each 10 µg of full length SV40-C/EBPβ 
(pSG5-NFM#16.3) and Utrless SV40-C/EBPβ (Utrless-pSG5-C/EBPβ) and 3 µg of Utrless CMV-C/EBPβ 
(pcDNA3-CCR). In addition, pCMV-β-gal (0.5 µg) was transfected.  24 hrs later the cells were harvested and 
lysed in SDS-Laemmli buffer. The transfection efficiency was calculated by measuring β-galactosidase 
activity and the loading of cell lysates was normalized. Samples were run on 10% SDS-PAGE followed by 
western blotting. The blot was probed with rabbit polyclonal antiserum as 1° Ab at 1:1000 dilution then anti-
rabbit HRP conjugated 2° Ab was used.  The different isoforms of C/EBPβ are indicated by arrows.  
 
However, to study the effect in detail, and to assess whether Hpdcd4 operates at the 
promoter level of C/EBPβ or at a different level, C/EBPβ was cloned without the 
upstream region into the PSG5 vector (Utrless SV40-C/EBPβ). The removal of upstream 
region changed the expression pattern, the truncated version of C/EBPβ was not 
expressed and the full length form was overexpressed in the K12 cells compared to the 
WT cells. To analyze the influence of SV40 promoter present in the pSG5 vector on the 
effect of Hpdcd4, C/EBPβ without upstream region expressed from CMV-promoter in 
pcDNA3 vector (Utrless CMV-C/EBPβ) was transfected into the WT and K12 cells. The 
higher molecular weight form of C/EBPβ was overexpressed in the K12 cells compared 
to the WT cells, but the truncated, lower molecular weight form disappeared in both the 
cells. The above experiments prove that Hpdcd4 has an inhibitory control over C/EBPβ, 
which is independent of the promoter.  Hpdcd4 may act by controlling C/EBPβ at a 
different level. In addition, the necessity of the upstream region for producing lower 
molecular weight forms of C/EBPβ was confirmed.  
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4.1.6 The search for Novel Molecular Targets of Hpdcd4 – A Proteomic 
Approach 
 
More than tens of thousands of proteins differing in abundance over six orders of 
magnitude and different in functions are expressed in the cell. The term proteome 
describes the entire complement of proteins in a given biological organism, cell or a 
system at a given time (Wasinger et al., 1995). Proteomics provides a comprehensive 
approach to the analysis of cellular molecular mechanisms by resolving the protein 
properties (expression levels, interactions, posttranslational modifications etc.,) of the 
cells using 2-dimensional-sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(2D-SDS-PAGE) followed by mass spectrometry (MS) (Williams and Hochstrasser, 
1997; Gorg et al., 2000). Such a holistic approach is essential for finding novel 
molecular targets of new genes like Pdcd4. Rather than looking for effect of Pdcd4 on 
specific proteins in 1D-SDS-PAGE which confines and limits the search for novel 
targets.  
 
The discovery of 2D gels in the 1970s provided the first feasible way of displaying 
almost 1000 proteins on a single gel (Klose, 1975; O’Farrell, 1975). Identification of 
those proteins in subpicomolar quantities via MS was made possible by soft ionization 
techniques like electrospray ionization (Wilm et al., 1996). Eventually, 2D-SDS-PAGE 
and MS together have become the core elements of the proteomics field.  
 
2D-SDS-PAGE (O’Farrell, 1975) sorts proteins according to two independent properties 
in two discrete steps. The first dimensional step, isoelectric focusing (IEF), separates 
proteins according to their isoelectric points (pI); the second dimensional step, 
SDS-PAGE, separates proteins according to their molecular weights (MW).MS is an 
analytical technique measures an intrinsic property of a molecule, the mass with high 
sensitivity, calculates the mass-to-charge ratio of ions and generates a mass spectrum 
for the sample components. Molecules are first ionized, next separated according to 
their mass-to-charge ratio (m/z) and finally detected. MS can give sequence data from 
any Coomassie stained gel spot/band. The proteins are digested enzymatically in the 
excised gel slice using trypsin and the resulting peptides are extracted and purified by 
reversed phase chromatography for peptide mapping and sequencing. A characteristic 
set of peptides is generated for each protein and subsequent mass spectrometric 
analysis of the generated peptides provides a peptide map or mass fingerprint. The 
obtained peptide maps are aligned with the standard peptide maps in the database and 
thus such sequence analysis allows protein identification. Database tools used are 
protein prospector, Mascot and PROWL. The principle of the mass spectrometric 
analysis of proteins is explained in the figure 18. 
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Figure 18: Proteomic analysis by mass spectrometry     
 
The proteins can be digested enzymatically in the excised gel slice using, for example trypsin. The resulting 
peptides are then extracted and purified for peptide mapping and sequencing. The peptide mass finger print 
of a sample protein is compared with the database entries and thus the protein is identified. 
The 2D-SDS-PAGE Targets 
To identify novel targets for Hpdcd4, Hela WT and K12 cells were analyzed by 
2D-SDS-PAGE (Fig.19). In the first dimension (1D) different pH ranges like 3-10, 4-7 
and 6-11 were used and in the second dimension (2D) 10% SDS-PAGE was performed. 
Five different proteins were reproducibly differentially expressed in K12 cells compared 
to WT cells. The five spots corresponding to the unknown proteins were sliced out from 
the gels and eluted proteins were further analyzed by MS from the proteomic facility 
available at the integrated functional genomics of IZKF, Muenster. 
 
The protein of spot S1 is overexpressed in the K12 cells compared to the WT cells and 
was identified as cytokeratin-17 (CK-17). The proteins corresponding to spots S2 and 
S3 were visible only in the K12 cells but not in the WT cells. They were identified as 
aldo keto reductase1 (AKR1) family members C2 and C3. There was no quantitative 
change in the expression level of the protein in spot S4, but two related small spots 
appeared right next to it. The protein of spot S4 was identified to be cytokeratin-8 
(CK-8). The protein of spot S5 was identified to be glutamyl and prolyl bifunctional 
tRNA synthetase (GluProRS) which was appearing as ‘5-6 pearls in a string’ (this term 
was coined to better visualize/imagine 5-6 discrete protein spots appear in a row with 
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uniform interval in less than 1 cm in the 2D-SDS-PAGE) in the K12 cells but as a single 
spot in WT cells. The following table 3 displays the name of the spots and their 
differential expression profile in the 2D-SDS-PAGE. 
 
Table 3: The novel molecular targets of Hpdcd4 
 
S.No HeLa WT HeLa K12 Name of the target 
S1 Less 
intense 
Overexpressed Cytokeratin–17 (CK-17) 
S2 Absent New spot appears Aldo Keto Reductase Family member C2 
(AKR1C2) 
S3 Absent New spot appears Aldo Keto Reductase Family member C3 
(AKR1C3) 
S4 Single 
spot  
2 more related 
spots appear 
Cytokeratin–8 (CK-8) 
S5 Single 
spot 
5-6 spots appear 
as pearls in string  
Glutamyl and Prolyl Bifunctional tRNA 
Synthetase (GluProRS) 
 
The table 4 describes about each target, such as the swissprot database ID, the 
molecular weight by MS and the functional importance. CK-17 and CK-8 belong to the 
acidic and basic intermediate filament families, respectively. They both are structural 
element of normal epithelial cells. They are used as tumor markers for the classification 
of tumors since their expression is different based on the origin of the tumor. AKR1C2 
and C3 reduce aldehydes and ketones to alcohols in normal tissues but are used as 
tumor markers in a variety of tumors. GluProRS is a bifunctional tRNA synthetase 
enzyme found to have RNA binding activity, which might carry some significance in the 
tumor tumor progression. 
 
Table 4: The molecular functions of the novel targets 
 
Swiss Prot ID Targets Mol.Wt (KDa) Molecular Function & Significance 
Q04695 CK-17 48.0 Marker of basal cell differentiation 
P52895 AKR1C2 36.7 Bile acid & electron transporter, 
upregulated in cancer 
P42330 AKR1C3 36.8 Reduces aldehyde &  ketones to 
alcohol 
P05787 CK-8 53.6 Structural & functional protein of 
intermediate filaments 
P07814 GluProRS  163.0 Bifunctional tRNA synthetase 
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Figure 19: Identification of novel molecular targets of Hpdcd4  
 
1-1.5 X 105 cells/ml each from the HeLa WT and K12 cells were seeded and harvested the next day. The 
proteins were isoelectrically focused in the 1D using immobiline dry pH gel (IPG) strip of pH (3-10) and 10% 
SDS-PAGE was performed in the 2D. The gels were stained by Coomassie brilliant bule (CBB). The 2D-SDS-
PAGE experiment was repeated three times and the reproducibly differentially expressed five spots were named 
as spot1-spot5 (S1-S5) and further analyzed.  
 
To prove the identity of each individual target, specific monoclonal or polyclonal 
antibodies were procured. All five targets were tested individually by 1D-SDS-PAGE 
immunoblotting. The following figure 20 shows the western blotting of WT, K11 and 
K12 cells probed for the novel molecular targets.  In addition, the western blot was 
probed with rabbit Polyclonal Hpdcd4 antibody to check the expression level of Hpdcd4. 
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Human aldo keto reductase 1C (AKR1C) isozymes are implicated in the pre-receptor 
regulation of steroid receptors, nuclear orphan receptors and membrane-bound 
ligand-gated ion channels (Bauman et al., 2004). AKR1C3 is one of the most 
interesting isoforms which is involved in the local production of active androgens within 
the prostate. Its expression in stromal cells is increased with benign and malignant 
diseases (Penning et al., 2006). Moreover, the tumor molecular profile from studies 
revealed the overexpression of few proliferative genes including elevated AKR1C3 in 
certain tumors (Mahadevan et al., 2006) and in prostate carcinoma (Fung et al., 2006). 
The loss of AKR1C1 and AKR1C2 was observed in breast cancer cells and prostate 
cancer cells (Ji et al., 2003; Ji et al., 2004). In the current study, AKR1C2 and C3 were 
highly expressed only in the K12 but not in the WT cells and also not in another 
knock-down clone, K11. This might be either due to clonal variation or due to the 
different extent of downregulation and thereby expression of Hpdcd4 in the two 
different knock-down clones. 
 
CK-17 is expressed in various epithelia (Troyanovsky et al., 1992), including 
myoepithelial cells, basal layers of transitional and pseudo-stratified epithelia of the 
respiratory and urinary tracts, and early developmental stages of stratified epithelia. 
Common characteristics of these cells are contractility and/or frequent changes in 
shape. Normal adult epidermis does not contain CK-17, but certain pathological states, 
including psoriasis as well as benign and malignant neoplasms, lead to CK-17 
expression (Jiang et al., 1994). Furthermore, CK-17 is identified to be overexpressed in 
invasive carcinomas (Carrilho et al., 2004) and during wound healing (Coulombe and 
Omary, 2004). As a rule, defined pairs of keratin proteins are coexpressed, but CK-17 
seems to be one of the exceptions to this rule, because its specific coexpression partner 
has never been found (Jiang et al., 1994). In the present work, CK-17 was found to be 
overexpressed in the K11 and K12 cells compared to the WT cells. 
 
Human GluProRS is a bifunctional tRNA synthetase enzyme that contains three tandem 
repeats linking the two catalytic domains and these repeat motifs were shown to be 
involved in protein-protein and protein-nucleic acid interactions with higher affinity 
(Jeong et al., 2000). The interest in GluProRS was due to the appearance of new spots 
as 5-6 pearls in a string in the Coomassie stained 2D-SDS-PAGE of K12 cells. In a 
1D-SDS-PAGE, it showed similar level of expression in all three cells (WT, K11 and 
K12) tested. 
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Figure: 20: The novel molecular targets on 1D Immunoblotting  
 
HeLa WT, K11 and K12 cells were harvested, lysed in SDS-Laemmli buffer and samples were electrophoresed 
on 10% SDS-PAGE followed by western blotting was performed. The blot was probed with specific mouse, 
rabbit or goat mono/polyclonal antibodies as 1° Ab at the mentioned dilution. Respective HRP conjugated 2° 
Ab was used. Loading of the cell lysates was normalized by using β-tubulin.  
4.1.7 The Effect of Hpdcd4 on the Biochemical Modification of CK-8 
 
CK-8 expression was similar in both WT and clone cells as observed in the 
1D-SDS-PAGE (Fig.20), but the interest in further analysis of CK-8 was due to the 
observation of 2 related spots appearing towards the lower pI side of CK-8 in the 
2D-SDS-PAGE which might represent biochemically modified, possibly, phosphorylated 
forms of CK-8. To study the biochemical modification of CK-8 in detail, the CK-8 related 
spots were analyzed by 2D-SDS-PAGE and immunoblotting. Firstly, WT, K11 and K12 
cells were analyzed in a narrower pH range (4-7) to confirm the appearance of CK-8 
related molecular weight spots on the lower pI side of CK-8 in the 2D-SDS-PAGE using 
CK-8/18 specific antibody, (Fig.21). It was observed that only one spot appeared in the 
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lower pI side of the CK-8 spot. The second CK-8 related spot has not appeared and 
therefore might not be related to CK-8. As CK-8 and the related spot were well 
separated by this particular pH range, for further CK-8 analysis, this pH range was 
used. Once the reproducibility of the appearance of the spot was proven in the K11 and 
K12 cells, it was confirmed that this new spot was the result of a biochemical 
modification by Hpdcd4. The next question was to identify the biochemical modification, 
which changes the pI of the CK-8 protein but not the molecular weight. As UV 
treatment is one of the best sources for inducing phosphorylation, the WT and K12 cells 
were treated with UV followed by 2D-SDS-PAGE. Immunoblotting was performed to 
check the status of the CK-8 related spot. After the UV treatment, in the WT cells, a 
new spot was visualized. It was found to be very similar to the spot which appeared in 
the K12 untreated cells (Fig.22). The UV treated K12 cells did not show any difference 
in the intensity of the new spot compared to the UV untreated K12 cells (Fig.22). 
 
CK-8
K11
K12
pH 7.06.05.04.0
55 KDa
WT
 
 
 
 
 
 
 
Figure 21: The effect of Hpdcd4 on the biochemical modification of CK-8 
 
HeLa WT, K11 and K12 cells were harvested and the whole protein extract was prepared by calbiochem 
proteoextraction kit. 1D isoelectric focusing was performed for the pH range of 4-7. In the 2D 10% 
SDS-PAGE was performed followed by western blotting. The blot was probed with mouse monoclonal CK-8/18 
as 1° Ab and then anti-mouse HRP conjugated 2° Ab was used. CK-8 is marked by a thick-short arrow at 55 
KDa and the appearance of CK-8 related spot is marked by thin-long arrows at the similar MW in the figure.  
It has already been shown that CK-8 can be phosphorylated by protein kinase C (PKC) 
(Ridge, 2005) or by Jun N-terminal Kinase (JNK) (Jian, 1997). To check the effect of 
Hpdcd4 on PKC mediated phosphorylation of CK-8, K12 cells were treated with TPA 
followed by 2D-SDS-PAGE and immunoblotting. The spot suspected to be 
phosphorylated CK-8 appeared to be more intense in the TPA treated K12 cells than in 
the DMSO treated control K12 cells (Fig.23). In addition to that two more CK-8 related 
spots appeared to the right and left of CK-8 in the TPA treated K12 cells, indicated by 
dashed arrows (Fig.23).  
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Figure 22: The effect of Hpdcd4 on biochemical modification of CK-8 during UV-
induction  
 
HeLa WT, K11 and K12 cells were harvested after UV 100 J/m2 (10 sec) treatment followed by 6 hrs incubation 
and the whole protein extract was prepared by calbiochem proteoextraction kit. 1D isoelectric focusing was 
performed with the pH range of 4-7. In the 2D 10% SDS-PAGE was performed followed by western blotting. 
The blots were probed with mouse monoclonal CK-8/18 as 1° Ab and then anti-mouse HRP conjugated 2° Ab 
was used. The appearance of CK-8 related spot is indicated by thin-long arrows in the figure.  
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4.1.8 Expression of Pdcd4 Targets at the RNA Level 
 
Figure 23:The effect of Hpdcd4 on biochemical modification of CK-8 during TPA 
treatment  
 
HeLa K12 cells were treated with DMSO (as control) and 250 nm TPA for 1 hr, harvested, and the whole 
protein extract was prepared by calbiochem proteoextraction kit. In the 1D isoelectric focusing was 
performed for pH range 4-7 and in the 2D 10% SDS-PAGE was performed followed by western blotting. The 
blots were probed with mouse monoclonal CK-8/18 as 1° Ab and anti-mouse HRP conjugated 2° Ab was 
used. The appearance of CK-8 related spot is indicated by a thick arrow in the figure. Two more spots 
appeared in the TPA treated 2D-SDS-PAGE, as indicated by dashed arrows. 
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In addition to its suspected role in protein translation, Pdcd4 was also shown to have 
RNA binding activity which is dependent on RNA binding domain present in the 
N-terminal part of the protein (Boehm et al., 2003). This raises the possibility of 
involvement of Hpdcd4 function at RNA level. The analysis of the effect of Hpdcd4 on 
differential protein expression has revealed a set of cancer related genes which were 
further analyzed at the RNA level.  
 
PolyA RNA was isolated from the WT and K12 cells and northern blotting was performed 
to check the effect of Hpdcd4 on c-Jun, c-Myc and CK-17 mRNAs (Fig.24). The 
respective mRNAs transcripted from the CK-17 and c-Myc genes were highly correlated 
with their differential protein expression profile except in case of c-Jun. The c-Jun 
mRNA level was quantitatively equal in both WT and K12 cells. The CK-17 showed 
higher mRNA levels in the K12 cells compared to the WT cells. In contrast, c-Myc mRNA 
was expressed less in the K12 cells than in the WT cells.  
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Figure 24: Expression of Pdcd4 targets at the RNA level 
 
HeLa WT and K12 cells were harvested and polyA RNA was isolated using oligo dT cellulose. The samples 
were electrophoresed on 1% Formaldehyde-Agarose gel, blotted onto a nylon membrane overnight, and 
hybridized with different probes. The specific DNA fragments were labeled by α-32P-dCTP and probes 
prepared by nick translation using Amersham G50 columns.  S17 was used as a loading control. The specific 
RNAs are indicated by arrow. The quantitative expression of mRNA is indicated in percentage after 
normalizing with S17 mRNA.  
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The effect of Hpdcd4 on CK-17 RNA  
The effect of Hpdcd4 on CK-17 was studied in further detail. Because it is possible that 
the probe used to detect CK-17 RNA also cross reacts with mRNAs of other 
cytokeratins, CK-17 mRNA was also analyzed by RT-PCR using CK-17 specific primers. 
Total RNA isolated from both HeLa WT and K12 cells was reverse transcribed and 
amplified by PCR reaction using β-actin and CK-17 specific primers (Fig.25). CK-17 
mRNA expression was higher in the K12 cells compared to the WT cells. This result is 
consistent with the previous northern blotting experiment (Fig.24). 
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Figure 25:  The effect of Hpdcd4 on CK-17 mRNA  
 
HeLa WT and K12 cells were harvested and the total RNA was isolated using Nucleospin total RNA isoloation 
kit. Reverse transcription was performed using oligo dT primers.  PCR amplification of CK-17 was done using 
ss cDNA as a template and using CK-17 specific primers (at 65°C as annealing temperature and 35 cycles of 
PCR).  Β-actin was used as an internal control, β-actin specific primers were used for PCR amplification at 
69°C as annealing temperature. – symbol in the figure is negative control without template, to confirm the 
specificity of the primers.  The β-actin (850 bp) and the CK-17 (650 bp) PCR products are marked by 
arrows. 
4.1.9 The effect of Hpdcd4 on mRNA Stability 
 
As Hpdcd4 is affecting the RNA level of CK-17 and c-Myc, it may be regulating the 
expression of CK-17 and c-Myc at the posttranscriptional level. Gene expression is 
finely regulated at the posttranscriptional level. Features of the untranslated regions of 
mRNAs that control their translation, degradation and localization include stem-loop 
structures, upstream initiation codons and open reading frames, internal ribosome 
entry sites and various cis-acting elements that are bound by RNA binding proteins 
(Mignone et al., 2002). Multiple mRNA binding proteins that interact specifically with 
defined regions in posttranscriptionally regulated mRNAs were characterized 
(Rajagopalan and Malter, 1997).  The binding proteins, in turn, are subdivided into 
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classes that either stabilize or destabilize mRNA. The proteins that regulate mRNA 
half-lives, affect, in turn, cell growth, differentiation and response to its environment 
(Ross, 1995). In general the mRNA half-life can be measured by culturing the cells with 
a transcription inhibitor and harvest at different time points thereafter. The most 
frequently used transcription inhibitors are actinomycin-D, cordycepin, α-amanitin and 
5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (Ross, 1995).  
 
Hpdcd4 binds RNA through its N-terminal RNA binding domain (Bohm et al., 2003). 
From the previous experiment, it was found that the level of CK-17 and c-Myc mRNAs 
was increased by Hpdcd4. It is possible that Hpdcd4 is either acting at the promoter 
level of these genes or is involved in the turn-over and thereby the stability of the 
mRNAs. To elucidate the effect of Hpdcd4 on the turn-over of CK-17 and c-Myc mRNA 
transcripts, the HeLa WT and K12 cells were treated with a transcription inhibitor. The 
cells were harvested at different time points after actinomycin-D treatment. 
Actinomycin-D forms a stable complex with DNA and blocks the movement of RNA 
polymerase which interferes with DNA-dependent RNA synthesis. This ensures that the 
change in the level of mRNA transcript is only due to the stability of the mRNA rather 
than due to the change in transcription. The following figure (Fig.26) shows the 
northern blot hybridized with different probes.  At the 5 hr time point, no mRNA was 
seen.  
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Figure 26: The effect of Hpdcd4 on mRNA stability 
 
HeLa WT and K12 cells were treated with and without actinomycin-D (10 µg/ml), incubated for 1, 2 and 5 
hrs and harvested. PolyA RNA was isolated using a oligo dT cellulose column. The RNA was fractionated on a 
1% Formaldehyde Agarose gel and blotted onto a nylon membrane overnight. The blot was hybridized with 
specific α-32P-dCTP labeled probe and S17 mRNA was used as an internal control. The blots were exposed to 
phosphor imager screen for quantitative analysis. – in the figure refers to actinomycin-D untreated cells. 
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The northern blot from the previous experiment was quantitated, normalized by S17 
mRNA and the data points were plotted (Fig.27). Compared with CK-17, c-Myc mRNA 
has a shorter half-life and degraded faster, in contrast CK-17 has a longer half-life. In 
case of both CK-17 and c-Myc, the WT cells degraded the mRNAs faster than the K12 
cells.  
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Figure 27: The effect of Hpdcd4 on mRNA stability  
The quantified and S17 normalized data from the northern blot shown in the figure 26 was used to plot the 
graph. The values from the actinomycin-D treated cells were normalized to the values from the untreated 
cells. The mRNA stability from the untreated cells was arbitrarily expressed as 100% a) CK-17 mRNA and b) 
c-Myc mRNA. 
4.1.10 The effect of Hpdcd4 on Nonsense-Mediated mRNA Decay  
 
In addition to the role of Hpdcd4 on the stability of normal mRNA transcripts, the effect 
of Hpdcd4 on degradation of mRNAs with a nonsense mutation in the coding region was 
also analyzed. Accurate gene function depends on a low error rate of each step of the 
gene expression pathway. The fidelity of gene expression is enhanced further by a 
phylogenetically widely conserved quality control mechanism against faulty mRNAs with 
premature translation termination codons (PTC), which has been termed 
nonsense-mediated mRNA decay (NMD) (Neu-Yilik et al., 2001). In all the organisms, 
mRNAs are destabilized by 10-fold or more when they contain PTCs (Ross, 1995). In 
mammals, NMD operates as a posttranscriptional mechanism in the nucleus. The NMD 
is thought to operate in two possible steps, the abnormal splicing followed by 
degradation of spliced mRNAs (Hentze and Kulozik, 1999). The β-Globin mRNA is the 
most stable mRNA having half-life of more than 24 hr and it is subjected to NMD due to 
the presence of PTC mutations in the 5´proximal exon of its mRNA. To study NMD, the 
degradation of a β-Globin gene construct with a nonsense mutation at the position of 
39 in the exon 2 which is compared to the corresponding WT construct degradation 
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(Neu-Yilik et al., 2001). The WT and mutant (NS39 at 2nd exon) β-Globin DNA 
constructs were transfected into the HeLa WT and K12 cells and mRNA was isolated 
followed by northern blotting using a β-Globin-specific probe (Fig.28). The mutant 
β-Globin mRNA was found to be degraded almost completely, but the degradation in 
the WT cells was slightly more efficient compared to the K12 cells, lacking Hpdcd4 
(Fig.29).  
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Figure 28: Effect of Hpdcd4 on NMD  
 
The WT and mutant β-Globin DNA were transiently transfected into HeLa WT and K12 cells with 
pCMV-β-galactosidase to check the transfection efficiency. 48 hrs later, the cells were harvested; PolyA RNA 
isolation was performed using oligo dT cellulose and northern blotting was performed overnight. The 
membrane was hybridized with the S17 and the NMD probe (α -32P-dCTP labeled β-Globin full length DNA). 
The blots were exposed to phosphor imager screen and quantitated. No T: Non-transfected cells.  S17 and 
β-Globin mRNA are marked by arrows.  
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Figure 29: Effect of Hpdcd4 on NMD  
The quantitative data from the northern blot was used to plot a graph. The transfection efficiency was 
normalized by using β-galactosidase values. The northern blot bands were quantified and values of NS-β-
Globin were normalized to the values of WT β-Globin. The WT β-Globin values of WT and K12 cells were 
arbitrarily expressed as 100%. 
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4.2 Downregulation of Pdcd4 – Knock-Out-System 
4.2.1 Targeted Disruption of the Chicken Pdcd4 gene  
 
In nature, homologous recombination is a DNA repair and maintenance pathway that 
protects chromosomes against damage affecting both strands, such as double strand 
breaks (DSB) or interstrand cross-links (Jasin, 2000). The recombination machinery 
has been conserved throughout the evolution, as an essential component of cell 
survival. This maintenance role of homologous recombination is used as a molecular 
biology tool in targeting the chromosomal DNA. To perform homologous recombination, 
the DNA sequence of the gene which will be replaced should be known. With this 
information, it is possible to replace any gene with a targeting construct containing a 
selection marker flanked by homologous gene sequences.  
 
DT40 is a chicken pre B lymphoblast suspension cell line, which shows high rates of 
recombination. Homologous recombination allows the precise replacement of a 
sequence with another. In order to replace parts of both the functional copies of the 
chicken Pdcd4 gene (Cpdcd4), two different targeting constructs with histidinol and 
puromycin resistance cassettes were received (Bitomsky, 2003).  
 
By screening a genomic library of chicken DNA with a probe derived from a chicken 
Pdcd4 (Cpdcd4) cDNA clone (Schlichter et al., 2001a) genomic clones that encompass a 
major part of the chicken Pdcd4 gene was isolated (Schlichter et al., 2001b). Two 
Cpdcd4 targeting constructs conferring histidinol and puromycin resistance were made 
by replacing part of the Cpdcd4 by respective antibiotic resistance cassette (Bitomsky, 
2003). Figure 30a shows the schematic diagram of the histidinol targeting construct 
and the expected fragment pattern of ApaI digestion in Southern blotting.  
 
DT40 cells were first transfected with the targeting construct conferring histidinol 
resistance followed by selection in the presence of 0.5 mg/ml L-histidinol. The resulting 
clones were then analyzed by Southern blotting for disruption of one copy of Cpdcd4 
using a probe derived from the 5’ end of the gene. A positive clone (K18) was identified 
in the Southern blotting by the appearance of an ~7 kb novel ApaI restriction fragment 
and retaining a ~13 kb fragment unlike the WT cells, which retains both the ~13 kb 
fragments of WT Cpdcd4 (Fig.32). 
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Figure 30: The schematic diagram of the targeting constructs and fragment pattern  
 
(a) and (b) Schematic representation of the Cpdcd4 locus (thick black line) and the two targeting constructs 
used (Grey line). The histidinol (His) and puromycin (Puro) resistance genes are marked by white boxes. 
Relevant ApaI (A), BamHI (Ba), KpnI  (Kp), SacI (S) and XhoI (Xh) restriction sites are shown. The probe 
fragment is indicated by a black bar. When ApaI digestion followed by Southern blotting is performed, the 
expected fragment pattern is indicated by dashed arrows. Cpdcd4(+/-) histidinol resistant clones were 
expected to give a new approximately 7 Kb fragment and one old ~13 Kb fragment in stead of two WT-~13 
Kb fragments. Puromycin resistant clones were expected to give a new ~8.3 kb fragment. As the puromycin 
construct was targeted to the second copy of the Cpdcd4(+/-), led to the disappearance of both the copies of 
13 kb parental ApaI fragment and appearance of two novel ApaI fragments of ~7 kb and ~8.3 kb from the 
histidinol and puromycin constructs, respectively. 
 
Among the 36 clones tested, only one clone with one mutated copy of Cpdcd4, K18, 
was identified. Then a second construct with puromycin resistance was transfected and 
more than 54 resistant clones were analyzed by Southern blotting. There was no 
double mutant clone identified. It is presumably as the right arm of the puromycin 
targeting construct made by Bitomsky (2003) was only 600 bp in length, which might 
target the Pdcd4 inefficiently. Therefore, another targeting construct with a longer right 
arm of approximately 2.2 kb, conferring puromycin resistance was generated (Fig.31). 
In the present work, the new puromycin targeting construct and the expected fragment 
pattern of ApaI digestion in Southern blotting is shown in figure 30b. This longer right 
arm might possibly enhance the specific targeting of Cpdcd4 by homologous 
recombination. 
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Figure 31: The Cpdcd4 new puromycin targeting construct 
 
In case of the new puromycin targeting construct, a 2.2 kb fragment containing exons 7 to 9 with the 
intervening sequences was inserted into the pbl-pdcd4-targetPuro thereby replaced the 600 bp right arm of 
the targeting construct. 
The puromycin targeting construct was transfected into the histidinol resistant clone 
(K18) by electroporation. After selection in the presence of 1 µg/ml puromycin doubly 
resistant clones were obtained. These clones were again analyzed by Southern blotting 
to identify cells in which both copies of Cpdcd4 had been disrupted. The Southern blot 
shown in Figure 33 illustrates the successful targeting of both copies of the Cpdcd4 
gene. The Pdcd4 double mutant clones lost both the WT copy of the Pdcd4 (two ~13 kb 
fragments), in stead they produced two new fragments of ~7 kb and ~8.3 kb, 
respectively. 
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Figure 32: Southern blotting of Cpdcd4 Knock-out clones   
 
The genomic DNA was isolated from the DT40 WT, Cpdcd4 single and double mutant clones and digested by 
ApaI overnight. Southern blotting was done and the DNA hybridized with the probe from the 5’ side of the 
Cpdcd4 gene labeled by α-32P-dCTP. Both the WT copies of the ~13 Kb fragments of Cpdcd4 were lost in the 
K3 and K33 clones and two new ~7Kb and ~8.3 Kb fragments appeared.  
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4.2.2 The effect of the Disruption of Cpdcd4 on the Growth Characteristics 
 
To determine if the absence of Cpdcd4 affected the proliferation rate of the cells, the 
growth of Cpdcd4(+/+), (+/-) and (-/-) cells were analyzed (Fig.33). All of the cells 
grew with indistinguishable doubling times of approximately 12 hr. In addition, the cell 
cycle distribution of the Cpdcd4(+/+) and (-/-) cell populations by flow cytometry was 
determined. The fractions of the cells residing in different phases of the cell cycle were 
similar for each cell population (Fig.34).  
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Figure 33: The proliferation rate of DT40 Cpdcd4(-/-) and (+/+) cells 
 
The cells (K3 and WT) were grown in culture for 18 days and counted.  
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Figure 34: The cell cycle distribution of DT40 Cpdcd(-/-) and (+/+) cells 
 
The cells (K3 and WT)were grown in the culture, harvested, washed with 1X PBS for 3 times and stained with 
propidium iodide. Cell cycle analysis was performed using Fluorescence Activated cell Sorting (FACS) 
instrument. S: DNA synthesis; G1 and G2: Check points before and after S phase, respectively; Gap: Small 
cells. 
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4.2.3 The effect of Cpdcd4 on Translation 
 
Previous work has implicated Pdcd4 in the control of translation. Most eucaryotic 
mRNAs are translated by a cap-dependent mechanism in which eIF4G acts as a scaffold 
for other proteins, including eIF4A (Gingras et al., 1999). It has been suggested that 
overexpression of Pdcd4 suppresses translation initiation by interfering with the RNA 
helicase activity of eIF4A and by preventing its interaction with eIF4G (Yang et al., 
2003b). 
  
A subset of cellular mRNAs contains internal ribosomal entry sites (IRES) which 
mediates cap-independent translation initiation. In general, it was observed that many 
of the RNAs containing IRES elements are involved in important cellular processes, 
such as cell cycle, apoptosis, differentiation or development (Vagner et al., 2001; 
Stoneley and Willis, 2004). As previous studies on the role of Pdcd4 in translation 
initiation relied exclusively on cells overexpressing Cpdcd4 or on the use of in vitro 
translation systems it was of interest to assess the effect of the disruption of Pdcd4 on 
both mechanisms of translation initiation.  
 
The effect of Cpdcd4 on Cap-Dependent Translation 
To measure the overall rate of protein synthesis by labeling DT40 WT and K3 cells were 
labeled with 35S-methionine for a short time followed by quantification of the 
radioactivity incorporated into TCA-precipitable material. This experiment measures the 
overall rate of total protein synthesis, as most of the protein synthesis is 
cap-dependent when the cells are in the normal conditions. As shown in figure 35a the 
incorporation of 35S-methionine was very similar in Cpdcd4(+/+) and (-/-) cells, 
suggesting that the lack of Pdcd4 has no global effects on cap-dependent protein 
synthesis.  
 
When the cells were UV induced, the cap-dependent translation is compromised by 
IRES-dependent translation. To investigate the effect of Cpdcd4 on the 
cap-independent translation, the cells were treated with UV, labeled with 
35S-methionine, shortly after TCA precipitated and the incorporated radioactivity was 
quantitated (Fig.35b). There was no change in the IRES-dependent translation of WT 
and K12 cells when they were UV treated.  
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Figure 35: Effect of Cpdcd4 on total protein synthesis  
Dt40 Cpdcd4(+/+) and (-/-) (WT and K3) cells were seeded, grown in the culture and starved without 
methionine for 30 min. Then cells were fed with 35S-methionine and incubated for 1 hr.  Cells were 
harvested, washed, spotted over whatman filter paper and precipitated by trichloroaceticacid. Then exposed 
to the phosphorimager screen and quantitated. b) For the UV experiment cells were treated with UV 100 
J/m2 (1 min) or left untreated and incubated for 4 hrs. Then the samples were processed in the similar way 
mentioned in (a). 
To discern the possible effects on IRES-dependent translation bicistronic reporter gene 
constructs carrying a cap-dependent renilla luciferase gene and an IRES-dependent 
firefly luciferase gene were employed (Fig.9). The reporter genes containing several 
previously characterized IRES elements, derived from the c-Myc, N-myc, Apaf-1, Mnt 
and Xiap genes were used (Stoneley et al., 1998; Jopling and Willis, 2001; Coldwell et 
al., 2000; Stoneley et al., 2001; Holcik and Korneluk, 2000). The reporter genes were 
transfected into Cpdcd4(+/+) and (-/-) cells followed by measurement of the activities 
of the two luciferases. As illustrated in figure 36, there were only slight increases in the 
ratio of firefly to renilla luciferase activity in few cases, suggesting that the absence of 
Cpdcd4 does not have a major impact on the IRES-dependent translation of these 
genes.  
 
Effect of Pdcd4 on Apaf-1 IRES 
The dual luciferase constructs of each gene were also analyzed individually after UV 
induction. The Apaf-1 IRES was analyzed after different doses of UV treatment and 
incubation for different times (Fig.37). But no difference in the IRES-dependent 
translation was observed after UV treatment of the DT40 WT and K3 cells.  
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Figure 36: Effect of CPdcd4 on IRES elements  
The cells were transiently transfected with pRApaf-1F, pRc-MycF, pRMntF, pRN-MycF, and pRXIAF of each 
5µg by electroporation. After 24 hr of transfection, cells were harvested and cell lysate prepared for 
luciferase assay using the promega dual luciferase assay kit.  
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Figure 37: Effect of CPdcd4 on Apaf-1 IRES  
 
The cells were transiently transfected with 5 µg of pRApaf-1F by electroporation, treated with UV 100 J/m2 
(30 sec and 5 min), incubated and harvested after 1 hr, 2 hr, 4 hr and 8 hr.  After harvesting, cell lysates 
were prepared for luciferase assay using the promega dual luciferase assay kit. 
 
Effect of Pdcd4 on N-Myc and Mnt IRES 
N-Myc and Mnt IRES were analyzed after inducing with different doses of UV and 
incubated for different time points (Fig.38 and Fig.39). Though the error bars are large, 
the N-Myc IRES was affected by UV treatment and with increasing UV dose the 
IRES-dependent translation also increased. After UV-treatment the N-Myc IRES activity 
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was higher in the K12 cells compared to the WT cells. The UV treatment has not 
affected the Mnt IRES-dependent translation. 
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Figure 39: Effect of CPdcd4 on Mnt IRES 
 
The cells were transiently transfected with 3 µg of pRMntF by electroporation and treated with UV 100 J/m2 
(30 sec and 5 min), incubated and harvested after 1 hr, 2 hr, 4 hr and 8 hr.  After harvesting, cell lysates 
were prepared for luciferase assay using the promega dual luciferase assay Kit. 
Figure 38: Effect of CPdcd4 on N-Myc IRES 
 
The cells were transiently transfected with 3 µg of pRN-MycF by electroporation and treated with UV 100 J/m2 
(30 sec and 5 min), incubated and harvested after 1 hr, 2 hr, 4 hr and 8 hr.  After harvesting, cell lysates 
were prepared for luciferase assay using the promega dual luciferase assay kit. 
 
For the comparison of proteomic profile of the DT40 Cpdcd4(+/+) and the two 
Cpdcd4(-/-) clones (K3 and K33), 2D-SDS-PAGE was performed. But there was no 
reproducible difference observed in the expression profile of various proteins (Fig.40). 
 
4.2.4 2D-SDS-PAGE Analysis of Cpdcd4 Knock-out Clones   
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4.2.4 2D-SDS-PAGE Analysis of Cpdcd4 Knock-out Clones  
 
 
 
 
 
Figure 40: 2D-SDS-PAGE analysis of Cpdcd4+/+) and (-/-) cells   
 
1-1.5 X 105 cells/ml each from WT, A14 and A19 were seeded and the next day harvested. The total proteome extract was prepared, proteins were 
isoelectrically focused in the 1D using immobiline pH gel (IPG) strip of pH (3-10) and 10% SDS-PAGE was done in the 2D. The gels were stained by CBB. 
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4.3 Upregulation of Pdcd4 - Overexpression System  
4.3.1 Overexpression of the Human Pdcd4 gene  
 
The human lung carcinoma cell line (A549) was found to express very low amounts of 
Hpdcd4 (Jansen, 2004). Therefore, A549 cells were chosen to overexpress the Hpdcd4 
to study its molecular functions. For this purpose, a Hpdcd4 overexpression construct 
was made in the pcDNA3 and pcDNA4 vectors. HTB-133, the breast cancer cells, which 
express high amounts of Pdcd4, were used to generate a full length copy of Hpdcd4 by 
PCR. Figure 41a shows that an approximately 1500 bp fragment of Hpdcd4, which was 
amplified by PCR from these cells. The PCR product was then cloned into the TOPO 
cloning vector, sequenced, and finally cloned into the pcDNA3 (Fig.41b) and pcDNA4 
mammalian expression vectors. 
  
1.5 Kbp
(a)
(b)
Hpdcd4
Fragment
 
 
 
 
 
 
 
 
Figure 41: (a) The Hpdcd4 fragment and (b) the overexpression construct  
 
a) The total RNA was isolated from HTB-133, breast carcinoma cell line and ss cDNA was prepared by 
reverse transcription. PCR amplification of Hpdcd4 was done using specially designed Hpdcd4 cloning 
primers, which add a BamHI site at the 5’ end and HA tag followed by XhoI site at the 3’ end. The PCR 
product of 1500 bp fragment was checked in the 1% Agarose gel. Hpdcd4 fragment is indicated by arrow. b) 
The 1500 bp fragment of Hpdcd4 was cloned into the pCR2.1-TOPO cloning vector.  The positive clones were 
sequenced using M13 and T7 primers. The middle HindIII fragment of the Hpdcd4 was subcloned into the 
pCR2.1-TOPO vector again and sequenced using the same sequencing primers. Then the sequenced BamHI 
and XhoI complete fragment was cloned into the pcDNA3 mammalian expression vector. 
 
Transient Transfection 
After generating the overexpression construct, transient transfection of Cpdcd4 and 
Hpdcd4 into QT6 cells was done to check the integrity of the constructs (Fig.42). The 
Cpdcd4 expression was always higher than Hpdcd4.  
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Figure 42: The overexpression of Hpdcd4 by transient transfection 
 
Transient transfection of pcDNA3-Cpdcd4-HA (pcDNA3-i11/6HA) and pcDNA3-Hpdcd4-HA (1-5µg) was done. 
In addition pCMV-β gal was transfected (0. 5µg). The cells were harvested 24 hrs later and β-galactosidase 
assay was done to measure the transfection efficiency. The samples have loaded onto a 10% SDS-PAGE 
followed by western blotting. Mouse monoclonal anti HA antibody was used as a primary antibody, HRP 
conjugated anti-mouse antibody as secondary. The Cpdcd4 and Hpdcd4 are indicated by arrow.  
Stable Transfection 
Later the doxycycline inducible Cpdcd4 or Hpdcd4 construct was stably cotransfected 
with the tetracycline repressor plasmid into the A549 cells for inducibly overexpressing 
the Pdcd4 using doxycycline (Fig.43). The clones were selected by Blasticidin and 
Zeocin antibiotics. The stable clones were checked for inducible overexpression of the 
Pdcd4 protein by western blotting. Hpdcd4 overexpressing clones were not found. 
However, three Cpdcd4 overexpressing clones (A14, A19 and A20) were identified. 
These clones were constitutively overexpressing the Cpdcd4 protein, but not inducibly. 
Further experiments were done with these overexpression clones for the functional 
analysis of Pdcd4.  
  
Cpdcd4
55 KDa
+-+-+-+-Doxycycline
A20A19A15A14Clone
 
 
 
 
 
 
 
 
 
Figure 43: The overexpression of Cpdcd4 by stable transfection  
 
Stable cotransfection of pcDNA4/TO/myc-his-i11/6HA (15 µg) with pcDNA6-TR (20 µg) was done. The 
clones were selected using blasticidin and zeocin, grown and analyzed.  The samples were loaded onto a 
10% SDS-PAGE and western blotting was performed. Mouse monoclonal anti HA antibody was used as a 
primary antibody and HRP conjugated anti-mouse antibody as secondary. The Cpdcd4 is indicated by an 
arrow at 55 KDa.  
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2D-SDS-PAGE analysis of A549 WT and Cpdcd4 overexpressing clones (A14 and A19) 
was performed. Though there was some difference in the expression profile of various 
proteins, due to lack of reproducibility, no differentially expressed candidates was 
identified (Fig.44).  
 
4.3.2 2D-SDS-PAGE Analysis of Cpdcd4 Overexpression Clones  
 
The A549 WT and Cpdcd4 overexpressing clones were observed under fluorescence 
microscopy after staining with fluorescently labeled HA antibodies. It was found that 
Cpdcd4 was not overexpressed in the cells. It could be that the A549 cells are 
continuously eliminating the overexpression of Cpdcd4, possibly one of the survival 
strategies of the cancer cells. In future, for studying the effect of Pdcd4 using 
overexpression system could be possibly done by generating inducible overexpression 
clones.  
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4.3.2 2D-SDS-PAGE Analysis of Cpdcd4 Overexpressing clones 
 
 
 
 
  
 
 
Figure 44: 2D-SDS-PAGE analysis of Cpdcd4 overexpressing clones  
1-1.5 X 105 cells/ml each from WT, A14 and A19 were seeded and the next day harvested. The total proteome extract was prepared, proteins were 
isoelectrically focused in the 1D using immobiline pH gel (IPG) strip of pH (3-10) and 10% SDS-PAGE was done in the 2D. The gels were stained by CBB. 
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5 DISCUSSION 
 
The research summary is shown in the figure 45 followed by a detailed discussion in 
the subsequent sections. 
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Figure 45: The schematic diagram of the research summary   
 
The schematic diagram outlines the summary of the present work, including the development and 
characterization of the three Pdcd4 models and the molecular functional analysis of Pdcd4 by utilizing these 
systems.  
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5.1 Analysis of Pdcd4 in the HeLa Cells   
5.1.1 Downregulation of Human Pdcd4 by siRNA Technology 
 
The whole human genome consisting of three billion base pairs was sequenced by 
human genome project and it is predicted that the human genome contains about 
~35,000-50,000 protein-coding genes. However, the function of approximately half of 
the genes is yet to be identified. Reverse genetics is the most effective way to study 
the function of any new gene, provided the sequence is available. Unlike the forward 
genetics, in this approach the gene of interest is disrupted or modified and then the 
phenotype is analyzed. RNA mediated interference (RNAi) has emerged as a powerful 
reverse genetic tool to silence gene expression in plants and in multiple organisms, 
including Caenorhabditis elegans and Drosophila melanogaster. RNAi is an 
evolutionarily conserved phenomenon and a multistep process that involves generation 
of active small interfering RNA (siRNA) of 21-25 nt fragments in vivo through the 
function of RNase III endonuclease and Dicer on RNA. The formed siRNA binds to 
several proteins to form a complex called the RNA-induced silencing complex (RISC). 
siRNA is unzipped by an ATP-dependent process, which activates the RISC to bind and 
cleave the targeted mRNA (Elbashir et al., 2001b; Bernstein et al., 2001; Ishizuka et 
al., 2002).  
 
During this decade, the discovery of synthetic double-stranded, 21 nt siRNA triggering 
gene-specific silencing in mammalian cells has further expanded the utility of RNAi in 
mammalian systems (Elbazhir et al., 2001a; Caudy et al., 2002). Given the ability to 
knock down the homologous gene of interest, RNAi using siRNAs has generated a great 
deal of interest in both basic and applied biology. There is an increase in the number of 
genes being studied by applying siRNA technology.  
 
Pdcd4 is a novel gene identified only in the last decade. While there is accumulating 
evidence that Pdcd4 is a tumor suppressor gene (Cmarik et al., 1999; Chen et al., 
2003; Jansen et al., 2005; Zhang et al., 2006) its molecular function is presently not 
well understood. This may be due to the lack of a well-characterized cell system to 
study the functions of Pdcd4. In the present work, to facilitate the analysis of functions 
of human Pdcd4 (Hpdcd4), a Hpdcd4 knock down system was developed by employing 
RNAi technology. Two different siRNAs targeting Hpdcd4 mRNA at two different 
positions were designed which were together stably transfected into the HeLa cells. 
Two stable knock down clones, K11 and K12, were used for the functional analysis of 
Hpdcd4.  
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5.1.2 Hpdcd4 inhibits Translation of Secondary Structured RNAs  
 
It has been shown that Pdcd4 inhibits translation of 5´UTR structured mRNAs 
approximately two fold in primary keratinocytes overexpressing Pdcd4 (Jansen et al., 
2005). A reporter gene construct producing structured mRNA was transfected into the 
HeLa wild-type (WT) and K12 cells, the translation was almost 50% higher in the 
absence of Hpdcd4. This suggests that Hpdcd4 has an inhibitory control over the RNA 
secondary structures. This observation is consistent with the results of a Pdcd4 
overexpression system by another group (Jansen et al., 2005). Moreover, the fold 
reduction in the translation due to the introduction of RNA secondary structure 
upstream of the gene was higher in the WT cells compared to the K12 cells, which 
again demonstrates the inhibitory effect of Hpdcd4 on mRNA secondary structures. For 
example, cyclin dependent kinase 4 (CDK4) and ornithinedecarboxlase (ODC) are 
controlled partially at the level of translation due to 5’ structured UTRs (Clemens, 
1999). Protein levels of CDK4 and ODC in Pdcd4 overexpressing primary keratinocytes 
were decreased by 40 and 46%, respectively (Jansen et al., 2005) as their mRNAs 
contain 5´structured UTRs. 
5.1.3 Hpdcd4 inhibits IRES-Dependent Translation 
 
In the present work, it was procured that the dual luciferase constructs containing IRES 
regions for four genes (Apaf-1, c-Myc, Mnt and N-Myc) which are involved in cell 
proliferation and programmed cell death (Coldwell et al., 2000; Stoneley et al., 1998; 
Stoneley et al., 2001; Jopling and Willis, 2001) were used to assess the effect of 
Hpdcd4 on IRES-dependent translation. The IRES dependent translation was 2.5 times 
higher in the K12 cells compared to the WT cells. This suggests that the Hpdcd4 has a 
direct or indirect negative control over these IRES elements. Comparing the RNA and 
protein levels of genes containing IRES elements would be the next necessary 
experiment to confirm the inhibitory effect of Hpdcd4 on these IRES elements.   
 
The internal ribosome entry mechanism requires the formation of a complex RNA 
structural element with the recruited ribosome in the presence of IRES-trans-acting 
factors (ITAFs). The interactions of several ITAFs with IRESs have been investigated in 
detail, and several mechanisms of action have been noted, including an action as 
chaperones or stabilization and remodelling of the RNA structure (Spriggs et al., 2005). 
Structural remodelling by the polypyrimidne tract-binding protein (PTB) was studied in 
detail and it was shown that PTB is able to facilitate recruitment of the ribosome to 
several IRESs by causing previously occluded sites to become more accessible (Mitchell 
et al., 2001).  From the present work, it is reasonable to speculate that Hpdcd4 might 
be acting as an inhibitor of an ITAF, possibly by hindering the binding of PTB to IRES.  
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The effect of Hpdcd4 on specific IRES element is discussed in detail below. Apaf-1, the 
apoptotic protease activating factor plays a central role in apoptosis and interaction of 
this protein with the procaspase-9 leads to cleavage and activation of the initiator 
caspase (Coldwell et al., 2000). The 578 nt long 5´ UTR contains a 233 nt long IRES 
and translation initiation of the mRNA is dependent on this IRES element. The Apaf-1 
IRES is active in almost all human cell types tested, including HeLa cells (Coldwell et 
al., 2000). Because of Hpdcd4 showed inhibitory control over this proapoptotic 
element, it is reasonable to speculate that Hpdcd4 may act as an anti-apoptotic 
element.  
 
The Apaf-1 IRES requires two trans-acting factors for its function. In addition to PTB, it 
also requires upstream of N-ras (unr), to attain the correct structural conformation of 
the IRES (Mitchell et al., 2001). Based on these evidence, there are many possible 
mechanisms can be proposed to explain by which Hpdcd4 might inhibit the 
IRES-dependent translation (e.g.) Hpdcd4 might directly bind to the mRNA secondary 
structure and thus inhibiting the binding of ITAFs to the mRNA, or interfere with the 
interaction between ITAFs in enhancing the IRES-dependent translation. In the future, 
investigation of Hpdcd4 binding to the apoptosis related mRNAs (Apaf-1, Bcl-2, Bag-1 
and DAP5) and binding partners of Hpdcd4 in regulating the IRES dependent 
translation of these genes might unravel the role of Hpdcd4 in apoptosis.     
 
The second IRES element found to be inhibited by Hpdcd4 was the c-Myc IRES. The 
myc gene family comprises of c-, N- and L-myc, and gives rise to nuclear 
phosphoproteins which function as transcription factors. In accordance with the 
stimulatory effect of the Myc proteins on cell growth, their overexpression is associated 
with a number of different cancers (Jopling and Willis, 2001). In the present work, it 
was shown that Hpdcd4 has a negative control over the IRES-element of c-myc and 
N-myc oncogenes thereby uncovering a possible mode of action of its tumor suppressor 
activity. Checking specifically on c-Myc protein level made only by the IRES-dependent 
translation is mandatory to confirm the effect of Hpdcd4 on IRES-dependent translation 
of c-Myc. Further, coimmunoprecipitation experiments could help to map the Hpdcd4 
binding region in the c-Myc and N-Myc IRES and to identify interaction partners for 
Hpdcd4 in regulating the IRES dependent translation of c-Myc proteins.   
 
Furthermore, Hpdcd4 also inhibits Mnt IRES element. Mnt is a transcriptional repressor 
related to the Myc/Mad family of transcription factors, expressed in proliferating, 
resting as well as differentiating cells and believed to antagonize the function of Myc 
(Stoneley et al., 2001). Mnt is involved in the control of cell proliferation, 
differentiation, apoptosis and tumor progression. In the present experiments, it was 
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shown that Hpdcd4 inhibited the Mnt IRES suggesting that Mnt is one of the target of 
Hpdcd4. Hpdcd4 may inhibit the IRES-dependent translation of both Myc and the Myc 
repressor Mnt. At first sight, it may be contradictory to explain the tumor suppressor 
behavior of Hpdcd4. However, a hypothesis could be postulated to explain these 
observations. Hpdcd4 is a primary threshold point which most cancer-prone cells have 
to disrupt to enter or progress to the cancerous state. Thereby activating the 
subsequent cancerous genes, this stimulates the aberrant cell growth and thus 
increases cell survival in their microenvironment. For the above reason, cells also have 
many second level defenses or failsafe mechanisms activated beyond Hpdcd4. A 
schematic diagram shows the activation of failsafe mechanisms by Hpdcd4 (Fig.46). 
  
Hpdcd4
Mnt C-Myc 
Tumor suppressor Genes Oncogenes
Threshold point
  
 
 
 
Figure 46: Hpdcd4 – A primary threshold point in tumorigenesis  
As a consequence of disruption of critical check points like Hpdcd4, secondary level failsafe mechanisms could be 
triggered through various tumor suppressor genes like Mnt, to balance or nullify the effect of activated 
oncogenes like c-Myc.  
It has been shown that IRESs are important to maintain protein expression under 
conditions when cap-dependent translation initiation is compromised; for example, 
during mitosis, apoptosis and under conditions of cell stress (Spriggs et al., 2005). 
Induction of stress also results in a large reduction in global protein synthesis rates. It 
was therefore also investigated whether the c-Myc IRES was active following DNA 
damage (Subkhankulova et al., 2001). After UV-irradiation, the HeLa WT cells showed 
increased c-Myc IRES-dependent translation. In contrast, there was no increase in the 
c-Myc IRES-dependent translation of the K12 cells. Moreover, there was no difference 
in the c-Myc IRES-dependent translation of the WT and K12 cells. It suggests that in 
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the absence of Hpdcd4, the cells might not be able to react to the UV-irradiation. This 
could imply that Hpdcd4 is a significant component of DNA-damage response. 
5.1.4 Novel Molecular Targets of Hpdcd4 
 
By 1D-SDS-PAGE several transcription factors were examined as potential targets for 
Hpdcd4. While c-Myc was downregulated, c-Jun was significantly overexpressed and 
phosphorylation of ATF-2 and c-Jun was less efficient in the K12 cells compared to the 
WT cells. In addition to such a reductionist approach, a holistic approach was applied to 
identify additional molecular targets of Hpdcd4.    
 
Proteomics is a high throughput and holistic approach to screen all the proteins of a cell 
or organism expressed at a particular time. It requires stringently controlled 
2D-SDS-PAGE, image detection and analysis and spot identification through mass 
spectrometry (MS) followed by database searches. 2D-SDS-PAGE is a technique 
(O’Farrell 1975), in which proteins are separated according to their charge by 
isoelectric focusing (IEF) in the first dimension and molecular weight by SDS-PAGE in 
the second dimension. It provides a two dimensional array, in which each spot 
corresponds to a single protein species in the sample. The highly purified single protein 
spots are analyzed by MS and identified by database search.  
 
Functional proteomics aims at the characterization of multiprotein complexes and 
signaling pathways. For example, a study was carried out previously to identify cellular 
targets regulated by the MKK/ERK cascade and 25 targets of this signaling pathway 
were identified (Lewis et al., 2000). Alternatively, expression proteomics aims to 
measure up- and downregulation of proteins (Mann et al., 2001).  Such strategy has 
been employed in several studies (Wasinger et al., 1995; Dencher et al., 2006; 
Welham et al., 2006). In the present study, a comparable strategy was applied to 
identify several novel molecular targets of Hpdcd4 using the 2D-SDS-PAGE followed by 
MS. The molecular targets are: Cytokeratin-17 (CK-17), aldo keto reductase1 (AKR1) 
family members C2 and C3, Cytokeratin-8 (CK-8) and Glutamyl Prolyl tRNA synthetase 
(GluProRS). CK-17 and AKR1C2 and C3 were overexpressed in the K12 cells compared 
to the WT cells. Furthermore, biochemically modified CK-8 and GluProRS related similar 
molecular weight spots appeared on the lower pH side of the respective mother spot, 
only in the absence of Hpdcd4. 
5.1.5 Expression of c-Myc is lower in the Absence of Hpdcd4  
 
The transcription factor c-Myc is one of the targets for Hpdcd4, shown to be 
downregulated in the absence of Hpdcd4. Myc genes comprise a small, multi-gene 
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family and are implicated in the development of different human tumors (Adhikary et 
al., 2005). To some degree most of the major processes such as proliferation, growth, 
differentiation, apoptosis and metabolism are regulated by c-Myc (Liu et al., 2006). The 
deregulation of these processes, in turn, influences the level of c-Myc expression as 
well as diverse pathophysiological signals which are directed to act on the c-Myc level 
by activating various proteins. Enhanced expression of Myc genes promotes and 
contributes to many aspects of the tumor cell phenotype. The present work has shown 
that in the absence of the tumor suppressor gene Hpdcd4, c-Myc expression is 
decreased. It is rational to assume that Hpdcd4 maintains c-Myc oncoprotein level in 
normal conditions. But, when Hpdcd4 is inactivated during many cancers, inhibition of 
c-Myc might occur due to the activation of failsafe mechanisms. The c-Myc RNA level 
was lower in the absence of Pdcd4 as well as the turn-over rate. This suggests that the 
reduced amount of c-Myc mRNA might not be due to the effect of Pdcd4 on the 
turn-over of mRNA but could be the other mechanisms operating at different level.  
5.1.6 Phosphorylation of ATF-2 is decreased in the Absence of Hpdcd4  
 
Another transcription factor affected by Hpdcd4 is ATF-2. ATF-2 is a bZip transcription 
factor which has been implicated in the regulation of a wide set of cAMP-response 
element (CRE)-dependent target genes. The transcriptional activity of ATF-2 requires 
homo or heterodimerization with other members of the bZip family, such as c-Jun. 
Moreover, it is stimulated by phosphorylation of threonine residues (T69 and T71) 
which is mediated by the JNK and p38 protein kinases (Livngstone et al., 1995). 
Furthermore, it has been shown that ATF-2 has an intrinsic histone acetyltransferase 
(HAT) activity that is controlled by phosphorylation. Phosphorylation of ATF-2 enhances 
its HAT activity, subsequently specific acetylation of H2B and H4 followed by 
CRE-dependent transcription (Kawasaki et al., 2000).  
 
In the present experiments it was observed that after UV exposure, ATF-2 expression 
and the extent of ATF-2 phosphorylation was lower in the absence of Hpdcd4 than in its 
presence. Several studies have implicated the phosphorylation of ATF-2 in regulating 
repair of DNA-damage caused by different agents, such as ionizing or UV radiation or 
cisplatin (Potapova et al., 1997; Potapova et al., 2001; Kabuyama et al., 2002; 
Hayakawa et al., 2003; Bhoumik et al., 2005). Hayakawa et al. (2004) have identified 
a set of genes whose expression is coordinately induced by activated ATF-2 following 
genotoxic stress. Many of these genes are involved in DNA-damage-repair, suggesting 
that the genotoxic stress response occurs at least partially via activation of ATF-2, 
leading to increased expression of DNA-damage repair genes. Therefore, it is logical to 
assume that in the absence of Hpdcd4, the ATF-2 phosphorylation is less efficient and 
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thus the response to DNA-damage. C-Myc induces the phosphorylation of ATF-2 at 
Thr-69 and Thr-71 to prolong the half-life of ATF-2 (Miethe et al., 2001). This raises 
the possibility that in the absence of Hpdcd4 the c-Myc protein is less abundant and as 
a consequence the phosphorylation of ATF-2 is also decreased.  
  
A study correlated the phosphorylation of ATF-2 by p38 and the cyclin D1 transcription 
in MCF-7 breast cancer cells (Lewis et al., 2005). D type cyclins are major downstream 
targets of extracellular signaling pathways which act to integrate mitogenic signals to 
the cell cycle machinery (Sherr, 1995). Future investigation of the effect of Hpdcd4 on 
the level of cyclin D1 may reveal the possible role of Hpdcd4 in tumor cell cycle 
progression.  
5.1.7 Expression of C/EBPβ is increased in the absence of Hpdcd4  
 
The ability of C/EBPβ to bind specific DNA sequences and to mediate protein-protein 
interactions makes it a bona fide transcription factor. C/EBPβ plays a pivotal role in 
numerous cellular responses, including proliferation, differentiation, inflammatory 
response, apoptosis, and control of metabolism. Several C/EBPβ isoforms 
corresponding to full length and amino-terminally truncated proteins were observed 
(Calkoven et al., 2000). These isoforms display contrasting functions in gene activation 
and cell proliferation (Descombes and Schibler, 1991).  Moreover, various experiments 
have shown that the ratio of different isoforms influences various cellular processes 
including tumorigenic conversion (Raught et al., 1996).  
 
The present work showed that C/EBPβ was expressed stronger in the absence of 
Hpdcd4, when an expression vector for full length C/EBPβ was transfected. This raised 
the possibility that Hpdcd4 inhibits the expression of C/EBPβ by binding to its upstream 
region. However, higher expression level of full length C/EBPβ isoform in the absence 
of Hpdcd4 was also observed, when expression vectors for C/EBPβ without upstream 
region were transfected. This shows that Hpdcd4 does not act on the upstream region 
but that the inhibitory effect is operating at a different level.  
5.1.8 Biochemical Modification of Cytokeratin-8 in the absence of Hpdcd4 
 
The Cytokeratin Family 
Although in various literatures the intermediate filaments are represented by different 
conventions (Keratin-8, cytokeratin-8, k8, k-8, ck8 and ck-8 etc.,), in the present 
work, cytokeratins are mentioned e.g. as CK-8 to enable a clear distinction between the 
conventions used to represent cytokeratins and the generated Pdcd4 clones.   
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Eucaryotic cells contain up to three families of cytoskeletal proteins that are responsible 
for the spatial organization of the cell. The three types are differentiated by the 
diameter of the filament and include thick microtubules (25 nm), thin actin filaments (7 
nm), and intermediate filaments (IF, 10-12 nm). More than twenty cytokeratin 
intermediate filament proteins are expressed in a cell type preferential manner (Knap 
and Franke, 1989).  
 
The large cytokeratin multigene family can produce more than 20 unique keratin gene 
products (CK1-CK20) which are characterized and classified into type I-Acidic 
(CK9-CK20) and type II-Basic (CK1-CK8) intermediate filaments (Coulombe et al., 
2002). An equimolar ratio (1:1) of each Type I and Type II keratin forms a noncovalent 
obligate heteropolymers either in a soluble tetrameric form or in a core complex 
filamentous cytoskeletal form. Since the cooperation of one member of each family is 
necessary for mutual costabilization and cytoskeletal assembly, defined pairs of keratin 
proteins are coexpressed. For example, it was coexpressed that the CK-8 and CK-18 in 
simple epithelia, CK-5 and CK-14 in basal layers of multilayered epithelia, and CK-1 
and CK-10 in differentiated layers of the epidermis (Steinert, 1988). 
 
Cytokeratin expression is a persistent phenotype which is used in diagnosing cancers, 
enabling identification of tumor type, metastatic tumor origin, and stage of disease 
(Nagle et al., 1993; Moll et al., 1982a). Tumors may either begin to express a novel 
cytokeratin or, alternatively, may reduce/cease the expression of cytokeratins which 
are normally present in this tissue. Furthermore, changes in the pattern of expression 
of cytokeratins during tumor progression can also involve a reversion to the simple 
epithelial from the CK-8/18 dimer (Moll, 1982b). These particular cytokeratins are also 
preferentially expressed in many carcinoma cell lines (Chan et al., 1986). 
 
Posttranslational Modification of CK-8 
Keratin posttranslational modifications like glycosylation, phosphorylation and 
transglutamination, are thought to modulate K8/K18 functions.  Glycosylation via 
O-GlcNAc, is a dynamic modification conclusively identified in three keratins including 
CK-8 (Omary et al., 1998). Phosphorylation is an important regulatory modification of 
keratins and in this regard many keratin family members were studied in detail. 
CK-8/18 phosphorylation also affects their functional assembly state and has been 
suggested to play a role in cell signaling (Ku et al., 1996a). Serine is the major 
physiological phosphorylated keratin residue (Oshima, 1982). In the case of CK-8/18, 
phosphorylation regulates filament reorganization in vivo, enhances keratin solubility, 
plays a role in dictating the localization in specific cellular compartments, regulates the 
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association with the 14-3-3 protein family and is associated with a variety of 
physiological stresses (Ku et al., 1996a). 
 
Phosphorylation of K8 was studied upon activation of the epidermal growth factor 
receptor (Baribault et al., 1989) and pro-urokinase stimulation (Busso et al., 1994). 
Drug-induced hepatotoxic stress, induced by feeding mice with a 
griseofulvin-supplemented diet resulted in a dramatic CK-8/18 hyperphosphorylation 
(Ku et al., 1996b). Pervanadate-mediated tyrosine phosphorylation of CK-8 and CK-19 
in a p38 kinase-dependent pathway was reported (Feng et al., 1999). Furthermore, it 
has been shown that cultured HT-29 cells were induced by anisomycin or etoposide and 
it was shown that hyperphosphorylation of CK-8 at Ser-73 was linked to apoptosis.  
 
So far, three in vivo CK-8 phosphorylation sites have been described. The first site, 
Ser-23 is located in the head domain of CK-8. This site is conserved in all type II 
keratins and phosphorylated by purified cAMP-dependent protein kinase (Ando et al., 
1996). The second site, Ser-431 is located in the tail domain of CK-8 and is 
phosphorylated after stimulation of cells by epidermal growth factor and is presumably 
a member of the mitogen-activated protein kinase family (MAPK) (Ku and Omary, 
1997). The third site, Ser-73 is phosphorylated either by p38 stress-activated protein 
kinase or by c-Jun N-terminal kinase (JNK) in a context-dependent manner (He et al., 
2002; Ku et al., 2002).  
 
It has been shown that in shear-stressed alveolar epithelial cells CK-8 S73 
phosphorylation occurs in a time-dependent manner by protein kinase Cδ (PKCδ) (Ridge 
et al., 2005). Protein kinase C is a family of well studied serine-threonine protein 
kinases, which is involved in many cellular functions, including proliferation, 
differentiation, apoptosis, and gene expression. Receptor-mediated activation of 
phospholipase C induces the generation of the second messengers calcium and 
diacyglycerol which contribute to the activation of PKC (Li et al., 2005). As a cellular 
target for the tumor-promoting phorbol esters, PKC has been implicated in tumor 
development for decades. Among the 12 members of PKC isozymes, PKCα and PKCε 
have been implicated in cell proliferation, whereas PKCδ and PKCη have been 
associated with apoptosis and terminal differentiation (Li et al., 2005). 
 
In a recent study CK-8 was identified as a cytoplasmic target for JNK during Fas 
receptor-mediated signaling (He et al., 2002). The MAPK family which is composed of 
the mitogen-activated (MAPK/ERK) and the stress-activated protein kinases (SAPK). 
They both are involved in cellular responses to physical stresses, inflammatory 
cytokines and apoptosis. The JNK belongs to the subgroup of SAPK family. 
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In the present experiments, in the 2D-SDS-PAGE analysis there appeared two similar 
molecular weight spots on the acidic side of the CK-8 spot. These unidentified spots 
were visible only in the K12 cells but not in the WT cells. Therefore, it was interesting 
to study the relationship between Hpdcd4 and the appearance of the CK-8 related 
spots. When 2D-immunoblotting was performed using CK-8 specific antibodies only one 
CK-8 related spot was observed. The second CK-8 related spot might be an unrelated 
protein. Another Hpdcd4 knock down clone, K11, also showed the additional CK-8 
related spot which was similar to the one observed in the K12 cells. The appearance of 
a CK-8 related spot was also confirmed by a different pH range (4-7) in the 
2D-SDS-PAGE.  
 
To elucidate the identity of the CK-8 related spot, the WT and K12 cells were treated 
with UV. When stress is induced by UV treatment, the cells are provided with activated 
protein kinases. The CK-8 related spots also appeared in the WT cells after 
UV-induction which confirmed that this spot could be due to the phosphorylation of 
CK-8. When K12 cells were induced with tumor promoter TPA, the CK-8 related spot 
became more prominent. These two experiments suggest that the spot might be due to 
phosphorylation of CK-8.  
 
Modulation of keratin phosphorylation occurs during multiple stimuli, including stress, 
apoptosis and mitosis with resultant regulation of keratin filament organization and 
keratin interaction with its binding partners (Ku et al., 1999). Furthermore, it has been 
shown that phosphorylation of CK-8 induces depolymerization of CK-8/18 pairs which 
enabled tumor progression (Ku et al., 1996). From the present experiments and other 
evidences it is reasonable to speculate that in the absence of tumor suppressor protein 
Hpdcd4, the phosphorylation of CK-8 and subsequently the disentanglement of CK-8 
from its bound partner may confer to the tumor cells an evolutionary advantage for 
tumor progression (Fig.47). Thence, it is essential to check whether Hpdcd4 inhibits 
phosphorylation of CK-8 by PKC or JNK as previous studies have shown that CK-8 is 
phosphorylated by PKC (Cadrin et al., 1992) and by JNK (He et al., 2002). This future 
experiment might provide interesting insight into the molecular mechanism of tumor 
suppression by Hpdcd4.  
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Figure 47: An extremely simplified schematic diagram outlines the possible molecular 
mechanism behind the tumor suppressor function of Hpdcd4 through CK-8.  
5.1.9 Expression of Cytokeratin-17 is higher in the absence of Hpdcd4 
 
Most of the earlier functional studies about keratins revealed that their major role is to 
protect the cell by providing cytological support. Later it has been shown that they are 
also  suitable as tumor markers. But recent studies shed light on how this structural 
support is modulated to meet the changing needs of cells, and reveal a novel role 
whereby intermediate filaments influence the cell growth and death through dynamic 
interactions with non-structural proteins (Coulombe et al., 2004). Other emerging 
functions of cytokeratins, in particular of CK-17 includes roles in cell signaling, the 
stress response and apoptosis (Coulombe and Omary, 2002).    
 
In the present work, it was shown that the CK-17 RNA and protein level is increased in 
the Hela K12 cells compared to the WT cells, suggesting that Hpdcd4 inhibits the CK-17 
expression. A previous study has revealed that the CK-17 is a target of interferon 
signaling. Interferons influence the gene expression by activating transcription factors, 
which in turn bind to specific DNA sequences known as interferon-stimulated response 
elements thereby activating transcription of nearby genes. It was found that 
interferon-γ (IFN-γ) strongly and specifically induced the promoter of the CK-17 gene 
(Jiang et al., 1994). The IFN-γ-activated sequence (GAS) was characterized in the 
CK-17 promoter. IFN-γ activates another protein, STAT-91 (signal-transducing 
activator of transcription), one of the four components of ISGF3 (the primary IFN-α 
responsive transcription factor). The activated STAT-91 binds to the CK-17 GAS and in 
turn, activates the transcription of CK-17. 
 
A recent study has shown that CK-17 has a role in cell growth. Cell growth is a highly 
regulated cellular event, by which the cells gain mass and size. The Akt/mTOR signaling 
pathway has a central role in the control of protein synthesis and thus the growth of 
cells, tissues and organisms (Kozma and Thomas, 2002). Three keratins (CK-6, CK-16 
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and CK-17) were rapidly upregulated in wound-activated skin epithelial cells, and the 
signaling pathway following CK-17 induction was studied in detail (Coulombe et al., 
2006). Moreover, the Akt (protein kinase B) serine/threonine kinase is a key mediator 
of phosphoinositide-2-kinase pathway involved in the regulation of cell proliferation, 
survival, and growth. It has been shown that Pdcd4 is phosphorylated by Akt kinase in 
two sites, at Ser-67 and Ser-457, both in vitro and in vivo (Palamarchuk et al., 2005).  
 
From these evidences it is logical to speculate that the role of Hpdcd4 in inhibiting 
CK-17 expression could possibly be extended to the cell growth through the mTOR 
signaling pathway (Fig.48). The phosphorylation of Hpdcd4 by Akt kinase might be one 
step among the multistep pathway. Furthermore, phosphorylation of Hpdcd4 might 
activate/inhibit its effect on CK-17. Further elucidating the role of Hpdcd4 on mTOR 
pathway will reveal the molecular mechanisms of Hpdcd4 in cell growth and thereby 
tumor suppression. 
 
From the current study, the finding of inhibition of CK-17 expression by Hpdcd4 raises 
many possibilities for the mechanism of action of Hpdcd4. Hpdcd4 could directly bind to 
the CK-17 promoter, thereby inhibiting the CK-17 expression. It would be interesting to 
generate a CK-17 promoter-reporter gene construct and check its activity in the Hela 
WT and K12 cells. Alternative to the direct binding to the CK-17 promoter, Hpdcd4 
could interfere with CK-17 activator proteins. Based on the above mentioned study 
(Jiang et al., 1994) Hpdcd4 could possibly hinder either the activation of STAT-91 or 
the binding of STAT-91 on the GAS of the CK-17 promoter. These future experiments 
may confirm the significance of the effect of Hpdcd4 on the structural element CK-17 in 
mTOR or IFN signaling and thereby the molecular mechanisms of tumor suppressor 
function of Hpdcd4. 
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Figure 48: An extremely simplified schematic diagram outlines the possible molecular 
mechanism behind the tumor suppressor function of Hpdcd4 through CK-17.  
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5.1.10 Expression of AKR1C2 and C3 are higher in the absence of Hpdcd4  
 
In the present study, when Hpdcd4 is silenced, AKR1C2 and C3 were found to be 
upregulated. The human aldo keto reductases (AKR) superfamily contains four isoforms 
of 3α_hydroxysteroid dehydrogenase (3 α-HSD). The enzymes correspond to type 
1-type 4 share at least 84% amino acid sequence identity. All enzymes act as 
NADPH-dependent 3-, 17- and 20-ketosteroid reductases and as 3α-, 17β- and 
20α-hydroxysteroid oxidases. The functional plasticity of these isoforms highlights their 
ability to modulate the levels of active androgens, oestrogens and progestins (Penning, 
2000).  
 
AKR1 family members have been the basis for tumor classification since few decades. 
Reduced levels of AKR1C2 and AKR1C3 were observed in breast carcinoma cells (Lewis 
et al., 2004). Moreover, it was also reported that the overexpression of AKR1C3 in 
myeloid leukemia cell lines prevents the cells from undergoing differentiation. Although 
they are well-characterized tumor markers, the molecular mechanism by which their 
altered expression is manifested in cancer is not yet clarified. However, a recent study 
on parathyroid hormone-related protein (PTHrP) revealed a molecular mechanism of 
the linkage of AKR1C2 and C3 to cancer (Tsigelney et al., 2005). PTHrP is known as the 
factor responsible for humoral hypercalcemia of malignancy. It regulates cell growth, 
apoptosis, cytokine production and angiogenesis in cancer cells and contributes to 
cancer progression and metastasis. In the present study, it was interesting, as AKR1C2 
and C3 were found to be upregulated in the absence of Hpdcd4. It partially reveals a 
mutual molecular mechanism by which AKR1 family members or Hpdcd4 might be 
involved in tumorigenesis. However, AKR1C2 and C3 were expressed differently in both 
the Hpdcd4 knock down clones, an observation which questions the identity of these 
genes as true Hpdcd4 targets.  
 
Similarly, although, both knock-down clones (K11 and K12) overexpress CK-17 
compared to the WT, the degree of overexpression varied between these clones. It is 
possible that these clones are either genetically different or that they vary in the extent 
of silencing of Hpdcd4. In the future, it will be important to confirm the effect of 
Hpdcd4 on AKR1C2 and C3. Conceivably, the identity of the AKR1C2 and C3 as targets 
of Hpdcd4 could be confirmed by reexpression of Hpdcd4 in the knock-down clones and 
assessing the expression of them. 
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5.1.11 Biochemical Modification of GluProRS in the absence of Hpdcd4 
 
Glutamyl Prolyl Bifunctional tRNA Synthetase (GluProRS) appeared as 5-6 spots on a 
string in the absence of Hpdcd4, but as a single spot in the presence of Hpdcd4. 
GluProRS catalyzes the ligation of amino acids to the tRNAs during translation. It has 
divergent functions in protein synthesis. In the multisynthetase complex, its 
aminoacylation activity supports global translation, but phosphorylation and thus 
translocation of GluProRS to an inflammation responsive mRNAP causes gene-specific 
translational silencing (Sampath et al., 2004). The appearance of GluProRS as 5-6 
spots as pearls on a string at the molecular weight of 163 KDa in the absence of 
Hpdcd4 suggests a possibility that the GluProRS is biochemically modified in the 
absence of Hpdcd4. However, further, 2D-SDS-PAGE imunoblotting using a 3-10 pI 
range is necessary to confirm the identity of GluProRS related spots in the absence of 
Hpdcd4. 
5.1.12 Potential Role of Hpdcd4 in mRNA Stability   
 
The function of Hpdcd4 at the protein level was traced back to the RNA level of the 
identified targets. Furthermore, in the present work, it was also found that Hpdcd4 may 
play a role in posttranscriptional level control of gene expression. Every eucaryotic cell 
contains the same 35,000-50,000 genes. The remarkable diversity in cell specialization 
is achieved through the tightly controlled expression and regulation of a precise subset 
of these genes in each cell lineage. The regulation of mRNA turn-over plays a major 
role in the posttranscriptional level control of gene expression (Saini et al., 1990) as 
there is a vast difference in the mammalian mRNA half-lives from 15-30 min to more 
than 24 hr (Sylke, 2004). The half-life of an mRNA represents a balance between the 
transcriptional activity and intracellular degradative processes. Half-life can be 
modulated by the presence of specific cis- and trans-acting elements in the mRNA 
(Ross, 1995).  
 
A mRNA can be stabilized or destabilized as a result of the combined actions of 
different trans-acting regulatory factors. There are some RNA-binding proteins which 
protect mRNA from degradation whereas, some mRNA-binding proteins tag mRNA for 
degradation (Ross, 1995). For example, PolyA-binding protein, proteins that bind to 
AU-rich elements (ARE), iron regulatory protein, ribonucleotide reductase 
mRNA-binding proteins and c-Myc coding region determinant-binding protein stabilize 
the mRNAs. 
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The present northern blotting experiments confirmed the effect of Hpdcd4 on CK-17 
and c-Myc mRNA. In the absence of Hpdcd4, the CK-17 and c-Myc mRNA transcript 
levels increase. This could be a consequence of an increase in the transcription or the 
stability of these mRNAs. The mRNA stability studies revealed that in the absence of 
Hpdcd4 the mRNA degradation was slightly less efficient for CK-17 and c-Myc mRNA 
than in the presence of Hpdcd4. This suggests that Hpdcd4 decreases the stability of 
the CK-17 and the c-Myc mRNA transcripts. However, this effect might be either 
general, affecting all mRNAs, or specific for Hpdcd4-functionally relevant mRNAs. 
Apparently, the S17 mRNA was unaffected by Hpdcd4, further confirming the specificity 
of the effect of Hpdcd4.  The observations suggest a possible role of Hpdcd4 in the 
stability of mRNAs.  
 
It has been shown that Pdcd4 has an N-terminal RNA binding domain (Boehm et al., 
2003). Furthermore, it has been shown that the mRNA binding proteins that bind to 
AREs of mRNA are predominantly nuclear but shuttle between the nucleus and the 
cytoplasm (Katz et al., 1994; Shim et al., 2002). Hpdcd4 has been also shown to be 
predominantly a nuclear protein and to shuttle between the nucleus and cytoplasm 
during serum withdrawal (Boehm et al., 2003). These observations support the 
assumption that Hpdcd4 might be binding RNAs and possibly plays a role in mRNA 
stability.  
 
It was somewhat contradictory that c-Myc mRNA is degraded faster but the c-Myc 
protein expression was higher in the presence of Hpdcd4. A possible explanation might 
be that in normal conditions, Hpdcd4 enables degradation of c-Myc mRNA but in most 
of the cancers when Hpdcd4 is downregulated, possibly some other not yet identified 
failsafe mechanisms acting to still lower the level of c-Myc oncoprotein. 
 
From the previous experiments, the effect of Hpdcd4 on IRES-dependent translation 
shows that Hpdcd4 negatively regulated the translation of specific mRNAs having 
secondary structures in the 5’ UTR. It is possible that Hpdcd4 also affect the secondary 
structured elements present in the 3’ UTR of mRNAs. The mode by which Hpdcd4 
facilitates the mRNA degradation, the significance and the interaction partners of 
Hpdcd4 that are involved in RNA metabolism are yet to be elucidated.  
5.1.13 Potential role of Hpdcd4 in Nonsense-Mediated mRNA Decay  
 
From the present study, the role of Hpdcd4 on mRNA stability was further extended to 
the metabolism of mRNAs having nonsense-mutations. When β-Globin mRNA with a 
nonsense mutation was expressed in the HeLa WT and knock-down cells, NMD 
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operated slightly lower in the absence of Hpdcd4. This suggests a possible role of 
Hpdcd4 in NMD. A correlation of sequence and structural motifs with several other 
proteins involved in RNA metabolism was made. Pdcd4 contains two conserved MA-3 
domains in the region of amino acids 164-275 and 329-440, respectively (Fig.2). 
Surprisingly, the MA-3 domain present in Pdcd4 is highly homologous to the domains 
present in proteins of several other eucaryotic proteins involved in translation and 
mRNA processing (Ponting, 1992).  However, further experiments are necessary to 
confirm the role of Hpdcd4 in NMD. Moreover, among the two MA-3 domains of Hpdcd4 
which is interacting or how both are coordinately interacting with the known members 
of the mRNA processing machinery like NMD pathway could be studied by generating 
deletion mutants of Hpdcd4 gene. 
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5.2. Analysis of Pdcd4 in the DT40 Cells 
5.2.1 Downregulation of Chicken Pdcd4 by Homologous Recombination  
 
The chicken pre-B cell line DT40 has exceptionally high rate of homologous 
recombination and because of that it is an extremely useful model system to study the 
role of genes that perform general cellular functions or that play specific roles in 
B-lymphoid cells. In chickens, Pdcd4 (Cpdcd4) is expressed in many tissues with 
particularly high levels found in hematopoietic tissues, such as the bursa and the 
thymus (Schlichter et al., 2001a). Therefore, DT40 cell line was chosen to explore the 
role of the tumor suppressor, Cpdcd4 gene (Cpdcd4) by knocking out both the copies 
of Cpdcd4. Among the generated and characterized 5 Cpdcd4(-/-) clones, two clones 
(K3 and K33) were further characterized and used for the functional analysis of 
Cpdcd4. 
5.2.2 Growth Characteristics are unaffected by Cpdcd4 
 
The analysis of the growth properties of the Cpdcd4 knock-out cells showed that the 
disruption of Cpdcd4 does not cause a detectable distortion of the cell cycle or a 
change in the proliferation rate of these cells. Thus it appears that Cpdcd4 does not 
play an essential role during cell proliferation, at least under normal growth conditions.  
 
These findings are at variance with the recent reports that have used overexpression 
of Pdcd4 to address its role in cell proliferation. It was observed that overexpression of 
Pdcd4 causes growth inhibition in the human carcinoid cell line Bon-1 (Lankat-
Buttgereit et al., 2004). Goke et al. (2002) reported that overexpression of Pdcd4 in 
HEK-293 cells causes resistance to apoptosis while Afonja et al. (2004) showed that 
Pdcd4 induces apoptosis in certain breast cancer cells. Pdcd4 overexpression reveals 
no effect on proliferation or apoptosis in HEK-293 cells (Bitomsky et al., 2004). One 
potential explanation for these divergent observations could be that the actual 
outcome of Pdcd4 overexpression might be highly dependent on the cell type used for 
the experiments. Since each cell line may have their own basal level of Pdcd4 
expression which could influence apoptosis to various extents. In addition to that fact, 
the degree of overexpression of Pdcd4 might vary between different systems which 
could affect the response of the cells. 
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5.2.3 Cpdcd4 has no Effect on Total Protein Synthesis    
 
Previous work has implicated Pdcd4 in the control of translation initiation. The majority 
of eucaryotic translation is cap-dependent and involves the association of the 
cap-binding complex (consisting of eIF4G, eIF4A and eIF4E) with the 5’-m7G cap 
structure of mRNAs (Gingras et al., 1999; Gebauer and Hentze, 2004). It has been 
suggested that Pdcd4 interferes with the function of eIF4A and eIF4G by binding itself 
to these proteins and by inhibiting the helicase activity of eIF4A (Yang et al., 2003b).  
 
The present experimental results showed that the disruption of the Cpdcd4 has no 
significant effect on total protein synthesis. Therefore, Cpdcd4 does not appear to 
exert a general inhibitory effect on cap-dependent translation. It is possible, however, 
that the inhibition of cap-dependent translation by Cpdcd4 is restricted to specific 
mRNAs, which cannot be detected by a global labeling approach. Further analysis of 
the role of Cpdcd4 in cap-dependent translation might be progressed through 
assessing the mRNA targets identified in the HeLa system.  
5.2.4 Cpdcd4 has no Effect on Cap-Independent Translation    
 
In an alternative translation initiation mechanism translation can be initiated at 
internal ribosomal entry sites (IRES) (Vagner et al., 2001; Stoneley and Willis, 2004; 
Gebauer and Hentze, 2004). Originally, IRES sequences were identified in viral mRNAs 
and later detected in a subset of cellular mRNAs. It is thought that IRES elements 
permit translation of mRNAs under conditions when cap-dependent translation is 
inhibited. Several IRES elements containing genes were transfected into the DT40 
system to study the effect of Cpdcd4 on IRES dependent translation. However, similar 
to cap-dependent translation it was found that the disruption of Cpdcd4 had no major 
effects on translation initiation mediated by IRES elements. The experiment on the 
effect of Hpdcd4 on IRES-dependent translation offered no consistent results between 
the HeLa knock-down and DT40 knock-out systems. This might be explained by an 
observation that the IRESs can show marked difference in the activity when 
transfected into different cell lines, and stimulated by different exogenous proteins 
(Coldwell et al., 2000; Coldwell et al., 2001). As avian and human cell lines differ in 
many aspects this could explain the variance in the effect of Hpdcd4 on the IRES 
dependent translation between the two different systems. 2D-SDS-PAGE experiments 
performed with DT40 WT and Cpdcd4 knock-out clones failed to identify novel targets. 
 
 
5 DISCUSSION  112 
5.3 Analysis of Pdcd4 in A549 Cells  
In addition to the Pdcd4 knock-down and knock-out system, a Pdcd4 overexpression 
system was also generated by stably expressing the chicken Pdcd4 in the lung tumor 
cells. However, after few generations of cells in the culture, it was found that Pdcd4 
was no longer overexpressed in these cells. Probably the tumor cells evolve to 
continuously eliminate the tumor suppressor proteins. In such case, a Pdcd4 inducible 
overexpression system might be used in future to study the functions of Pdcd4. 
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6 FUTURE PERSPECTIVES 
 
In the future, concerning the role of Hpdcd4 on IRES-dependent translation, more 
apoptosis related genes having IRES elements have to be tested to confirm the effect 
of Pdcd4 on IRES-dependent translation of stress related genes and thereby on 
apoptosis. It would be interesting to find an effect of Hpdcd4 on IRES-dependent 
translation of a gene which is unrelated to apoptosis to prove the specificity of this 
effect. 
 
Regarding the ATF-2 and c-Jun, it might be interesting to study that the enzyme by 
which Hpdcd4 is phosphorylating these transcription factors to further elucidate the role 
of Hpdcd4 in DNA-damage response.   
 
As CK-8 is proved to be biochemically modified in the absence of Hpdcd4, it is essential 
to confirm the nature of the biochemical modification of CK-8 and the enzyme(s) 
mediating it. This might reveal the possible mechanism of tumor suppressor function of 
Hpdcd4 via inhibition of CK-8 biochemical modification. In addition, as CK-8 is the 
molecular target of Hpdcd4, the binding partner CK-18 might be also a potential target 
of Hpdcd4. In the future, the effect of Hpdcd4 on CK-18 should also be tested. Further, 
2D-SDS-PAGE imunoblotting using a 3-10 pH range is necessary to confirm the 
biochemical modification of GluProRS in the absence of Hpdcd4. 
 
The effect of Pdcd4 on CK-17 could be studied in detail at the promoter level. Besides, 
it would be interesting to explore the effect of Hpdcd4 on the structural element CK-17 
in connection to mTOR or IFN signaling and thereby the molecular mechanisms of 
tumor suppressor function of Hpdcd4. Conceivably, the identity of the AKR1C2 and C3 
as targets of Hpdcd4 could be confirmed by reexpression of Hpdcd4 in the knock-down 
clones and assessing their expression. 
 
Furthermore, the binding of Hpdcd4 to AU rich elements (ARE) might be checked, as 
Hpdcd4 has been shown to have some effects already on the IRES elements present in 
the 5’ untranslated region (UTR). As AREs are present in the 3’ UTR of the mRNA 
transcripts and play roles in the stability of mRNAs, the effect of Hpdcd4 on ARE might 
reveal the mechanism of Hpdcd4 role in mRNA stability. The experiment on NMD has to 
be repeated to confirm the potential role of Hpdcd4 on NMD. 
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8.1 Clone Charts 
The following constructs have been made during the work 
 
Clone Chart pbl-pdcd4-targetPuronew 
Description Eucaryotic expression vector codes for the targeting construct 
directed against chicken Pdcd4 
Size ~ 10.3 Kb 
Vector ~3.0 Kb 
Insert ~7.3 Kb 
Promoter -- 
Resistance Puromycin, expressed under β-actin promoter 
Construction This vector derived from the pbl-pdcd4-targetPuro vector 
(Bitomsky, 2003). The right arm (600 bp) of the targeting 
construct was replaced by a 2.2 Kb fragment derived from the 
exon 7-9 of the chicken Pdcd4. For this purpose, first the 
pUC18#141 was made by cloning the 2.2 Kb fragment (from 
KpnI/XbaI digest of the vector p15-1.6x/#141) into the same 
sites of pUC18 vector. The 2.2 Kb fragment of KpnI/SalI digest 
(from pUC18#141 vector) was cloned into the KpnI/XhoI sites of 
pbl-pdcd4-targetPuro vector by replacing the 600 bp right arm. 
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Clone Chart pCR2.1-TOPO-Hpdcd4-HA 
Description T/A cloning vector  
Size ~5.4 Kb 
Vector ~3.9 Kb 
Insert ~1.5 Kb 
Promoter -- 
Resistance Ampicillin and kanamycin 
Construction Total RNA was isolated from HTB-133 cells and human Pdcd4 
(Hpdcd4) was amplified by using designed HPdcd4 cloning primers 
(human_pdcd4_cp_for and human_pdcd4_cp_rev). The primers 
insert BamHI site and KOZAK in the 5’ end and HA tag followed 
by XhoI site in the 3’ end). This PCR fragment (~1.5 Kb) was 
cloned into the pCR2.1-TOPO cloning vector (Invitrogen) by T/A 
cloning protocol. The positive clones (clone2 and clone5) were 
sequenced using M13 reverse and T7 primers. The clone 2 and 5 
are cut with HindIII and the middle fragment was subcloned into 
the pCR2.1-TOPO vector again and sequenced using the same 
primers from both the sides. The clone5 codes for the full length 
Hpdcd4-HA tagged. 
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Clone Chart pcDNA3-Hpdcd4-HA 
Description Eucaryotic expression vector codes for the human Pdcd4-HA 
Size ~6.9 Kb 
Vector ~5.4 Kb 
Insert ~1.5 Kb 
Promoter CMV 
Resistance Ampicillin and neomycin 
Construction The pCR2.1-TOPO-Hpdcd4-HA construct, codes for the correct 
Hpdcd4-HA tagged sequence was double digested with 
BamHI/XhoI and cloned into the same restriction sites of pcDNA3 
(Invitrogen). 
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Clone Chart pcDNA4-Hpdcd4-HA 
Description Eucaryotic expression vector code for the human Pdcd4-HA 
Size ~6.6 Kb 
Vector ~5.1 Kb 
Insert ~1.5 Kb 
Promoter CMV-Tetracycline Operator 
Resistance Ampicillin and zeocin 
Construction The pCR2.1-TOPO-Hpdcd4-HA construct, codes for the correct 
Hpdcd4-HA tagged sequence was double digested with 
BamH1/XhoI and cloned into the same restriction sites of 
pcDNA4/TO/myc-His (Invitrogen). 
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Clone Chart Utrless-pSG5-C/EBPβ 
Description Eucaryotic expression vector code for the C/EBPβ without 
upstream region 
Size ~5.1 Kb 
Vector ~4.1 Kb 
Insert ~1.0 Kb 
Promoter SV40 
Resistance Ampicillin  
Construction For cloning the utrless C/EBPβ into the pSG5 vector, the 
EcoRI/NarI fragment (425 bp) from pcDNA3-CCR vector and the 
NarI/BamHI fragment (712 bp) from pSG5-NFM#16.3 vector 
were cloned into the EcoRI/BamHI fragment (~4.1 Kb) from the 
pSG5-NFM#16.3 construct (Stratagene). 
 
 
 
 
β
 
 
8 APPENDIX  130 
Clone Chart pTER+-siRNA A 
Description Eucaryotic expression vector codes for the siRNA A directed 
against Hpdcd4 mRNA at position 603 
Size ~5.3 Kb 
Vector ~5.3 Kb 
Insert ~60 bp 
Promoter Modified H1 promoter (Inserted with tetracycline operator region) 
Resistance Ampicillin and zeocin 
Construction The siRNA oligos (siRNAhumpdcd4_603s and 
siRNAhumpdcd4_603as) were annealed and cloned into the 
BamH1/HindIII restriction sites of the pTER+ vector (van de 
Watering et al., 2003). Later the sequence was confirmed by 
sequencing, using BGH reverse primer. 
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Clone Chart pTER+-siRNA B 
Description Eucaryotic expression vector codes for siRNA B directed against 
Hpdcd4 at position 1260 
Size ~5.3 Kb 
Vector ~5.3 Kb 
Insert ~60 bp 
Promoter Modified H1 promoter (Inserted with tetracycline operator region) 
Resistance Ampicillin and Zeocin 
Construction The siRNA oligos (siRNAhumpdcd4_1260s and 
siRNAhumpdcd4_1260as) were annealed and cloned into the 
BamH1/HindIII restriction sites of the pTER+ vector (van de 
Watering et al., 2003). Later the sequence was confirmed by 
sequencing, using BGH reverse primer. 
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Clone Chart pUC18#141 
Description A cloning vector has the ~2.2 Kb fragment of the chicken Pdcd4 
exonss 7-9 
Size ~4.9 Kb 
Vector ~2.7 Kb 
Insert ~2.2 Kb 
Promoter LacZ Promoter 
Resistance Ampicillin  
Construction The KpnI/SalI restricted fragment (~2.2 Kb) from the p15-1.6x 
vector was cloned into the KpnI/XbaI sites of the pUC18 vector 
(~2.7) to construct the pUC18#141 construct.  
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8.2 Sequence 
The sequence of the human Pdcd4 in the pCR2.1-TOPO clone5 and the restriction map 
are given below. 
 
The Sequence 
            1  gaattcgccc ttctggatcc gccacaatgg atgtagttta tgagcatgag 
      51  cagatactga atgtaaaccc tgcagatcct gataacttaa gtgactctct 
     101  cttttccggt gatgaagaaa atgctgggac tgaggaagta aagaatgaaa 
     151  taaatggaaa ttggatttca gcatactcca ttaacgaagc tagaattaat 
     201  gccaaggcaa aaaggcgact aaggaaaaac tcatcccggg actctggcag 
     251  aggcgattcg gtcagcgaca gtgggagtga cgcccttaga agtggattaa 
     301  ctgtgccaac cagtccaaag ggaaggttgc tggataggcg atccagatct 
     351  gggaaaggaa ggggactacc aaagaaaggt ggtgcaggag gcaaaggtgt 
     401  ctggggtaca cctggacagg tgtatgatgt ggaggaggtg gatgtgaaag 
     451  atcctaacta tgatgatgac caggagaact gtgtttatga aactgtagtt 
     501  ttgcctttgg atgaaagggc atttgagaag actttaacac caatcataca 
     551  ggaatatttt gagcatggag atactaatga agttgcggaa atgttaagag 
     601  atttaaatct tggtgaaatg aaaagtggag taccagtgtt ggcagtatcc 
     651  ttagcattgg aggggaaggc tagtcataga gagatgacat ctaagcttct 
     701  ttctgacctt tgtgggacag taatgagcac aactgatgtg gaaaaatcat 
     751  ttgataaatt gttgaaagat ctacctgaat tagcactgga tactcctaga 
     801  gcaccacagt tggtgggcca gtttattgct agagctgttg gagatggaat 
     851  tttatgtaat acctatattg atagttacaa aggaactgta gattgtgtgc 
     901  aggctagagc tgctctggat aaggctaccg tgcttctgag tatgtctaaa 
     951  ggtggaaagc gtaaagatag tgtgtggggc tctggaggtg ggcagcaatc 
    1001  tgtcaatcac cttgttaaag agattgatat gctgctgaaa gaatatttac 
    1051  tctctggaga catatctgaa gctgaacatt gccttaagga actggaagta 
    1101  cctcattttc accatgagct tgtatatgaa gctattataa tggttttaga 
    1151  gtcaactgga gaaagtacat ttaagatgat tttggattta ttaaagtccc 
    1201  tttggaagtc ttctaccatt actgtagacc aaatgaaaag aggttatgag 
    1251  agaatttaca atgaaattcc ggacattaat ctggatgtcc cacattcata 
    1301  ctctgtgctg gagcggtttg tagaagaatg ttttcaggct ggaataattt 
    1351  ccaaacaact cagagatctt tgtccttcaa ggggcagaaa gcgttttgta 
    1401  agcgaaggag atggaggtcg tcttaaacca gagagctact acccctacga 
    1451  cgtgcccgac tacgcctaac tcgaggaaag ggcgaattc 
 
The Restriction Map 
 
bp
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8.3 Zusammenfassung 
Krebs ist eine der Haupttodesursachen beim Menschen und seine Bekämpfung ist seit 
Jahrzehnten eine große Herausforderung. Krebs ist eine Krankheit, die dynamische 
Veränderungen im Genom hervorruft. Dabei wird das Genom der Zellen ständig an 
verschiedenen Stellen verändert. Zwei Arten von Genen sind während der 
Tumorentwicklung entscheidend involviert, die Onkogene und die 
Tumorsuppressorgene.   
Das Pdcd4-Gen („Programmed Cell Death 4“)  ist ein neues Tumorsupressorgen, das 
ursprünglich als ein Gen identifiziert wurde, das während der Apoptose aktiviert wird. 
Es konnte gezeigt werden, dass Pdcd4 die durch den Tumorpromotor TPA induzierte 
Transformation von Keratinozyten unterdrückt. Da Pdcd4 mit dem eucaryontischen 
Translations-Initiationsfaktor eIF4A interagiert, wurde vermutet, dass Pdcd4 in der 
Regulation der Translation von einigen, bisher unbekannten Proteinen involviert sein 
könnte. Das Fehlen eines gut charakterisierten Zellsystems jedoch erschwerte bis jetzt 
die Analyse der molekularen Funktionen von Pdcd4.    
 
Um die molekularen Funktionen des Pdcd4 Tumorsuppressorgens durch einen reversen 
genetischen Versuchsansatz studieren zu können, wurde ein Knock-Down-System 
entwickelt. Das System wurde unter Verwendung der RNAi Technologie hergestellt, bei 
der siRNA gegen das humane Pdcd4-Gen (Hpdcd4) in Hela-Zellen eingesetzt wurden. 
Zur Analyse des Pdcd4-Einflusses auf die Cap-unabhängige Translation und der 
möglichen Funktion als Regulator des Zellwachstums/ Zelltodes, wurden Luciferase-
Reportergenanalysen durchgeführt. Diese Luciferase-Doppelkonstrukte enthielten 
interne Ribosomen-Eintrittstellen (IRES) von unterschiedlichen Genen, die am 
Zellwachstum, der Zellzykluskontrolle und an der Apoptose beteiligt sind. Die 
Ergebnisse zeigten, dass Pdcd4 unter normalen physiologischen Bedingungen 
inhibierend auf einige IRES-Elemente wirkten. 
 
Durch 1D-SDS-PAGE-Analyse konnte gezeigt werden, dass die Expression einiger 
Transkriptionsfaktoren durch Hpdcd4 beeinflusst wird. Während die Expression von c-
Myc in der Abwesenheit von Hpdcd4 niedriger war als in seiner Anwesenheit, wurden 
für c-Jun und C/EBPβ höhere Expressionen registriert. Weiterhin zeigten die Hpdcd4-
Knock-Down-Zellen eine geringere Phosphorylierung von ATF-2 und c-Jun als die HeLa-
Wildtypzellen. Um neue molekulare Ziele von Hpdcd4 in seiner Gesamtheit zu 
identifizieren, wurde eine Proteom-Analyse der HeLa-Wildtypzellen und der Hpdcd4-
Knock-Down-Zellen mittels 2D-SDS-PAGE und anschließender Massenspektroskopie 
durchgeführt. Hierbei konnten einige neue Zielproteine von Hpdcd4 ermittelt werden. 
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In der Abwesenheit von Hpdcd4 wurde sowohl Cytokeratin 17 (CK 17) als auch C2 und 
C3 überexprimiert, die zur Familie der  Aldo-Keton-Reduktase 1 (AKR1) gehören. 
Zusätzlich scheinen Cytokeratin 8 (CK 8) und die Glutamyl-Prolyl-Bifunktionale tRNA 
Synthetase (GluProRS) im Gegensatz zu den  HeLa-Wildtypzellen in den Pdcd4-Knock-
Down-Zellen biochemisch modifiziert zu sein. Die differentielle Expression dieser 
Zielproteine wurde durch 1D/2D-SDS-PAGE mit anschließendem Immunoblotting unter 
Verwendung von spezifischen Antikörpern bestätigt. Die Überexpression von CK 17 und 
die biochemische Modifikation von CK 8 in der Abwesenheit von Hpdcd4 waren 
reproduzierbar. Die Identität von AKR1-C2 und von -C3 sowie GluProRS als mögliche 
Ziele von HPdcd4 muß in weiteren Versuchen festgestellt werden.  
 
Es wurde auch untersucht, ob Hpdcd4 einen Effekt auf die mRNA-Menge von CK 17, 
c-Myc und c-Jun hat. Das mRNA-Expressions-Niveau dieser Gene war mit der 
jeweiligen Proteinexpression vergleichbar; außer bei c-Jun. Weiterhin wurde analysiert, 
ob Hpdcd4 die Transkription oder die Stabilität der mRNA-Transkripte beeinflusst. Um 
den Effekt von Hpdcd4 auf den Turn-Over der CK 17- und der c-Myc-mRNA zu 
analysieren, wurden die Zellen mit dem Transkriptionsinhibitor Aktinomycin D 
behandelt und die mRNA-Menge mittels Northern-Blot in einer zeitabhängigen Weise 
detektiert. Es scheint, dass Hpdcd4 die Degradation der CK 17- und c-Myc-mRNA-
Transkripte erhöht. Zusätzlich scheint es, dass Hpdcd4 in Nonsense-vermittelten 
mRNA-Abbau (NMD) involviert ist.    
 
Neben dem HeLa-Knock-Down-System wurde auch ein Knock-Out-System in der 
Hühner B-Zell-Linie DT40 entwickelt, in der beide funktionierende Kopien des Pdcd4-
Gens durch homologe Rekombination entfernt wurden. Es zeigte sich, dass die Hühner-
Pdcd4-Knock-Out-Zellen lebensfähig waren und mit der gleichen Teilungszeit wie 
DT40-Wildtypzellen wachsen. Es konnte jedoch kein Unterschied bezüglich der 
gesamten Rate der Proteinsynthese zwischen den Knock-Out-Zellen und den 
Wildtypzellen festgestellt werden. Diese beiden Systeme könnten weiterhin einen 
wesentlichen Beitrag zur Klärung der molekularen Funktionen des Tumorsuppressor 
Pdcd4 leisten. Auch die weitere Analyse der hier identifizierten molekularen 
Zielproteine von Pdcd4 werden zum besseren Verständnis seiner Funktion beitragen. 
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